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Summary 
Viruses are a constant threat to mankind causing diseases ranging from mild symptoms to fatal 
outcome.  
A rapid and efficient antiviral response is therefore crucial for the survival of the host. RIG-I-like 
receptors (RLR) and other immune receptors, like protein kinase R (PKR), specifically detect viral 
RNA species in the host cytoplasm. The sensing of virus infection triggers intracellular defense 
mechanisms resulting in viral alertness in the infected and surrounding cells, and forms the link to the 
adaptive immune system. Viruses, in turn, have evolved sophisticated countermeasures to dampen the 
antiviral response. The molecular mechanisms involved range from a broad shut-off of the host cell 
metabolism to a selective interference with key components of the immune system.  
For a better understanding, which viral RNA structures are detected by immune receptors like RIG-I 
and PKR and what kind of viral antagonists lead to their inhibition, it is crucial to be able to determine 
their activation status. Hence, limited protease digestion and native polyacrylamide gel electrophoresis 
(PAGE) were established to directly monitor RIG-I and PKR conformational switching and 
oligomerization upon activation, respectively.  
Various studies helped to identify RIG-I stimulating RNA features in vitro, but the first viral structure 
triggering an antiviral interferon response in the natural context of virus infection remained to be 
resolved. We identified 5`triphosphorylated (5`ppp) panhandle structures packaged into nucleocapsids 
as physiological RIG-I agonists. Independent of virus transcription and replication, the incoming 
encapsidated genomes of bunyaviruses (La Crosse virus; LACV and Rift Valley fever virus; RVFV) 
and orthomyxovirus (influenza A virus; FLUAV) were able to stimulate RIG-I activation and an 
antiviral signaling cascade. Surprisingly, antiviral activity of RIG-I against FLUAV was already 
promoted by binding to the 5`ppp panhandle and was independent of RIG-I downstream signaling 
ability. In addition to RIG-I, we also identified PKR as an immune sensor of incoming nucleocapsids. 
PKR thereby interacts with the intergenic region (IGR) of viral genome segments using ambisense 
coding strategy. Association of PKR with the IGR of incoming RVFV (Bunyaviridae) and arenavirus 
nucleocapsids promotes PKR phosphorylation and conformational switching and hence full PKR 
activation.  
To antagonize immediate recognition by RIG-I and PKR, viruses need to adapt. RIG-I activation by 
FLUAV nucleocapsids was altered by an adaptive mutation of the polymerase complex subunit PB2. 
Mammalian adaptation mutation PB2 E627K stabilizes the polymerase complex association with the 
nucleocapsid thereby preventing RIG-I recognition of the 5`ppp panhandle. Additionally, Lassa virus 
(Arenaviridae) nucleoprotein interacts with PKR and promotes its degradation via the proteasomal 
pathway.  
Therefore, we identified entry of viral nucleocapsids as the first time-point of immune recognition in 
the natural context of virus infection and give further insights how viruses have evolved to counteract 
immediate recognition. 
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Zusammenfassung 
Viren stellen eine ständige Bedrohung der Menschheit dar, die Krankheiten mit milden Symptomen 
bis hin zu letalem Ausgang verursachen. Für das Überleben des Wirts ist daher eine schnelle und 
effiziente antivirale Immunantwort von entscheidender Bedeutung. Die meisten der bekannten neu 
auftretenden und hochpathogenen Viren besitzen ein RNA-Genom. RIG-I ähnliche Rezeptoren (RLR; 
RIG-I like receptors) und andere Immunrezeptoren, wie die Proteinkinase R (PKR), reagieren auf 
RNA-Strukturen im Zytoplasma der Wirtszelle. Die Detektion von Virusinfektionen induziert 
intrazelluläre Abwehrmechanismen, die einen antiviralen Zustand in der infizierten und den 
Nachbarzellen vermittelt und zudem das adaptive Immunsystem aktiviert. Viren wiederum haben 
komplexe Abwehrmaßnahmen entwickelt um die Immunreaktion zu verhindern. Die molekularen 
Mechanismen reichen vom unspezifischen Eingreifen in den Wirtszellmetabolismus bis hin zu einer 
spezifischen Inhibition von Schlüsselfaktoren der Immunantwort.  
Für ein besseres Verständnis welche viralen RNA-Strukturen durch Immunrezeptoren, wie RIG-I und 
PKR, detektiert werden und welche Art von viralen Antagonisten zu ihrer Inhibition führen, muss man 
den Aktivierungszustand von Immunrezeptoren genau bestimmen können. Hierfür wurde der limitierte 
Proteaseverdau und die native Polyacrylamid-Gelelektrophorese (PAGE), für einen direkten Nachweis 
der RIG-I und PKR Konformationsänderung beziehungsweise Oligomerisierung nach Aktivierung, 
etabliert. 
Verschiedene Studien haben geholfen, RIG-I stimulierende RNA-Strukturen in vitro zu identifizieren. 
Die erste Virusstruktur, welche die initiale antivirale Immunreaktion im natürlichen Kontext der 
Virusinfektion auslösen kann blieb jedoch ungeklärt. Im Rahmen dieser Studie konnten wir die 5` 
triphosphorylierte (5`ppp) Pfannenstielstruktur viraler Nukleokapside als physiologischen RIG-I 
Agonisten identifizieren. Unabhängig von viraler Transkription und Replikation konnten die 
eintretenden enkapsidierten Genome von Bunyaviren (La Crosse Virus; LACV und Rift Valley Fieber 
Virus; RVFV) und Orthomyxoviren (Influenza A Viren; FLUAV) RIG-I Aktivierung und eine 
antivirale Signalkaskade stimulieren. Überraschenderweise wurde die antivirale Aktivität von RIG-I 
gegen FLUAV bereits durch die Bindung an die 5`ppp Nukleokapside vermittelt, und war unabhängig 
von der RIG-I vermittelten Signalweiterleitung. Neben RIG-I konnte auch PKR als Immunsensor 
eintretender Nukleokapside identifiziert werden. PKR interagiert dabei mit der intergenischen Region 
(IGR; intergenic region) der viralen Genomsegmente mit Ambisense-Kodierungsstrategie. Die 
Assoziation von PKR mit der IGR eintretender RVFV (Bunyaviridae) und Arenavirus Nukleokapside 
vermittelt PKR-Phosphorylierung und Konformationsänderung und damit volle PKR Aktivierung.  
Um einer unmittelbaren Detektion durch RIG-I und PKR zu entgehen, müssen sich Viren anpassen. So 
wird die RIG-I Aktivierung durch FLUAV Nukleokapside durch eine adaptive Mutation der PB2-
Polymeraseuntereinheit verändert. Die Adaptionsmutation PB2 E627K stabilisiert die Interaktion des 
FLUAV Polymerasekomplexes mit dem Nukleokapsid und verhindert dadurch die RIG-I vermittelte 
  
 Summary 
8 
Detektion. Zudem interagiert das Lassa Virus (Arenaviridae) Nukleoprotein mit PKR und induziert 
dessen Abbau über das Proteasom.  
Somit konnte das Eintreten der viralen Nukleokapside in die Wirtszelle als erster Zeitpunkt der 
Immunerkennung im natürlichen Kontext der Virusinfektion nachgewiesen werden. Des Weiteren 
ergeben sich aus dieser Arbeit Einblicke, wie Viren sich entwickelt haben um dieser unmittelbaren 
Immundetektion zu entkommen.  
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Abbreviations  
A… ActD actinomycin D 
 Asp aspartic acid 
B… BDV Borna disease virus (Bornaviridae) 
C… CARD caspase activation and recruitment domains 
 CHX cycloheximide 
 CL13 RVFV Cl 13 
 Co-IP co-immunoprecipitation 
 CTD carboxy-terminal domain 
 CTRL control 
D… dsRBD dsRNA binding domain (PKR) 
 dsRNA double-stranded RNA 
 D.mel-2 Drosophila melanogaster Schneider 2 cells 
E… E glutamic acid 
 eIF2α eukaryotic initiation factor 2 alpha 
F… FLUAV influenza A virus 
G… Glu glutamic acid 
 GP glycoprotein  
 GSD ground state depletion microscopy 
H… HIV human immunodeficiency virus (Retroviridae) 
 His histidine 
I… IFN type I interferon (IFN-alpha/beta) 
 IFNAR interferon-alpha receptor 
 IGR intergenic region 
 IKKε/α/β inhibitor of nuclear factor kappa-B kinase subunit ε/α/β 
 IRES internal ribosomal entry site 
 IRF3/7 IFN regulatory factor 3/7 
 ISG IFN stimulated gene 
 IVM Ivermectin 
J… JAK Janus kinase 
 JUNV Junin virus (Arenaviridae)  
K… K lysin 
L… LACV La Crosse virus (Bunyaviridae) 
 LASV Lassa virus (Arenaviridae) 
 LGP2 laboratory of genetics and physiology 2 
 LMB Leptomycin B 
  
 Abbreviations 
10 
M… MAVS mitochondrial antiviral signaling protein 
 MAM mitochondrial associated membrane 
 MAPK mitogen activated protein kinase 
 MDA5 melanoma differentiation association factor 5 
N… N nucleoprotein (Bunyaviridae) 
 NF-κB nuclear factor κ-light-chain-enhancer of activated B cells 
 NP nucleoprotein (Arenaviridae and Orthomyxoviridae) 
 NS1 non-structural protein 1 (FLUAV) 
 NSs non-structural protein encoded on the S segment (RVFV) 
 NSV negative-strand RNA virus 
P… ppp triphosphate 
 PA polymerase acidic protein 
 PACT protein activator of PKR 
 PAGE polyacrylamide gel electrophoresis 
 PB1/2 polymerase basic protein 1/2 
 PCR polymerase chain reaction 
 PHV Prospect Hill virus (Bunyaviridae) 
 PKR protein kinase R 
Q… qRT PCR quantitative reverse transcription polymerase chain reaction 
R… RIG-I retinoic acid inducible gene I 
 RLR RIG-I like receptor 
 RNA ribonucleic acid 
 RVFV Rift Valley fever virus (Bunyaviridae) 
S… SAP shrimp alkaline phosphatase 
 siRNA small interfering RNAs 
 STAT signal transducer and activator of transcription 
T… TAR transactivation RNA (HIV) 
 TBK1 TANK-binding kinase 1 
 TCRV tacaribe virus (Arenaviridae) 
 TRAF 3/6 TNF receptor-associated factor 3/6 
 TRIM25 tripartite motif containing 25 
U… UAP56 56 kDa U2AF65-associated protein 
 URH49 UAP56-related helicase, 49 kDa 
W… wt wildtype 
Z… Z matrixprotein (Lassa virus) 
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1. Introduction 
1.1. Induction of antiviral defense mechanisms by RIG-I like receptors 
Viruses are a constant threat to mankind. Thereby, most of the known emerging and highly pathogenic 
viruses are RNA-genome based. They give rise to epidemic and rarely pandemic diseases, as often 
reported for influenza viruses [30]; or cause hemorrhagic fever, like members of the families 
Arenaviridae (Lassa fever virus and Junin virus) [35, 147] and Bunyaviridae (Rift Valley fever virus 
and Crimean Congo haemorrhagic fever virus) [6, 51]. Thus, to rapidly control virus infection an 
immediate recognition of the viral intruder is required.  
 
1.1.1. RIG-I like receptors 
The germ-line encoded RLR (RIG-I (retinoic acid inducible gene I) like receptors) represent a group 
of cytoplasmic sensor proteins able to detect RNA virus infection. RLR belong to the DExD/H-box 
helicase family (refers to Asp-Glu-x-Asp/His, where x can be any amino acid) within the helicase 
superfamily 2. RIG-I, the closely related MDA5 (melanoma differentiation association factor 5) and 
LGP2 (laboratory of genetics and physiology 2) form the family of RLR. RIG-I and MDA5 
complement each other by responding to diverse virus families and initiate antiviral type I interferon 
(IFN-alpha/beta) responses [144]. The role of LGP2 in cytosolic virus sensing is less well 
characterized and currently controversially discussed. However, it is widely accepted that LGP2 
represents rather a modulator of RIG-I and MDA5 activity then being involved in immune sensing or 
signaling [107, 109, 151].  
 
1.1.2. RIG-I like receptor agonists 
Studies have demonstrated that RIG-I and MDA5 recognize mainly distinct virus families. RIG-I is 
required to initiate an antiviral response against Filoviridae (Ebola and Marburg virus), 
Paramyxoviridae (New Castle Disease virus and respiratory syncytial virus), Rhabdoviridae (vesicular 
stomatitis virus), Orthomyxoviridae (Influenza virus), Bunyaviridae (Rift Valley Fever virus) and 
Flaviviridae (Japanese encephalitis virus). On the other hand, MDA5 responds to representatives of 
the Picornaviridae (Encephalomycarditis virus). Together, RIG-I and MDA5 react to Reoviridae and 
representatives of the Flaviviridae group (West Nile virus and Dengue virus) [112, 145]. An essential 
feature of the RLR is specificity to distinguish between host cell (self) and viral (non-self) patterns. 
Thereby, MDA5 is known to sense longer dsRNA (double-stranded RNA) molecules up to two kilo 
bases [58, 92], ideally with higher order RNA structures [92]. RIG-I mainly responds to 5′ ppp blunt-
ended dsRNA of a minimal length of 10 base pairs [46, 60, 91, 111, 113]. Also dsRNA stretches 
bearing a 5`diphosphate were recently identified to stimulate a RIG-I dependent response [33]. Long 
dsRNA molecules of more than 200 base pairs (irrespective of the 5′ ends) [9], 3′-monophosphorylated 
cleavage products of RNase L [73], and polyuridine or polyriboadenine stretches were also decribed as 
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RIG-I agonists [103, 108, 112]. Importantly, these RNA structures and modalities are absent in the 
cytoplasm of non-infected cells, allowing the discrimination between self and non-self.  
 
1.1.3. Structure-based RIG-I activation  
All RLR share a similar structure (manuscript 4.5, Fig. 2). Thereby, RIG-I is composed of a CTD 
(carboxy-terminal domain) and a conserved RNA helicase core (formed by Hel1 and Hel2 with the 
insertion domain Hel2i). Both domains are required for agonist recognition in which the CTD has high 
affinity for the 5`ppp and the helicase domain recognizes dsRNA [128]. The helicase domain also 
promotes ATP hydrolysis. The CTD is connected to Hel2 via the pincer domain (also named bridging 
domain), which transmits the information of ligand recognition to the helicase core [57, 65, 71, 98]. 
Additionally, RIG-I possesses two amino-terminal CARDs (caspase activation and caspase 
recruitment domains) for signal transduction [64, 72, 144]. MDA5 has a similar structure whereas 
LGP2 lacks CARDs for downstream signaling [139, 144].  
In resting state, RIG-I is present as an extended monomer in an open auto-repressed conformation [62, 
71]. Thereby, the CARDs contact each other and CARD2 interacts with Hel2i, which sterically 
impedes ligand and coactivator engagement and initiation of downstream signaling [65, 97]. The CTD 
is, however, flexibly exposed and surveys the environment for 5`ppp-dsRNA. CTD binding to the 
5`ppp brings the dsRNA in close proximity to the helicase domain [62]. The helicase core 
cooperatively binds the phosphate backbone of the dsRNA and ATP and the associated 
conformational switch promotes the release of CARDs [65]. CARDs are then freely accessible for 
polyubiquitinylation by the E3 ligase TRIM25 [29] or unanchored polyubiquitin chains [149]. 
Polyubiquitinylation prevents reassociation of the CARDs with the helicase domain to return into the 
auto-repressed state [62]. Furthermore, ubiquitinylation allows association of RIG-I molecules into a 
tetrameric complex [56, 89] leading to the fully signaling competent RIG-I complex.  
 
1.1.4. RIG-I mediated type I interferon response 
Activated RIG-I complexes recruit the adaptor protein MAVS (mitochondrial antiviral signaling) via 
CARD-CARD interaction [140]. Thereby, a transient interaction is sufficient to promote self-
perpetuating MAVS filament association and thus, leading to a large-scale amplification of the 
antiviral signaling cascade [47]. Although the majority of MAVS is present on the mitochondria, it is 
also localized to peroxisomes [23]. Both organelles act sequentially as signaling platforms. Thereby, 
peroxisomes induce a rapid and transient IFN-independent expression of ISGs whereas mitochondrial 
MAVS initiates a sustained IFN-dependent response with delayed kinetics [23]. MAM (mitochondrial 
associated endoplasmatic reticulum membrane) directs relocalization of MAVS between the 
organelles, thus coordinates signaling between peroxisomes and mitochondria [45]. MAVS filament 
formation initiates the recruitment of several molecules to assemble a signaling platform [47, 55, 142]. 
Interaction of MAVS with TRAF3 and TRAF6 (TNF receptor-associated factor 3 and 6, respectively) 
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promotes activation of TBK1 (TANK-binding kinase 1) and IKKε (inhibitor of nuclear factor kappa-B 
kinase subunit ε) responsible for the phosphorylation of IRF3 and IRF7 (IFN regulatory factor 3 and 7, 
respectively), and IKKα and IKKβ promote NF-κB (nuclear factor κ-light-chain-enhancer of activated 
B cells) activation. Phosphorylated IRF3/7 forms dimers and translocates, like NF-κB, into the nucleus 
to initiate expression of IFN, proinflammatory cytokines and RIG-I and MDA5, providing a positive 
feedback mechanism for the amplification of the antiviral response [32, 103]. IFN binding to IFNAR 
(interferon-alpha receptor) stimulates the JAK (janus kinase)-STAT (signal transducer and activator of 
transcription) signaling pathway leading to selective transcriptional activation of numerous IFN-
stimulated genes (ISGs) [44, 52]. ISGs represent effector proteins of the IFN response, which directly 
act against multiple steps of virus replication to establish an antiviral state in infected and neighboring 
cells [87, 116]. Furthermore, costimulatory molecules, cytokines and chemokines favor the initiation 
of adaptive immune responses [70, 115, 117]. The innate immune system thus controls virus infection 
at early phases and permits a subsequent specific adaptive immune response to clear infection and 
establish an immunogenic memory [41]. 
 
1.1.5. Protein kinase R  
One well studied effector protein of the innate immune response is PKR (protein kinase R). PKR is 
expressed at a low constitutive level in the cytoplasm, but can casually be detected in the nucleus. To 
stimulate PKR activation there is a minimal length requirement of dsRNA of approximately 16 base 
pairs, but also specific structural modalities, like RNA bulges and loops, and nucleotide modifications, 
like a 5`ppp, support PKR stimulation [7, 25, 84]. PKR thereby contacts the dsRNA in a sequence-
independent manner [7]. However, during stress PACT (protein activator of PKR) can activate PKR in 
absence of a stimulating dsRNA ligand [88]. Concerning PKR structure, the protein is composed of 
two amino-terminal dsRBD (dsRNA binding domains), a carboxy-terminal serine/threonine kinase 
domain, whereby both domains are linked by a flexible linker [126]. In absence of a stimulus, PKR is 
present as a monomer with an extended, open conformation and the dsRBDs are impeding kinase 
domain activity. Agonist recognition induces structural rearrangements to a closed conformation 
allowing dimerization and auto-phosphorylation [16-18, 67, 126]. Once activated, PKR is a 
multifunctional protein involved in the regulation of cap-dependent translation, it participates in the 
formation of virus induced stress granules required for IFN signaling and controls NF-κB, p38 MAPK 
and insulin pathways, among others [18, 22, 85, 148].  
 
1.2. Viral evasion strategies to prevent immune recognition 
Induction of the IFN response acts as a major barrier to virus infection, which must be circumvented to 
enable a productive infectious cycle. Thus, viruses have evolved multiple mechanisms to target key 
signaling molecules of the RLR pathway to prevent establishment of an antiviral state. A common 
strategy of RNA viruses comprises the modification and concealing of the viral genomes and 
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replicative intermediates. One mechanism presents packaging of the viral RNA with multiple copies of 
viral nucleoprotein and the polymerase into nucleocapsids [106]. Furthermore, some viruses possess 
the ability to enzymatically remove their 5`ppp in order to avoid RIG-I detection [36]. Other viruses 
hide their genomes by replicating in the nucleus or in inaccessible cellular compartments [152]. In 
course of the viral replication cycle, accumulation of erroneous, misencapsidated replication products 
might serve as RLR agonists. Viruses therefore mask [41, 42, 95], degrade these erroneous side 
products [38, 41, 63, 93] or use cellular helicases to unwind dsRNA replication intermediates [136, 
137]. 
Overall, viruses have evolved sophisticated strategies to prevent RLR recognition and the subsequent 
IFN response. Further knowledge of viral evasion strategies is, however, required to comprehend the 
complexity of virus-host interactions to gain insights into RLR signaling and also virus pathogenesis 
itself.  
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1.3. Objectives of the underlying thesis 
Despite the discoveries about stimulating RIG-I structures, the question of the physiological RIG-I 
agonist in the authentic infection context remained largely unresolved. Long dsRNA is not produced 
in a detectable amount during the course of negative-strand RNA virus (NSV) infection [131]. 
However, NSV possess complementary sequences at the termini of their genomes leading to the 
formation of the “panhandle” conformation with a short dsRNA stretch. Furthermore, because of 
initiation of RNA synthesis via a single nucleoside triphosphate, all NSV were believed to possess a 
5`ppp at the termini of their genomes [36]. Therefore, the 5`ppp panhandle structure represents all 
hallmarks of a potential RIG-I agonist. Nevertheless, the genomes of NSV do not exist as free RNA, 
but are instead hidden in a complex with multiple copies of viral nucleoprotein and the polymerase, 
the so-called nucleocapsid. It has remained unclear, whether RIG-I can also recognize RNAs packaged 
into nucleocapsids, the main viral RNA state in the infected host cell.  
First aim of this study was hence the identification of the physiological RIG-I agonist during virus 
infection. Thereby, we aimed to pin down the first viral structure to be detected by RIG-I and able to 
stimulate the host innate immune system. We focused at first on stimulating RNA structures of the 
cytoplasmic bunyaviruses and extended then our study towards influenza viruses, which are only 
briefly accessible to RIG-I during their cytoplasmic transit to the nucleus for genome replication. 
Besides RIG-I, we wondered whether other immune receptors would promote an immediate antiviral 
response. PKR is able to respond to dsRNA, but also specific structural modalities, like bulges and 
loops [25]. Interestingly, intergenic regions of viral genomes using ambisense coding strategies 
resemble loop structures with a dsRNA stem. Thus, we hypothesized that PKR could be able to induce 
immediate antiviral defense mechanisms by recognizing intergenic regions of incoming viral genomes. 
To validate this hypothesis was the second aim of this thesis.  
On the contrary, to counteract immediate recognition viruses have evolved sophisticated methods. 
Viral immune evasion strategies thereby range from an unspecific shut-off of the host cell metabolism 
to a selective interference with key components of the IFN system. In our research, we intended to 
assess whether NSVs have evolved so far unknown mechanisms to specifically evade immediate 
immune recognition.  
Overall, we intend to provide further insights in immediate virus detection in the natural context of 
infection and how viruses, on the other hand, have adapted to evade immune recognition to allow 
efficient virus replication and spread. 
  
 Results 
16 
2. Results 
2.1. Monitoring the activation status of RIG-I and PKR  
For a better understanding, which viral RNA structures are detected by immune receptors, like RIG-I 
and PKR, and what kind of viral antagonists lead to their inhibition, it is crucial to be able to 
determine their activation status. So far, techniques to measure downstream events like antiviral gene 
expression are commonly used, but since viruses interfere with RLR and IFN signaling, results might 
not reflect the direct activation status of RIG-I or PKR. Here, we present limited protease digestion 
and native polyacrylamide gel electrophoresis (PAGE) as sensitive and direct measurements of two 
distinct markers of RIG-I and PKR activation (manuscript 4.1, [133]). Upon agonist recognition RIG-
I and PKR undergo conformational switching [2, 107, 121] allowing formation of oligomeric 
complexes [22, 56, 107]. Sensitive validation of the RIG-I and PKR activation status helps to gain 
further insights in physiological agonists and how viruses interfere with RIG-I and PKR activation.  
In absence of a specific agonist, RIG-I has an open auto-repressed conformation [62, 71]. Agonist 
recognition induces conformational switching of RIG-I and formation of a much more ordered RIG-I 
molecule [62, 72]. PKR is also present as a monomer with an extended open conformation in the 
absence of a stimulus. Binding to a specific agonist leads to structural rearrangements to a closed 
conformation allowing dimerization and auto-phosphorylation [17, 67, 126]. Conformational 
rearrangements lead to alterations in protease sensitivity, which can be determined by limited protease 
digestion. This technique, to monitor RIG-I and PKR conformational switching, was previously 
described by M. Gale Jr. [107] and T. Fujita [121], and J.L. Cole [2], respectively.  
To monitor RIG-I and PKR conformational switching upon virus infection, human A549 cells were 
either mock infected or infected with Rift Valley fever virus clone 13 (Cl 13). Cl 13 lacks a functional 
IFN antagonist NSs and is hence a strong activator of RIG-I and PKR [36, 37, 50]. Trypsin digestion 
of mock infected cell lysates results in a rapid degradation of RIG-I whereas Cl 13 infection leads to 
the generation of a 30 kDa protease resistant RIG-I fragment (manuscript 4.1, Fig. 1A). Also PKR 
shows partial resistance to trypsin digestion in Cl 13 infected samples, which coincides with its 
phosphorylation at threonine 466, a widely accepted marker of PKR activation (manuscript 4.1, Fig. 
1A). 
RIG-I and PKR conformational rearrangements form the prerequisite to associate multiple monomers 
into oligomeric complexes. Accumulation of RIG-I oligomers allows enhanced recruitment of 
downstream signaling molecules to form a platform for antiviral signal transduction [72]. In case of 
PKR, dimerization supports auto-phosphorylation required for its full activation [17, 22]. The 
formation of oligomeric complexes was assayed by native PAGE. Proteins and protein complexes are 
thereby not separated by their charge to mass ratio, but rather by their size [138]. 
By applying native PAGE, formation of RIG-I and PKR oligomeric complexes in Cl 13 infected cell 
lysates could be demonstrated whereas these proteins remained as monomers in mock infected 
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samples (manuscript 4.1, Fig. 2, upper and middle panel). As an additional control for the 
functionality of the oligomerization assay the IFN transcription factor IRF3 was included. Validation 
of IRF3 dimerization is widely performed to monitor activation of the IFN system [54]. Indeed, IRF3 
dimerization coincides with RIG-I and PKR oligomerization in Cl 13 infected samples (manuscript 
4.1, Fig. 2, lower panel). 
Taken together, these results demonstrate limited trypsin digestion and native PAGE as useful and 
sensitive tools to directly monitor two distinct markers of RIG-I and PKR activation. 
 
2.2. Characterization of the physiological RIG-I agonist  
2.2.1. Incoming bunyavirus nucleocapsids as RIG-I agonists 
Most studies on the identification of RIG-I agonist were performed by allowing full viral replication or 
by transfecting naked viral or synthetic RNA. These results helped to gain insights into RNA features 
required for RIG-I activation, like dsRNA and a 5`ppp, but did not answer the question about the RIG-
I activating structure in the natural virus infection. Therefore, the first objective of this thesis was the 
identification of the earliest infection step exposing a viral RNA pattern able to activate RIG-I and 
stimulate an antiviral IFN response in an authentic virus infection (manuscript 4.2, [132]).  
The infection cycle of NSV starts with particle attachment to the host cell, followed by entry of the 
viral genome into the cytoplasm, mRNA (messenger RNA) synthesis during primary transcription via 
the viral polymerase, genome replication via a positive-sense template, assembly and finally release of 
progeny viruses. It has been demonstrated that full-length and defective RNAs produced during viral 
replication serve as RIG-I stimulators [5, 101]. However, whether these RNA structures represent 
naked erroneous side products of viral replication was not addressed. During virus infection, the viral 
genomic and intermediate RNA products never exist as free RNA, but are instead hidden within the 
nucleocapsid [131]. So far, it has remained unresolved whether RIG-I can also recognize RNAs 
packaged into nucleocapsids, the main viral RNA state in the infected host cell.  
Nucleocapsids of NSVs represent hallmarks of a potential RIG-I agonist. Terminal complementary 
sequences of the viral genomes allow hybridization into a short dsRNA stretch, classified as the 
“panhandle” conformation. Moreover, the 5`ppp is generated during initiation of RNA synthesis via a 
single nucleoside triphosphate [110]. To study whether the incoming 5`ppp nucleocapsids would 
suffice to trigger an IFN response the peculiar characteristics of the bunyaviruses were exploited. 
Bunyavirus transcription is dependent on on-going translation [94]. Hence, treatment with the 
translation inhibitor CHX (cycloheximide) aborts primary transcription and allows validation of 
incoming nucleocapsids as IFN stimulators. Infections were performed with two representatives of the 
Bunyaviridae, RVFV (Rift valley fever virus) and LACV (La Crosse virus). To test induction of an 
IFN response, IFN-beta and ISG56 mRNA upregulation were measured by qRT PCR (quantitative 
reverse transcription PCR). Results indicate that independent of primary transcription or genome 
replication, already the incoming LACV and RVFV nucleocapsids stimulate an IFN response 
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(manuscript 4.2, Fig. 1B). To validate the influence of the 5`ppp, PHV (Prospect Hill virus), another 
bunyavirus, which processes its 5`terminus to a 5`p (monophosphate) [31, 36] was included into the 
study. This allows a direct comparison of the antiviral response by nucleocapsids with (LACV and 
RVFV) or without (PHV) the 5`ppp. By performing the experiment with PHV no upregulation of IFN-
beta and ISG56 was detected (manuscript 4.2, Fig. 2A). This indicates that the induction of the IFN 
response by nucleocapsids seems to be dependent on the presence of a 5`ppp.  
To further validate induction of the IFN response by 5`ppp nucleocapsids, the activation status of the 
IFN transcription factor IRF3 was analyzed. Thereby, phosphorylation, dimerization and translocation 
of IRF3 into the nucleus represent central features of its activation [143]. Indeed, LACV and RVFV 
nucleocapsids promote phosphorylation, dimerization (manuscript 4.2, Fig. S3D and S4D, 
respectively) and translocation of IRF3 (manuscript 4.2, Fig. S3E) whereas PHV 5`p nucleocapsids 
do not stimulate a detectable IRF3 activation (manuscript 4.2, Fig. S3F). This data supports the 
previous result that triggering an antiviral IFN response requires 5`ppp nucleocapsids.  
To test which RLR is responsible for the induction of the immune response, knockdown cells were 
generated by transfecting siRNA (small interfering RNAs) against non-specific target (CTRL), MDA5 
or RIG-I. Knockdown of MDA5 did not affect the ability of incoming LACV nucleocapsids to 
stimulate IFN-beta and ISG56 expression (manuscript 4.2, Fig. 2B). However, absence of RIG-I 
resulted in an impaired IFN response. This indicates that RIG-I is required to sense nucleocapsids. 
Taken together, incoming 5`ppp nucleocapsids promote a RIG-I dependent antiviral IFN response.  
To analyze whether RIG-I is able to interact with the incoming nucleocapsids, confocal 
immunofluorescence microscopy and co-IP (co-immunoprecipitation) assay were performed. 
Detection of the nucleoprotein N served thereby as a marker for the viral nucleocapsids. Confocal 
immunofluorescence microscopy revealed that RIG-I colocalized with LACV and RVFV 
nucleocapsids (manuscript 4.2, Fig. 4A and S4E). Incoming nucleocapsids also showed a 
colocalization with peroxisomes (manuscript 4.2, Fig. S4B), which are known organelles for 
induction of an immediate antiviral response [23]. This interaction between RIG-I and incoming 
nucleocapsids was further validated by co-IP. With a RIG-I specific co-IP, also LACV nucleocapsids 
could be precipitated (manuscript 4.2, Fig. 4B). This demonstrates that RIG-I is able to interact with 
incoming nucleocapsids. Whether RIG-I interaction with the incoming nucleocapsids would promote 
RIG-I activation was validated by the previously described assays (manuscript 4.1, [133]). Therefore, 
we performed limited protease digestion and native PAGE to monitor RIG-I conformational switching 
and oligomerization, respectively. Full viral replication and incoming LACV and RVFV 
nucleocapsids induced trypsin resistant RIG-I fragments as a marker of conformational switching 
(manuscript 4.2, Fig. 3G and S4D). However, PHV full replication cycle and PHV incoming 5`p 
nucleocapsids only poorly stimulated RIG-I conformational changes. Also RIG-I oligomerization 
increased upon full LACV and RVFV replication and remained at a constant, but clearly detectable 
level if replication cycle was aborted after entry of the viral nucleocapsids (manuscript 4.2, Fig. 3F 
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and S4D). In contrast, PHV infection and incoming 5`p nucleocapsids failed to promote accumulation 
of RIG-I oligomeric complexes (manuscript 4.2, Fig. 3H).  
An insect cell system was additionally employed to investigate whether RIG-I activation by viral 
nucleocapsids is direct or mediated by one of the abundant cellular cofactors of RIG-I [61, 81, 87, 
146]. Therefore, isolated nucleocapsids from purified RVFV or LACV virions were used to stimulate 
human RIG-I expressed from D.mel-2 (Drosophila melanogaster Schneider 2) cells. In absence of 
mammalian cofactors, purified nucleocapsids promote RIG-I conformational switching (manuscript 
4.2, Fig. 6C). Thus, mammalian cofactors are not required for nucleocapsid-stimulated RIG-I 
activation. To test the requirement of the 5`ppp and dsRNA for RIG-I activation by incoming 
nucleocapsids, purified nucleocapsids were either treated with a ssRNA-specific RNase A, a dsRNA-
specific RNase III or SAP (shrimp alkaline phosphatase). By destroying the dsRNA stretch (RNase 
III) or removal of the 5`ppp (SAP), the nucleocapsids lost their ability to promote RIG-I 
conformational switching, whereas RNase A treatment did not have an effect (manuscript 4.2, Fig. 
6E). This indicates that the 5`ppp dsRNA panhandle is required for RIG-I activation. Furthermore, by 
employing super-resolution GSD (ground state depletion) microscopy we were able to display the 
pseudocircular structure of LACV nucleocapsids and that accumulations of RIG-I contact the 
nucleocapsids via a single contact site, most likely the 5`ppp dsRNA panhandle (manuscript 4.2, Fig. 
7).  
In summary, RIG-I interacts with incoming nucleocapsids comprising a 5`ppp dsRNA panhandle. This 
interaction leads to RIG-I conformational switching and oligomerization independent of other 
mammalian cofactors. Once activated, RIG-I promotes, partially via the peroxisomal signaling 
platform, activation of the IFN transcription factor IRF3 and the antiviral type I IFN response. This 
defines nucleocapsid entry as the first time-point when the host immune system encounters the viral 
intruder to promote an immediate antiviral response.  
 
2.2.2. Incoming influenza virus nucleocapsids serve as RIG-I agonists 
Influenza A viruses (FLUAV) belong to the family Orthomyxoviridae containing a segmented, single-
stranded RNA genome with negative-strand polarity. Each FLUAV particle comprises eight genome 
segments encapsidated by the viral nucleoprotein NP and the polymerase complex subunits PB1, PB2 
and PA. The 5` and 3` ends of each viral RNA contain partially complementary sequences forming, as 
described for other NSVs, a panhandle conformation with a short dsRNA [48, 90]. Since incoming 
5`ppp nucleocapsids of the bunyaviruses could be identified as physiological RIG-I agonists 
(manuscript 4.2, [132]), we wondered if also FLUAV nucleocapsids would serve as RIG-I 
stimulators. However, FLUAV transcription and replication occur in the nucleus. Due to the viral 
replication cycle, the incoming FLUAV nucleocapsids are only shortly exposed to cytoplasmic 
immune receptors. Here, we addressed the question if the short cytoplasmic exposure of FLUAV 
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nucleocapsids during their transit to the nucleus is sufficient to activate RIG-I (manuscript 4.3, 
(Weber et al., in press)). 
To study, whether RIG-I is able to recognize incoming FLUAV nucleocapsids, diverse inhibitors were 
used to restrict virus infection. CHX (cycloheximide) blocks protein synthesis and therefore viral 
genome replication, LMB (Leptomycin B) inhibits nuclear export of nucleocapsids, ActD 
(actinomycin D) is an inhibitor of viral transcription, and IVM (Ivermectin) is known to block nuclear 
import of viral nucleocapsids [130]. Furthermore, to ensure analysis of an immediate response 
infection was stopped one hour post infection. Indeed, independent of the applied inhibitor, incoming 
A/PR/8/34 (H1N1) nucleocapsids promote RIG-I conformational switching and oligomerization and 
thus its full activation (manuscript 4.3, Fig. 1A and B).  
To verify an interaction between RIG-I and the incoming FLUAV nucleocapsids various approaches 
were applied. Super-resolution GSD microscopy revealed that RIG-I is attached to the rod-like 
FLUAV nucleocapsids via a single contact site (manuscript 4.3, Fig. 2A). Association of RIG-I with 
FLUAV nucleocapsids was further confirmed by co-IP and co-sedimentation assays. Thereby, 
FLUAV nucleocapsids could be coprecipitated with a RIG-I specific IP (manuscript 4.3, Fig. 2B). 
Likewise, by performing co-sedimentation assay, RIG-I and FLUAV nucleocapsids partially shifted 
together into the same fractions (manuscript 4.3, Fig. 2C). This indicates that RIG-I is indeed able to 
interact with incoming FLUAV nucleocapsids. 
To test the influence of mammalian RIG-I cofactors the D-mel.2 in vitro system was applied. Also in 
absence of any mammalian factors, purified FLUAV nucleocapsids induced RIG-I conformational 
switching (manuscript 4.3, Fig. S2F), oligomerization (manuscript 4.3, Fig. S2G) and a RIG-I shift 
in a co-sedimentation assay (manuscript 4.3, Fig. S2H). Therefore, also in absence of other 
mammalian factors RIG-I interacts and gets activated by FLUAV nucleocapsids. RIG-I activation is, 
however, dependent on the presence of a 5`ppp and a dsRNA structure since the FLUAV 
nucleocapsids lose their RIG-I activating potential after treatment with a dsRNA-specific RNase III or 
the phosphatase SAP, respectively (manuscript 4.3, Fig. 2D).  
To validate whether FLUAV nucleocapsids can promote an IFN response, the activation status of 
IRF3 was validated. IRF3 phosphorylation, one marker of its activation, was induced upon presence of 
FLUAV nucleocapsids (manuscript 4.3, Fig. 1D).  
As a conclusion, incoming FLUAV nucleocapsids serve as natural RIG-I agonist independent of RNA 
synthesis or presence of mammalian cofactors, triggering a signaling cascade that culminates in the 
activation of the IFN transcription factor IRF3. 
 
2.3. PKR as an immediate sensor of virus infection 
As previous results indicate, incoming RVFV and LACV (Bunyaviridae) and FLUAV 
(Orthomyxoviridae) nucleocapsids serve as physiological RIG-I agonists enabling an immediate 
antiviral type I IFN response (manuscript 4.2, [132] and manuscript 4.3, (Weber et al., in press)). 
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However, whether other host immune receptors would likewise contribute to immediate virus 
recognition remained unresolved.  
One well-characterized cytoplasmic immune sensor is PKR. With its ability to recognize dsRNA 
stretches or specific structural RNA modalities, like bulges and loops [18], PKR comprises the 
potential to recognize dsRNA replicative intermediates of NSVs [20]. However, whether PKR can be 
activated by incoming viral RNA structures packaged within the nucleocapsids was not addressed so 
far (manuscript 4.4, (Weber et al., manuscript in preparation)).  
Upon agonist recognition, conformational rearrangements of PKR lead to partial protease resistance 
allowing dimerization and auto-phosphorylation (manuscript 4.1, [133]). By comparing the potential 
of the two closely related LACV and RVFV to promote PKR conformational switching and 
phosphorylation, interesting differences were observed. LACV full infectious cycle and incoming 
LACV nucleocapsids stimulate only weakly these two markers of PKR activation (manuscript 4.4, 
Fig. 1B). On the contrary, full RVFV replication and incoming nucleocapsids of RVFV lead to a 
robust detection of PKR conformational switching and phosphorylation. Interaction of PKR with 
bunyavirus nucleocapsids was validated by co-sedimentation assay and co-IP. By performing co-
sedimentation assay, PKR shifted to similar fractions as RVFV nucleocapsids whereas upon 
stimulation with LACV nucleocapsids PKR showed a similar distribution in the gradient as upon 
mock infection (manuscript 4.4, Fig. 1C). Co-IPs confirmed PKR interaction with RVFV, but not 
LACV, nucleocapsids (manuscript 4.4, Fig. 1D). This indicates that incoming RVFV nucleocapsids 
can be recognized by PKR and stimulate its activation. Hence, incoming RVFV nucleocapsids serve as 
natural PKR agonists.  
To identify the PKR stimulating structure present within RVFV, but absent in LACV nucleocapsids, 
the coding strategies of these two viruses were analyzed. Bunyaviruses divide their genome into three 
segments, which are named L (large), M (middle) and S (small) according to their size [11]. RVFV L 
and M segment and all segments of LACV are present in negative polarity with one transcriptional 
unit coding for one or more proteins. RVFV S segment, however, uses ambisense coding strategy 
(manuscript 4.4, Fig. 2B). Thereby, two open reading frames in opposite directions are separated by a 
non-coding intergenic region (IGR). RVFV IGR resembles a hairpin structure with a central dsRNA 
stem disordered by internal loops (manuscript 4.4, Fig. 2A). To test whether this peculiar structure is 
responsible for PKR activation, RVF VLP (RVF virus like particles) containing either M (no IGR) or 
S (with IGR) segmented nucleocapsids were generated. Due to the same 5`ppp dsRNA panhandle of 
M and S segments the nucleocapsids promote RIG-I conformational switching to the same extent 
(manuscript 4.4, Fig. 2C). However, only S segmented nucleocapsids possessing the IGR are able to 
stimulate PKR conformational switching. As detected by super-resolution GSD microscopy, RIG-I 
colocalized with both M and S segmented nucleocapsids whereas PKR only showed interaction with S 
segmented nucleocapsids (manuscript 4.4, Fig. 2D). Taken together, PKR activation by incoming 
nucleocapsids requires the presence of a structured IGR.  
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To further support this result, arenavirus nucleocapsids were validated based on their potential to 
promote PKR activation. According to antigenicity, phylogeny and geographical distribution, 
arenaviruses are classified into Old World and New World viruses [63]. Arenavirus particles comprise 
two genome segments both using ambisense coding strategy with an IGR for transcriptional control. 
Compared to RVFV IGR, representatives of the arenaviruses, like the Old World LASV (Lassa virus) 
and New World JUNV (Junin virus) and TCRV (Tacaribe virus) possess also a highly structured IGR 
with a central dsRNA stem (manuscript 4.4, Fig. 3A). By validating PKR activation, TCRV, JUNV 
and LASV nucleocapsids induce PKR phosphorylation and conformational rearrangements 
(manuscript 4.4, Fig. 3B, right panel). Thus, incoming arenavirus nucleocapsids serve, like RVFV 
nucleocapsids, as natural PKR agonists.  
This data demonstrate that PKR is able to recognize IGRs exposed from the incoming nucleocapsid 
complex. IGR engagement promotes PKR conformational switching and phosphorylation identifying 
IGRs of RVFV S segment, New World arenavirus TCRV and JUNV and Old World arenavirus LASV 
nucleocapsids as natural PKR activators. This emphasizes PKR as an immune sensor of immediate 
virus infection.  
 
2.4. Viral immune evasion strategies to prevent immediate recognition 
2.4.1. Segmented negative-strand RNA viruses as strong immune stimulators 
The reviews included in this cumulative doctoral thesis briefly summarize the current understanding of 
immune evasion strategies of segmented and non-segmented NSVs (manuscript 4.5, [135] and 
manuscript 4.6, [134]). However, in our research, we focused on the molecular mechanisms of NSVs 
with a segmented genome to evade immediate immune recognition.  
Besides Orthomyxoviridae with up to eight genome segments, members of the Arenaviridae and 
Bunyaviridae have two and three genome segments, respectively. Viruses with a segmented genome 
possess complementary sequences at the termini of their genomes leading to the formation of the 
panhandle conformation [26, 27, 76]. As outlined above, 5`ppp dsRNA panhandle structures of 
incoming bunyavirus (manuscript 4.2, [132]) and influenza virus (manuscript 4.3, (Weber et al., in 
press)); and arenavirus nucleocapsids (manuscript 4.4, (Weber et al., manuscript in preparation)) 
serve as natural RIG-I and PKR agonists, respectively. Hence, NSVs with segmented genomes 
immediately present an increased number of potential immune receptor agonists leading to an early 
activation of antiviral defense mechanisms (manuscript 4.5, Fig. 3). To evade early immune 
recognition and the subsequent antiviral IFN response sophisticated countermeasures are thus 
required. Here, we address the question how influenza viruses and arenaviruses prevent immediate 
nucleocapsid detection by the host immune receptors RIG-I and PKR, respectively. 
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2.4.2. Influenza virus PB2 627K modulates nucleocapsid detection by RIG-I 
Adaptation of FLUAV to humans is required for establishment of an efficient virus infection. The 
influenza virus polymerase subunit PB2 has been described as a major determinant of host switching 
[74]. In particular, amino acid substitution at PB2 residue 627 from an avian E (glutamic acid) 
signature to mammalian adapted K (lysin) has been extensively characterized [120]. It was described 
that mammalian adaptation mutation PB2 627K results in an increased replication in mammalian cells 
whereas in chicken cells no major replication differences between avian PB2 627E and mammalian 
PB2 627K were detectable. Furthermore, different groups observed reduced interaction of avian PB2 
627E with the viral nucleocapsid and this failure in nucleocapsid assembly was absent in chicken cells 
[66, 80, 96]. The molecular background for replication advantages of mammalian PB2 627K remained 
elusive [15, 74, 118]. Interestingly, chicken cells, where no major differences between avian PB2 
627E and mammalian PB2 627K could be observed, lack RIG-I [4]. This raises the question whether 
adaptation mutation PB2 627K might be an influenza virus evasion strategy to avoid immediate RIG-I 
recognition in mammalian cells to enhance virus replication (manuscript 4.3, (Weber et al., in 
press)).  
To address this question, the potential of the incoming nucleocapsids of four diverse influenza virus 
strains (A/quail/Shantou/2061/00 (H9N2), A/Thai/KAN-1/04 (H5N1), pandemic A/Hamburg/05/2009 
(pH1N1), or A/WSN/33 (H1N1)) with either the avian PB2 627E or mammalian PB2 627K to 
promote RIG-I conformational switching was compared. Strikingly, nucleocapsids with the avian PB2 
627E induced a robust RIG-I activation, which was strongly reduced in the presence of the 
mammalian signature PB2 627K (manuscript 4.3, Fig. 3A). Also by performing co-sedimentation 
assay, avian PB2 627E induced a more robust shift of RIG-I, TRIM25 and MAVS containing fractions 
in the gradient indicating an enhanced activation of the RIG-I signaling pathway in comparison to 
nucleocapsids bearing mammalian PB2 627K (manuscript 4.3, Fig. 3C).  
Despite the clear effect on RIG-I activation, no significant differences between induction of the IFN 
response by an aborted replication cycle of avian PB2 627E or mammalian PB2 627K containing 
FLUAV were observed (manuscript 4.3, Fig. 3D). Likewise, the activation of the IFN transcription 
factor IRF3 by FLUAV nucleocapsids bearing either PB2 627E or PB2 627K did not differ. This 
indicates that mammalian adaptation mutation PB2 627K prevents RIG-I activation without major 
effects on IFN induction.  
To test the influence of RIG-I on virus replication, wt (wildtype) or ∆RIG-I (RIG-I deficient) HEK293 
cells were infected with A/Thai/KAN-1/04 (H5N1) with avian PB2 627E or mammalian PB2 627K 
signature. Allowing multi-cycle growth for 24 hours, titer differences between viruses with avian and 
mammalian polymerase complex were reduced from 50.000 fold in wt cells to 400 fold in ∆RIG-I 
cells (manuscript 4.3, Fig. 4D). These results could be further supported by monitoring the 
expression of viral nucleoprotein NP. Compared to wt cells, in ∆RIG-I cells viruses with the avian 
PB2 627E show an earlier NP synthesis, whereas viruses with the mammalian PB2 627K are not 
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strongly affected by the presence or absence of RIG-I (manuscript 4.3, Fig. 4E, S4C and S4D). 
Likewise, in chicken DF-1 cells, naturally lacking RIG-I [4], FLUAV bearing the avian PB2 627E or 
mammalian PB2 627K express NP to a similar extent (manuscript 4.3, Fig. 4C, upper panel). 
However, overexpression of human RIG-I severely reduces NP expression of the avian PB2 627E 
virus, whereas replication efficiency of FLUAV with the mammalian PB2 627K is not strongly 
influenced (manuscript 4.3, Fig. 4C, middle panel).  
As mentioned above, no striking differences in IFN induction stimulated by nucleocapsids bearing 
avian or mammalian polymerase complex could be observed (manuscript 4.3, Fig. 3D). Therefore, 
we wondered whether the IFN response has an influence on the different replication efficiencies of 
FLUAV with either avian PB2 627E or mammalian PB2 627K. Curiously, by using ∆MAVS (MAVS 
depleted) HEK293 cells incapable to transmit RIG-I signaling for IFN induction, no rescue of NP 
expression of FLUAV with avian PB2 627E could be detected (manuscript 4.3, Fig. 5A). This 
indicates that inhibition of RIG-I signaling seems to be not sufficient to regain replication potential of 
avian viruses. To support this hypothesis, ∆RIG-I cells or chicken DF-1 cells were 
transcomplementated with either RIG-I wt or signaling incompetent RIG-I K270A mutant. Strikingly, 
RIG-I K270A did impair PB2 627E virus as much as RIG-I wt (manuscript 4.3, Fig. 5B and Fig. 
5C). Antiviral activity of RIG-I against nucleocapsids bearing the avian PB2 627E is consequently 
independent of RIG-I downstream signaling function. Thus, RIG-I binding to the avian nucleocapsids 
seems to be sufficient to impair virus replication suggesting a novel direct antiviral RIG-I activity. 
Mammalian PB2 627K adaptation was described to enhance association of the polymerase complex 
with the nucleocapsid [66]. To test whether RIG-I affects association of the avian polymerase complex 
with the nucleocapsids in mammalian cells, co-IPs were performed. In wt cells the avian polymerase 
complex was less efficiently coprecipitated with the nucleocapsids whereas the PB2 627E-
nucleocapsid interaction was slightly increased in ∆RIG-I cells (manuscript 4.3, Fig. 6A). By 
performing a RIG-I specific co-IP, more nucleocapsids with the avian PB2 627E could be 
coprecipitated in comparison to nucleocapsids bearing PB2 627K (manuscript 4.3, Fig. 6B). 
Although less nucleocapsids of a mammalian adopted strain could be precipitated, more PB2 627K 
was associated. This indicates that stronger binding of the mammalian polymerase complex to the 
5`ppp panhandle prevents RIG-I recognition and hence displacement of the polymerase complex. To 
test this, a polymerase complex disassembling compound (PB1-T6Y) was applied [141]. 
Destabilization of the viral polymerase complex converts nucleocapsids with the mammalian PB2 
627K to strong RIG-I activators (manuscript 4.3, Fig. 6D). However, the potential of PB2 627E 
bearing nucleocapsids to promote RIG-I conformational switching is more modestly affected. This 
implies that the strength of the polymerase complex-nucleocapsid interaction influences RIG-I 
activation.  
In summary, we found that RIG-I acts as an influenza virus restriction factor by promoting the 
dissociation of the weakly interacting avian polymerase complex, thus impairing virus replication. The 
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inhibitory effect of RIG-I represents moreover a so far undescribed direct, signaling independent 
antiviral activity. On the other hand, influenza viruses have adapted to allow efficient replication in 
mammalian cells. Mammalian adaptation mutation PB2 627K enhances binding to the nucleocapsid, 
thereby preventing RIG-I recognition.  
 
2.4.3. Lassa virus nucleoprotein promotes proteasomal degradation of PKR 
Also arenaviruses need to adapt to evade immune recognition for a productive infection. It is known 
that arenaviruses have evolved diverse strategies to simultaneously attack diverse steps of RIG-I 
signaling [134, 135]. However, it remained elusive how arenaviruses prevent immediate detection by 
PKR. Interestingly, we observed that arenavirus nucleocapsids stimulated PKR phosphorylation and 
conformational switching only if the translation inhibitor CHX was applied (manuscript 4.4, Fig. 
3B). This raises the question whether arenaviruses encode for a yet unidentified PKR antagonist. To 
investigate this hypothesis, we focused on LASV. By performing co-IP, an interaction of PKR with 
incoming (manuscript 4.4, Fig. 4A, right panel) and newly synthesized LASV nucleocapsids could 
be observed (manuscript 4.4, Fig. 4A, left panel). However, phosphorylated PKR could only be 
detected if protein synthesis was inhibited. As a control, a RIG-I specific co-IP was included. RIG-I 
does not interact with incoming LASV nucleocapsids (manuscript 4.4, Fig. 4A, left panel), which is 
in agreement with the results of Marq et al. that 5`overhang structures impair RIG-I recognition [75, 
76]. A weak interaction of RIG-I with LASV nucleocapsids could only be observed if full replication 
cycle was allowed, which might reflect erroneous replication intermediates (manuscript 4.4, Fig. 4A, 
right panel). To identify the protein responsible for PKR inhibition, LASV NP (nucleoprotein), GP 
(glycoprotein) and Z (matrixprotein) were transfected with increasing concentrations together with 
PKR at a constant plasmid amount. Thereby, overexpression of PKR alone resulted in PKR activation 
due to proximity of the single PKR molecules allowing auto-phosphorylation. LASV GP and Z further 
increased the phosphorylation status of PKR whereas increasing amounts of LASV NP dramatically 
reduced PKR activation (manuscript 4.4, Fig. 4B). By performing co-IP, an interaction of LASV NP, 
but not GP or Z, with PKR was identified (manuscript 4.4, Fig. 4C). Thus, LASV NP is able to 
interact with PKR and impair PKR phosphorylation. To validate the involvement of the proteasome, 
the proteasomal inhibitor MG132 was tested. In absence of MG132, LASV NP overexpression results 
in decreased PKR phosphorylation as expected (manuscript 4.4, Fig. 4D, left panel). However, PKR 
activation in LASV NP-overexpressing cells can be rescued if the proteasomal degradation pathway is 
blocked (manuscript 4.4, Fig. 4D, right panel). Also during LASV infection MG132 application can 
prevent NP promoted PKR inhibition (manuscript 4.4, Fig. 4E). Surprisingly, MG132 treatment 
likewise rescued PKR activation in TCRV and JUNV infected cells. 
In summary, we discovered that LASV NP interacts with PKR and promotes the proteasomal 
degradation of activated PKR. This seems to be a conserved mechanism within the arenavirus family 
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since MG132 treatment rescues PKR activation during Old World LASV infection, but also in New 
World TCRV and JUNV infected cells. 
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3. Discussion 
3.1. RIG-I as an immune sensor of incoming viral nucleocapsids  
A rapid immune response to virus infection is crucial to ensure survival of the host. In vitro studies 
helped to identify major determinants triggering a RIG-I dependent antiviral IFN response, like 
dsRNA and a 5`ppp [46, 91, 111, 113]. However, in the natural context of infection the first viral 
structure able to stimulate RIG-I activation still needed to be resolved.  
Here, RIG-I is presented as an immune sensor of incoming bunyavirus and influenza virus 
nucleocapsids enabling an immediate antiviral response. RIG-I directly interacts with the incoming 
nucleocapsids independent of viral or cellular RNA synthesis or mammalian cofactors. RIG-I contacts 
the nucleocapsids via a single site, most likely via the 5`ppp dsRNA panhandle. Thereby, interaction is 
dependent on the presence of a 5`ppp and a dsRNA, since viral nucleocapsids lacking these features 
failed to mediate RIG-I activation. This is in contrast to the observation that 3` untranslated regions of 
the influenza virus genome induce RIG-I activation independent of a 5`ppp [21]. However, these data 
are based on in vitro assays transfecting unpackaged viral or synthetic RNA into cells. During 
infection, RIG-I activation seems to be dependent on a 5`ppp. This was also proposed by the A.M. 
Pyle group, who likewise detected RIG-I activation in absence of a 5`ppp in in vitro experiments, but 
postulated that during virus infection the 5`ppp would be required for robust RIG-I binding and 
activation in presence of a less abundant agonist [60]. Indeed, our results demonstrate that during virus 
infection, an interaction of RIG-I with 5`ppp nucleocapsids stimulates conformational switching and 
oligomerization, two hallmarks of RIG-I activation. Activated RIG-I promotes then a signaling 
cascade that stimulates the activation of the IFN transcription factor IRF3 and eventually culminates in 
the induction of the antiviral IFN response. This defines the release of viral nucleocapsids as the first 
time-point of a RIG-I-dependent immune recognition in the natural context of virus infection.  
In former studies, transfected measles and vesicular stomatitis virus nucleocapsids could already be 
identified as immune stimulators [124, 125]. However, during transfection the correct assembly of the 
viral nucleocapsids cannot be ensured and furthermore, the immune response was not associated with 
RIG-I. Immune recognition of incoming nucleocapsids is, however, in contrast to previous reports 
suggesting that replication intermediates occurring later during viral infection cycle would trigger 
RIG-I-dependent immune responses [5, 101]. Especially for FLUAV, in a recent paper it was argued 
that the IFN induction is dependent on RNA synthesis [59, 86]. Killip et al. observed an activation of 
the IFN transcription factor IRF3 only if RNA synthesis and nuclear export of the progeny 
nucleocapsids was permitted [59]. However, we detected IRF3 activation even if the transcription 
inhibitor ActD was applied or nuclear export was blocked by LMB treatment. The discrepancy could 
be due to the chosen time-point of analysis. In case of Killip et al., IRF3 translocation was validated 
eight hours post infection, a time-point where IRF3 might have already disappeared from the nucleus 
[59]. In our study, IRF3 activation was observed as early as one hour post-infection. This indicates 
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that also incoming FLUAV nucleocapsids serve as stimulators of the antiviral IFN response, as 
previously demonstrated for influenza B viruses [86].  
It is somewhat intriguing how RIG-I gains access to the 5`ppp panhandle, which is covered by the 
viral polymerase. Recent structural data of the bat influenza virus panhandle further complicates the 
view of the accessibility of the 5`terminus [90]. The 5`terminus folds by intrastrand base-pairing into a 
hook-like structure followed by a dsRNA stretch of 14 base pairs. Moreover, the whole structure is 
deeply covered within the polymerase complex. It can be hypothesized that during the transit to the 
nucleus the association of the polymerase complex with the panhandle is dynamic and to some extend 
flexible. This is in agreement with the observation that that the polymerase complex, especially PB2, 
is mobile within the structure [102]. A partial release of the 5`terminal hook may enable RIG-I binding 
to the 5’ppp. Because of the four base-paired nucleotides forming the hook structure, the nucleotide 
bearing the 5`ppp is base-paired enabling a robust interaction of the RIG-I CTD domain. Additionally, 
dsRNA stretches are associated with a stabilization of the RNA helix in a fixed conformation 
supporting engagement of the RIG-I helicase domain [62]. Due to the high affinity of RIG-I for the 
5`ppp [128], RIG-I can rapidly entrap its agonist, even if it is only shortly exposed. RIG-I interaction 
with the 5`ppp may allow first structural rearrangements of RIG-I thereby triggering a disposition of 
the polymerase complex. This is supported by the hypothesis of Schmidt et al., who argue that RIG-I 
can drive an ATP-dependent removal of proteins [114]. It seems also plausible, that the panhandle is 
briefly exposed allowing RIG-I to rapidly interact. Both hypotheses, however, require further 
investigation. 
In summary, RIG-I is in a yet to be identified mechanism able to engage the 5`ppp dsRNA panhandle 
of incoming nucleocapsids. This interaction induces RIG-I activation, enabling downstream signaling 
for induction of an immediate antiviral response.  
 
3.2. PKR contributes to immediate pathogen recognition 
Immune recognition of incoming nucleocapsids allows an immediate antiviral response. However, 
viruses have evolved to evade RIG-I recognition. Therefore, alternative immune receptors are required 
to ensure immediate induction of antiviral defense mechanisms or to support RIG-I immune 
recognition for a sustained response.  
In the present thesis, we identified PKR involvement in immediate virus recognition. PKR interacts 
with the IGR of incoming bunyavirus RVFV S segmented nucleocapsids and incoming New World 
arenavirus TCRV and JUNV and Old World arenavirus LASV nucleocapsids. Like RIG-I, PKR 
interacts with the nucleocapsids only via a single contact site. By analyzing the predicted RVFV and 
arenavirus IGR, a hairpin structure can be observed with a central dsRNA stem with internal loops and 
sporadic mismatches. A 16 base pair dsRNA stem with additional 10 to 15 nucleotides of single-
stranded tails was previously described as the minimal requirement for PKR activation [150]. Thereby, 
the dsRNA does not have to possess perfect base pairing since PKR can tolerate non-Watson-Crick 
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structures and also internal loops as long as the overall A-form geometry of the RNA is retained [7, 8]. 
Hence, the IGR of the RVFV small genome segment and all genome segments of TCRV, JUNV and 
LASV present all criteria of a potential PKR agonist. Previous studies demonstrated an interaction of 
PKR with structured elements of viral RNA, like Hepatitis C virus IRES (internal ribosomal entry site) 
[119] or dimerized stem-loop structures of TAR (transactivation RNA) of HIV [43].  
In vitro experiments by Dauber et al. suggest that 5`ppp panhandle structures also serve as PKR 
agonists [19]. Our data indicates, however, that RIG-I, but not PKR, interacts with the 5`ppp dsRNA 
panhandle structure in the natural context of infection. Thereby, RVFV M segmented nucleocapsids 
presenting a 5`ppp dsRNA panhandle, but lacking the IGR promoted RIG-I conformational switching 
and failed to stimulate PKR activation. It can be postulated that RIG-I outcompetes PKR for 5`ppp 
panhandle interaction. Another plausible explanation could be that engagement of the 5`ppp terminus 
by PKR plays a role only during later time-points of infection, when misencapsidated side products of 
viral replication occur. So far, PKR was not associated with the ability to remove proteins from RNA 
as it was postulated for RIG-I [114]. Thus, PKR might not gain access to the panhandle of incoming 
nucleocapsids covered by the viral polymerase.  
However, the question about the accessibility of the IGR within the nucleocapsid complex remains 
elusive. In case of orthobunyaviruses, like LACV, the RNA is deeply buried within the nucleocapsids 
[3] hindering PKR association. However, RVFV and arenavirus nucleocapsids are less tightly 
packaged leaving the viral genome partially accessible [40, 99, 100]. Exposure of the viral RNA alone 
is nevertheless not sufficient for PKR activation since RVF VLPs containing either M or S segment, 
with the same packaging grade of the viral RNA within the nucleocapsid, do only activate PKR if the 
IGR is present. Moreover, data by Moy et al. indicates that the IGR is exposed for host protein 
interaction [83]. The group thereby identified an interaction of human DDX17 or Drosophila Rm62 
with the IGR of RVFV S segment indicating that also PKR could gain access to the IGR. Indeed, our 
data demonstrates that PKR is able to engage the IGR within the viral nucleocapsid in the natural 
context of virus infection. Protein interaction with the IGR was proposed to have a negative impact on 
virus replication [83]. It can therefore be hypothesized that PKR association with the RVFV and 
arenavirus IGR could also impair virus replication independent of its downstream signaling activity. 
This represents an exciting assumption, but still requires further investigation. 
Taken together, PKR contributes to immediate virus recognition by interacting with the IGR of 
incoming viral nucleocapsids.  
 
3.3. Immune evasion strategies to prevent immediate recognition 
Antiviral immunity acts as a major barrier to virus infection, which must be circumvented to enable a 
productive infection. Viruses have therefore evolved to prevent immediate recognition and activation 
of antiviral defense mechanisms.  
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As presented above, incoming FLUAV nucleocapsids serve as immediate triggers of a RIG-I-
dependent IFN response. To ensure an efficient replication cycle, influenza viruses have evolved 
multiple strategies to circumvent immune recognition by RIG-I, downstream signaling and activation 
of an antiviral response. On one hand, during evolution Orthomyxoviridae have located viral 
transcription and replication to the nucleus thereby limiting exposure of potential agonist to 
cytoplasmic immune sensors. Furthermore, immune recognition is actively impaired by sequestering 
dsRNA by viral NS1 [42] or dsRNA unwinding via the cellular helicases UAP56 and URH49 [136, 
137]. Also FLUAV polymerase complex interferes with the host immune system. Thereby, MAVS 
downstream signaling ability is impaired by influenza virus polymerase subunits PB1, PB2 and PA 
[34, 53] and a variant of PB1-F2 [24, 127]. Like NS1 protein [49], the polymerase complex is already 
present within the virion allowing a rapid interference with immune recognition.  
Here, we present a single substitution at position 627 of PB2 from avian adapted glutamic acid (E) 
signature to mammalian lysin (K) as a novel FLUAV strategy to impair immediate immune 
recognition by RIG-I. A change from avian PB2 627E to mammalian PB2 627K has been extensively 
characterized in the context of host adaptation [74]. Also adaptation to the host immune system is 
required to ensure efficient replication in a new host. Previous data suggested that adaptation mutation 
PB2 627K positively affects viral replication in mammalian cells, which was accompanied with 
increased nucleocapsid stability [66, 80, 96]. The PB2 627 position is in close proximity to the NP 
binding site and hence an unstable binding between PB2 627E and NP might lead to a failure in 
nucleocapsid assembly [80, 82].  
Our data indicates that RIG-I specifically recognized and got activated by nucleocapsids with avian 
polymerase complex whereas nucleocapsids bearing mammalian PB2 627K failed to promote RIG-I 
activation. Furthermore, RIG-I specifically interfered with the association of the avian polymerase 
complex with the nucleocapsids. This is in agreement with previous reports describing a disturbed 
interaction of PB2 627E with the viral nucleocapsids in mammalian cells, but the responsible host 
factor or mechanisms was not identified [66, 80, 96]. In contrast, Cauldwell et al. argued that 
mammalian adaptation mutation PB2 627K does not enhance stability of the polymerase complex, but 
rather increases the amount of replicated RNA [14]. This would consequently lead to the false 
interpretation of co-IP data that more mammalian polymerase complex associated to the nucleocapsids 
excluding the fact that less avian nucleocapsids are present. However, in our case cells were treated 
with CHX and LMB to block viral replication and still, in presence of RIG-I, more mammalian PB2 
627K was associated to the incoming nucleocapsids in comparison to avian PB2 627E. In RIG-I 
depleted cells, interaction of the avian PB2 627E bearing polymerase complex with the nucleocapsids 
was partially rescued. This implicates that RIG-I specifically affects the association of a destabilized 
avian polymerase complex. PB2 627K, however, enhances interaction of the polymerase complex with 
the nucleocapsid thus limiting RIG-I recognition of the incoming nucleocapsids. This is also supported 
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by the observation that disturbance of the polymerase complex assembly through applying competing 
peptides reverts PB2 627K nucleocapsids to a RIG-I stimulating agonist. 
It was furthermore described that the mutation at position 627 of influenza virus PB2 does not alter the 
structure of the polymerase subunit, but rather disrupts a basic patch on the surface of the protein 
[122]. The change of surface charge might alter the association of the polymerase complex with host 
factors. Interaction with either enhancing or suppressing cellular proteins might therefore be 
responsible for the diverse polymerase activity between PB2 627E and 627K [96]. Indeed, the García-
Sastre group described several proteins differentially regulating polymerase activity depending if there 
is an E or K at position 627 of PB2. Interestingly, DDX17, a DEAD box RNA helicase like RIG-I, 
was among the identified proteins [10]. In our hands, an interaction of RIG-I specifically with avian 
PB2 627E or the mammalian PB2 627K could not be detected. However, others did identify an 
association of FLUAV polymerase complex subunits with RIG-I [69]. Due to sensitivity problems, our 
experiments might have failed to detect this interaction. The biological significance of polymerase-
RIG-I interaction still needs to be resolved. It was, however, demonstrated that the interaction does not 
affect RIG-I mediated IFN signaling [69]. It can be postulated that RIG-I entraps the viral polymerase 
complex to the panhandle promoter region and blocks polymerase processivity by interaction, since 
the RIG-I CTD is anchored via association to the 5`ppp. This might promote an IFN signaling-
independent block of viral replication. Our data likewise indicate an IFN-independent mechanism of 
inhibiting virus replication of FLUAV with the avian signature. Firstly, by validating the ability of 
incoming nucleocapsids bearing either avian PB2 627E or mammalian PB2 627K to stimulate IFN 
induction no striking differences were observed. Furthermore, depletion of cells of the signaling 
molecule MAVS did not rescue replication of the FLUAV with avian PB2 627E. Likewise, a 
signaling-incompetent mutant RIG-I with an active binding capacity inhibited replication of FLUAV 
with avian PB2 627E as much as RIG-I wt did. Taken together, not the downstream IFN signaling 
ability of RIG-I promotes the antiviral effect against FLUAV with the avianized polymerase complex, 
but rather already the association with the panhandle promoter. This indicates a novel direct antiviral 
activity of RIG-I independent of its signaling ability. 
In conclusion, RIG-I detects incoming influenza virus nucleocapsids. Activation of RIG-I is thereby 
enhanced in presence of an avian PB2 627E. Poor association of the polymerase complex with the 
nucleocapsid might allow full engagement of RIG-I with the 5`ppp panhandle promoting its activation. 
RIG-I interaction with the panhandle alone dislocates the avian polymerase and impairs virus 
replication independent of RIG-I mediated IFN signaling. However, a polymerase complex with the 
mammalian signature PB2 627K shows enhanced interaction with the nucleocapsid impairing RIG-I 
recognition. This suggests that also for recognizing other viral nucleocapsids the polymerase needs to 
be disposed for enabling RIG-I binding and activation. It would be hence interesting to investigate 
whether other viruses possess similar adaptation mutations to avoid immediate RIG-I recognition. 
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Despite RIG-I, also PKR contributes to immediate recognition of virus infection. PKR, however, 
detects the IGR of incoming nucleocapsids presented by viruses using ambisense coding strategy, like 
RVFV S and arenavirus genome segments. RVFV NSs promotes the proteasomal degradation of PKR 
thereby limiting PKR recognition and its antiviral activity [37]. An evasion strategy by arenavirus able 
to inhibit PKR activation was not identified so far.  
Here, we present that arenaviruses promote, like RVFV, the proteasomal degradation of PKR. 
Specifically, LASV NP could be identified as the responsible PKR antagonist. LASV NP interacts 
with PKR and promotes PKR degradation via the proteasomal pathway in a dose dependent manner. 
However, NP encapsidating the viral genome did not affect the activation status of PKR indicating that 
only free LASV NP was comprising PKR antagonistic properties. LASV NP possesses the ability to 
bind dsRNA [39], which could serve as a scaffold for PKR interaction. Co-IP data of LASV proteins 
expressed in absence of viral RNA indicates, however, that the interaction of LASV NP with PKR is 
rather independent of viral RNA. Nevertheless, a complex formation of LASV NP with cellular RNA 
cannot be excluded. It was reported in this regard that recombinant nucleoproteins of NSV can 
associate with cellular RNA into nucleocapsid like structures [106]. Moreover, LASV NP comprises 
the ability to oligomerize [68]. Whether NP monomers or LASV oligomeric complexes promote PKR 
antagonism still needs to be clarified. It was, however, previously described that the NP 
oligomerization is no strict requirement for impairing the IFN response [68]. Hastie et al. reported that 
the dsRNA specific 3` to 5` exonuclease activity of LASV NP is essential for inhibiting IFN signaling 
[39]. Since incoming nucleocapsids do not present long dsRNA stretches to the host immune system, 
degradation of dsRNA might play a distinct immune evasion strategy during later infectious stages.  
Arenavirus NP is well conserved among Old and New World arenaviruses, suggesting that an IFN 
antagonistic activity may be a shared feature [39, 40]. Indeed, lymphocytic choriomeningitis virus 
(Old World arenavirus) and Whitewater Arroyo virus, Pichinde virus, JUNV, Machupo virus and 
Latino virus, but not TCRV, (New World arenaviruses) were able to impair the IFN and 
proinflammatory response [77, 78, 104]. Likewise, arenaviruses use proteasomal degradation as a 
common PKR antagonism, but the responsible TCRV and JUNV protein inducing PKR inhibition 
remains elusive. TCRV, incapable to impair IFN signaling [78], inhibited PKR activation. This 
highlights the requirement to prevent early recognition by PKR to ensure efficient virus propagation, 
even in the case of apathogenic viruses like TCRV. 
Despite of proteasomal degradation of PKR by arenaviruses, other viruses have also evolved strategies 
to prevent antiviral activity of PKR. Thereby, Kaposi-sarcoma herpesvirus vIRF2 and vaccinia virus 
K3L block PKR auto-phosphorylation [13, 105]. Hepatitis C virus E2 protein presents homologies 
with PKR and eIF2α and can serve as a pseudosubstrate [123]. This broad spectrum of viruses ranging 
from DNA to RNA viruses antagonizing PKR indicates the relevance of PKR inhibition for efficient 
virus replication.  
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In summary, we found that LASV NP and a yet to be identified TCRV and JUNV protein promote the 
proteasomal degradation of PKR. Thereby, LASV NP interacts with PKR most likely independent of 
viral RNA and induces PKR degradation via the proteasomal pathway. Therefore, arenavirus have 
evolved an efficient strategy to counteract immediate recognition and activation of antiviral defense 
mechanisms. 
 
3.4. Concluding remarks 
The presented data provides evidence that incoming bunyavirus, FLUAV and arenavirus 
nucleocapsids are rapidly recognized by RIG-I and PKR. RIG-I recognition is dependent on the 
presence of a 5`ppp dsRNA panhandle, whereas PKR detects the IGR of genome segments using 
ambisense coding strategy. Hence, the first host response to virus infection already occurs 
immediately after virus entry. Furthermore, we describe a novel antiviral activity of RIG-I that is 
independent of its signaling ability. In this regard, already binding of RIG-I to the 5`ppp panhandle 
limits FLUAV replication.  
Viruses evade immune recognition by various mechanisms. Here, we present two diverse strategies of 
FLUAV and arenaviruses to prevent immediate detection by the host immune system. For FLUAV, 
the mammalian adaptation PB2 627K stabilizes the polymerase complex association with the 
nucleocapsids, thus preventing RIG-I recognition of the 5`ppp dsRNA panhandle. In case of 
arenaviruses, we show that LASV NP prevents PKR sensing of the incoming nucleocapsids via 
induction of the proteasomal degradation of PKR. This later seems to be common within the 
arenavirus family since not only Old World arenavirus LASV, but also New World TCRV and JUNV 
induce PKR degradation via the proteasomal pathway.  
It is known that the constant immune pressure leads to positive selection of viruses combining potent 
immune evasion with efficient replication strategies within the host cell. FLUAV bearing PB2 627K is 
associated with enhanced pathogenicity [120], like LASV being the causative agent of fatal human 
hemorrhagic fever [79]. This supports the idea that viral proteins involved in circumventing RLR and 
IFN signaling represent also determinants of virulence and pathogenesis [12, 129].  
In conclusion, we pin down entry of viral nucleocapsids as the first time-point of immune recognition 
in the natural context of virus infection and give further insights how viruses have evolved to 
counteract immediate detection.  
Despite these achievements, future studies are required to comprehend the complexity of virus-host 
interactions. It remains to be clarified how RIG-I gains access to the 5`ppp dsRNA panhandle covered 
by the viral polymerase and nucleoproteins. Furthermore, the direct antiviral activity of RIG-I 
combined with the fact that cofactors are not essential for RIG-I activation raises the question whether 
RIG-I would also perform an antiviral activity in the nucleus. Indeed, RIG-I was previously observed 
in the nucleus [69], however, no antiviral activity was associated. Interestingly, it was hypothesized 
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that an unknown factor interacts with avian PB2 627E in the nucleus, thereby limiting mobility and 
disturbing nucleocapsid assembly [28]. Whether RIG-I represents this factor is a tempting assumption. 
For FLUAV, several adaptation mutations associated with increased pathogenesis were described [15]. 
The effect of these mutations on cellular defense mechanisms was not addressed so far. It would be 
thus of interest to validate the influence of other adaptive mutations, despite PB2 627K, on the host 
immune response.  
To effectively control virus infections, the generation of new therapeutically tools is required. 
Interestingly, peculiar poly-C (viral sense) and poly-G (viral anti-sense) repeats within the IGR were 
previously described as essential transcription termination signals [1]. These structures are therefore 
less likely to be altered by the virus despite the existing immune pressure. Moreover, interaction of a 
protein with the IGR of viral genomes was associated with reduced viral replication [83]. Thus, 
targeting of this conserved region, by for instance aptamers, might be a promising therapeutic 
approach to limit virus replication and ensure survival of the host.  
Conclusively, detailed knowledge how viruses interfere with the RLR detection and signaling system 
may provide not only new insights into RLR signaling, but also virus pathogenesis itself. A better 
understanding of the pathogenic potential of viruses would thereby allow to rapidly react and provide 
preparedness for future epidemics or even pandemics.  
 
Immediate virus recognition by RIG-I and PKR and viral counterstrategies.  
Exemplarily, immune recognition of incoming influenza A virus (FLUAV) and Lassa virus (LASV) nucleocapsids by RIG-I 
and PKR is shown, respectively. RIG-I rapidly detects the 5`ppp dsRNA panhandle upon release of FLUAV nucleocapsids 
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into the host cytoplasm. PKR, however, reacts to the intergenic region of incoming nucleocapsids. To antagonize immediate 
immune recognition, FLUAV mammalian adaptation mutation PB2 627K stabilizes association of the polymerase complex 
with the nucleocapsids, thereby preventing RIG-I recognition. For PKR evasion, LASV nucleoprotein (NP) interacts with 
PKR and promotes its degradation via the proteasome.  
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4. Original publications and manuscripts 
4.1. Monitoring activation of the antiviral pattern recognition receptors 
RIG-I and PKR by limited protease digestion and native PAGE  
 
Own contribution:  
I established the techniques in our lab and performed all experiments shown in Fig. 1 and 2. I 
contributed to writing of the manuscript. 
 
 
Michaela Gerlach 
  
Journal of Visualized Experiments www.jove.com
Copyright © 2014  Journal of Visualized Experiments July 2014 |  89  | e51415 | Page 1 of 7
Video Article
Monitoring Activation of the Antiviral Pattern Recognition Receptors RIG-I
And PKR By Limited Protease Digestion and Native PAGE
Michaela Weber1, Friedemann Weber1
1Institute for Virology, Philipps-University Marburg
Correspondence to: Friedemann Weber at friedemann.weber@staff.uni-marburg.de
URL: http://www.jove.com/video/51415
DOI: doi:10.3791/51415
Keywords: Infectious Diseases, Issue 89, innate immune response, virus infection, pathogen recognition receptor, RIG-I, PKR, IRF-3, limited
protease digestion, conformational switch, native PAGE, oligomerization
Date Published: 7/29/2014
Citation: Weber, M., Weber, F. Monitoring Activation of the Antiviral Pattern Recognition Receptors RIG-I And PKR By Limited Protease Digestion
and Native PAGE. J. Vis. Exp. (89), e51415, doi:10.3791/51415 (2014).
Abstract
Host defenses to virus infection are dependent on a rapid detection by pattern recognition receptors (PRRs) of the innate immune system. In
the cytoplasm, the PRRs RIG-I and PKR bind to specific viral RNA ligands. This first mediates conformational switching and oligomerization,
and then enables activation of an antiviral interferon response. While methods to measure antiviral host gene expression are well established,
methods to directly monitor the activation states of RIG-I and PKR are only partially and less well established.
Here, we describe two methods to monitor RIG-I and PKR stimulation upon infection with an established interferon inducer, the Rift Valley fever
virus mutant clone 13 (Cl 13). Limited trypsin digestion allows to analyze alterations in protease sensitivity, indicating conformational changes
of the PRRs. Trypsin digestion of lysates from mock infected cells results in a rapid degradation of RIG-I and PKR, whereas Cl 13 infection
leads to the emergence of a protease-resistant RIG-I fragment. Also PKR shows a virus-induced partial resistance to trypsin digestion, which
coincides with its hallmark phosphorylation at Thr 446. The formation of RIG-I and PKR oligomers was validated by native polyacrylamide
gel electrophoresis (PAGE). Upon infection, there is a strong accumulation of RIG-I and PKR oligomeric complexes, whereas these proteins
remained as monomers in mock infected samples.
Limited protease digestion and native PAGE, both coupled to western blot analysis, allow a sensitive and direct measurement of two diverse
steps of RIG-I and PKR activation. These techniques are relatively easy and quick to perform and do not require expensive equipment.
Video Link
The video component of this article can be found at http://www.jove.com/video/51415/
Introduction
A crucial event in antiviral host defense is the rapid detection of the pathogen by the so-called pattern recognition receptors (PRRs)1,2.
Intracellular detection of RNA virus infection is dependent on two cytoplasmic RNA helicases, RIG-I (retinoic acid inducible gene I) and MDA5
(melanoma differentiation associated protein 5)3-5. RIG-I is composed of two N-terminal caspase recruitment domains (CARDs), a central DECH-
box type RNA helicase domain, and a C-terminal domain (CTD)4,6. Whereas the CTD and the helicase domain are required for recognition of
non-self (viral) RNAs, the CARDs mediate downstream signaling leading to establishment of an antiviral host status.
If RIG-I is in the silent state, i.e. in the absence of a specific RNA ligand, the second CARD interacts with the central helicase domain and keeps
RIG-I in an auto-inhibitory conformation7-11. RIG-I binds to short double-strand (ds) RNA bearing a 5’-triphosphate (5’PPP), long dsRNA, and
polyU/UC-rich RNA, classic signature structures which are present on the genomes of many RNA viruses12-16. Two major characteristics of RIG-
I activation are a switch to a closed conformation6,17 and the homo-oligomerization6,18,19. The conformational switch enhances RNA binding,
exposes the CARDs for downstream signaling, and reconstitutes an active ATPase site8,9,11,20. The formation of oligomeric RIG-I complexes
leads to enhanced recruitment of downstream signaling adaptor molecules to form a platform for antiviral signal transduction11. The RIG-I-
regulated signaling chain eventually activates the transcription factor IRF-3 for up-regulation of interferon (IFN-alpha/beta) genes and hence the
gene expression of interferon stimulated genes (ISGs) for a full antiviral response21,22. One of the best characterized ISGs is the RNA-activated
protein kinase (PKR) 23. PKR belongs to the family of eukaryotic translation initiation factor 2 alpha (eIF2α) kinases and is composed of an
N-terminal double-stranded RNA binding domain and a C-terminal kinase domain. The kinase domain constitutes the dimerization interface
crucial for PKR activation and carries out the catalytic functions of the protein. Binding of PKR to viral dsRNA leads to its conformational change
permitting dimerization and auto-phosphorylation at Thr 446 among other residues. PKR then mediates phosphorylation of eIF2α, thereby
blocking the translation of viral mRNAs23-27.
Both RIG-I and PKR undergo major structural rearrangements, form oligomeric complexes and are post-translationally modified by
phosphorylation/dephosphorylation and ubiquitination10,11,19,23,24,26-29. For a better understanding of which viral RNA structures are activating
RIG-I and PKR (and at what stage viral antagonists could be interfering), it is important to precisely determine the activation status. For
both PRRs it was previously described that activation leads to the emergence of trypsin-resistant protein fragments6,17,30 and higher-order
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oligomers6,18,19. However, given the wealth of literature on these key factors of the antiviral host response1,2,24, application of direct methods
seems comparatively rare. In the hope of stimulating broader usage, we provide convenient and sensitive protocols to robustly analyze the
activation states of RIG-I and PKR. The IFN competent human cell line A549 is infected with an established activator of RIG-I and PKR, the
attenuated Rift Valley fever virus mutant clone 13 (Cl 13)31,32. After a simple lysing procedure, the extracts of infected cells are tested by limited
trypsin digestion/western blot analysis to evaluate conformational switching, and by blue native polyacrylamide gel electrophoresis (PAGE) /
Western blot analysis to measure formation of oligomers.
Protocol
1. Seeding of A549 Cells for Infection
1. Cultivate a T75 flask of A549 cells at 37 °C and 5% CO2 in cell culture medium (DMEM supplemented with 10% FCS, 526.6 mg/l L-glutamine,
50.000 U/l penicillin, and 50 mg/l streptomycin).
2. Before starting to harvest the cells, warm up cell culture medium, PBS and 0.05% trypsin-EDTA in a waterbath heated to 37 °C.
3. Remove the medium and wash the cells with 10 ml PBS. Remove the PBS again.
4. Add 3 ml of trypsin-EDTA and distribute equally in the flask. Transfer the flask in an incubator with 37 °C and 5% CO2.
5. When all cells are detached, add 7 ml of cell culture medium, resuspend the cells, and transfer the cell suspension into a 15 ml Falcon tube.
6. Centrifuge the cells at 800 x g for 5 min at RT, remove the supernatant and resuspend the pellet in 10 ml fresh cell culture medium.
7. Count the cells with a counting chamber.
8. Add 2.5 x 106 cells in 5 ml of cell culture medium in two T25 flasks each. Incubate for 16 hr at 37 °C and 5% CO2. One flask serves for the
mock control and one for Cl 13 infection.
2. Infection with Rift Valley Fever Virus Clone 13 (Cl 13)
1. NOTE: Cl 13 is an attenuated virus mutant which in Germany can be handled under BSL-2 conditions. Please refer to relevant national
guidelines. Other typical IFN inducers would be Sendai virus (strain Cantell) or Newcastle disease virus.
2. Pre-warm PBS, serum-free medium, and cell culture medium containing 5% FCS.
3. Prepare 1.25 x 107 PFU/ml of Cl 13 in serum-free medium to infect 2.5 x 106 A549 cells with a multiplicity of infection (MOI) of 5. Prepare a
slightly (roughly 10%) greater amount than needed to account for pipette errors.
4. Wash the cells with PBS as described under 1.3.
5. Add 1 ml of the Cl 13 dilution or of serum-free medium (uninfected control, mock) to the cells, and incubate for 1 hr at 37 °C and 5% CO2.
Move the flask carefully every 15 min to ensure equal distribution of Cl 13 dilution and serum-free medium, respectively.
6. After 1 hr of infection, remove the inocula, add 5 ml of pre-warmed cell culture medium with 5% FCS, and incubate for 5 hr at 37 °C and 5%
CO2.
3. Preparation of Cell Lysates
1. Prepare PBS / 0.5% Triton X-100 at 4 °C. Do not add serine protease inhibitors.
2. Wash the cells with cold PBS and add 10 ml of fresh PBS.
3. Scrape the cells off, transfer the cell suspension in a falcon tube, and centrifuge at 800 x g for 5 min at RT.
4. Remove the supernatant and resuspend the cell pellet in 30 µl PBS / 0.5% Triton X-100. Transfer the lysate into a fresh 1.5 ml tube and
incubate for at least 10 min at 4 °C.
5. Centrifuge the lysate at 10.000 x g for 10 min at 4 °C and transfer the clarified cell lysate (supernatant) into a fresh tube.
6. Determine the protein concentration by Bradford assay as described elsewhere33.
7. Store at -20 °C or proceed to trypsin digestion (4.1) or native PAGE (5.1).
4. Determination of Conformational Changes of Pattern Recognition Receptors
1. TPCK-trypsin Treatment of Cell Lysates
1. Dilute L-1-tosylamido-2-phenylethyl chloromethyl ketone-treated (TPCK) trypsin in PBS to a final working concentration of 2 µg/µl.
2. Adjust in two new tubes a final protein concentration of 25 µg of each protein lysate (mock or Cl 13) in a final volume of 9 µl with
PBS. Hence, it should be four tubes with 25 µg lysate each, two times mock and two times Cl 13 infection. One set as input control
(untreated) and one set for treatment with TPCK-trypsin.
3. Add 1 µl of PBS (untreated) or 1 µl of 2 µg/µl TPCK-trypsin (final concentration: 0.2 µg/µl) to the cell lysates and mix the reactions by
pipetting. DO NOT freeze and thaw TPCK-trypsin aliquots, because it will compromise the efficiency of digestion.
4. Incubate the lysates at 37 °C for 25 min. Stop the reaction by adding 5x denaturing sample buffer (250 mM Tris-HCl pH 6.8, 10% SDS,
50% glycerol, 25% β-mercaptoethanol, 0.5% bromphenol blue) and by boiling for 5 min at 95 °C. It is important to NOT extend the
trypsin incubation time. In case no protease-resistant fragments are detectable, the time of trypsin digestion must be shortened.
5. After boiling, the samples can be stored at -20 °C.
2. SDS Polyacrylamide Gel Electrophoresis (PAGE) and Western Blotting
1. Load the samples on a sodium dodecyl sulfate (SDS) polyacrylamide gel containing a 5% stacking over a 12% resolving gel. Separate
the proteins at 25 mA per gel until the bromphenol blue runs out.
2. Activate a polyvinylidene fluoride (PVDF) membrane for 30 sec with methanol and put it into transfer buffer (48 mM Tris, 39 mM glycin,
1.3 mM SDS, 20% methanol).
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3. Prepare the blotting with a semidry blotting system and allow the transfer of the proteins at 10 V for 1 hr. Take the membrane out, rinse
it briefly with water, and let it dry.
4. Reactivate the membrane by shortly transferring into methanol. Wash for 5 min with TBS. Block with 10% skim milk in TBS for 1 hr at
RT or at 4 °C O/N. Wash the membrane 3x for 5 min each with TBS.
5. Prepare antibody dilution as recommended in table 1 and incubate the membrane for 1 hr at RT or at 4 °C O/N.
6. Wash the membrane 3x for 10 min each with TBS-T. Add the appropriate secondary antibody coupled with horseradish peroxidase at a
1:20,000 dilution in 1% skim milk in TBS. Incubate 45 min at RT.
7. Wash the membrane 3x for 10 min each with TBS-T, and one additional time with TBS.
8. For signal detection use a commercial chemiluminescense kit and a digital gel imaging system.
3. Coomassie Brilliant Blue G-250 Staining
1. Perform SDS-PAGE as described in 4.2.1. Load samples on an SDS polyacrylamide gel and run the gel at 25 mA per gel until
bromphenol blue runs out.
2. Perform Coomassie Brilliant Blue G-250 staining at RT. Do all incubations under constant shaking.
3. Transfer the gel to the fixation solution containing 40% methanol and 10% acetic acid for 30 min.
4. Exchange the buffer to destaining solution (25% ethanol and 8% acetic acid) and incubate for 5 min.
5. Stain the gel with 0.2% Coomassie Brillant Blue G-250 in 40% methanol and 10% acetic acid for 1 hr.
6. Destain the gel with the destaining solution and exchange the buffer after 10 min, 30 min, and 60 min.
7. Store the gel in 25% ethanol, 8% acetic acid, and 4% glycerol at 4 °C.
8. Perform imaging and analysis as described under 4.2.8.
5. Analysis of Oligomeric States of Pattern Recognition Receptors
1. Native PAGE
1. Prepare 50 µg of cell lysate in a final volume of 10 µl with PBS and add 5× native sample buffer (250 mM Tris-HCl pH 6.8, 1% sodium
deoxycholate, 50% glycerol, 0.5% bromphenol blue) to a final concentration of 1x.
2. Load the samples IMMEDIATELY on a native polyacrylamide gel with 5% as stacking and 8% as resolving gel. Any delay will result in a
loss of native complexes34.
3. Run the gel at 20 mA per gel at 4 °C with 50 mM Tris-NaOH pH 9.0, 384 mM glycin as as anode and 50 mM Tris pH 8.3, 384 mM
glycin, 1% sodium deoxycholate as cathode buffer. After 1.5-2 hr (bromphenol blue band has left the gel approximately 45 min earlier)
the electrophoresis is finished.
2. Western Blotting
1. Activate a polyvinylidene fluoride (PVDF) membrane for 30 sec with methanol and put it into Towbin buffer (25 mM Tris, 192 mM glycin,
0.1% SDS, 20% methanol).
2. Assemble a wet blot chamber according to the manufacturer’s instructions and fill the tank with Towin buffer.
3. Perform the blotting with 250 mA for 1.5 hr at 4 °C.
4. When blotting is finished proceed as described from 4.2.3 on.
Representative Results
Recognition of a viral agonist by RIG-I or PKR triggers conformational switching6,17,30 and oligomerization6,18,27. We assayed these two activation
markers by limited protease digestion and native polyacrylamide gel electrophoresis (PAGE), respectively.
Human A549 cells were infected with Rift Valley fever virus clone 13 (Cl 13), which is characterized by a mutation of the IFN antagonist NSs35,36.
Due to the absence of functional NSs, Clone 13 strongly induces RIG-I and PKR, leading to the establishment of a robust antiviral state in the
cells12,31,32,37.
Trypsin digestion of mock infected cell lysates results in a rapid degradation of RIG-I, whereas Cl 13 infection leads to the generation of a 30
kDa resistant RIG-I fragment Figure 1A. Also PKR shows partial resistance to trypsin digestion in infected samples, which coincides with its
phosphorylation Figure 1A. To monitor efficiency and specificity of trypsin digestion, gels were stained with Coomassie Brilliant Blue G-250.
Untreated samples show equal amounts of loaded proteins Figure 1B. Subjecting mock and Cl 13 cell lysates to trypsin digestion leads to a
comparable decrease of global protein amounts. This demonstrates that trypsin treatment has the same efficiency for mock and Cl 13-infected
samples.
The formation of oligomeric complexes was assayed by native PAGE. In uninfected cells, only monomers of RIG-I and PKR were detected
Figure 2. As additional control we included the transcription factor IRF-3, which is present as a monomer but known to dimerize upon activation
via e.g., RIG-I38. Cl 13 infection leads to a strong accumulation of RIG-I oligomeric complexes in form of a smear and of PKR and IRF-3 dimers/
oligomers as a defined protein band.
These results demonstrate that limited trypsin digestion and native PAGE are useful tools to monitor conformational changes and oligomer
formation of RIG-I and PKR upon infection.
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 Figure 1. Conformational switch of RIG-I and PKR. A549 cells were mock infected or infected with Cl 13 at an MOI of 5. After 5 hr, cells were
lysed in PBS supplemented with 0.5% Triton X-100 and cleared cell lysates were either left untreated or treated with trypsin. Samples were
subjected to SDS PAGE followed by Western blotting (A) or Coomassie staining (B). Blots were stained against RIG-I, PKR, phosphorylated PKR
(Thr 446) and against RVFV nucleoprotein (RVFV N) and beta-actin as infection and loading control, respectively. Please click here to view a larger
version of this figure.
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 Figure 2. Oligomerization of RIG-I, PKR, and IRF-3. Cell lysates of mock and Cl 13-infected cell lysates were subjected to native PAGE followed
by Western blot analysis. Staining was performed with antibodies against RIG-I, PKR, IRF-3, and beta-actin as loading control. PKR oligomers most
likely represent dimers27.  Please click here to view a larger version of this figure.
Discussion
Sensing the presence of viruses and activation of the antiviral type I IFN system are crucial for successful innate immune responses22. Virus
detection is thereby mediated by pathogen recognition receptors (PRRs) like RIG-I and PKR, enabling a rapid response and activation of antiviral
defense mechanisms. Here, we describe two methods to directly evaluate the activation status of RIG-I and PKR.
Limited protease digestion as a tool to monitor conformational changes of RIG-I and PKR was first described by the groups of M. Gale Jr. and
T. Fujita6,17, and J. L. Cole30, respectively. It represents a sensitive method to evaluate sensitivity alterations to trypsin treatment caused by
conformational changes. Applying trypsin digestion, we detected rapid degradation of RIG-I and PKR in mock infected samples, whereas trypsin
treatment of virus-infected cell lysates led to trypsin resistant RIG-I fragments. Similarly, a trypsin resistant PKR fragment was detected upon Cl
13 infection. This was accompanied by PKR phosphorylation at Thr 446, a widely used marker of PKR activation. Comparing trypsin digestion of
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mock and Cl 13 cell lysates by Coomassie staining demonstrates a comparable decrease of global protein levels. This indicates that formation of
resistant fragments is specific for proteins like RIG-I and PKR.
The formation of oligomeric complexes of RIG-I, PKR and IRF-3 was monitored by native PAGE. Subjecting Cl 13-infected cell lysates to native
PAGE, we detected RIG-I, PKR and IRF-3 oligomers, whereas these proteins remained as monomers in mock infected samples. RIG-I needs
to form oligomers to activate downstream pathways. It was hypothesized that RIG-I oligomerization supports recruitment of cofactors to form a
signaling platform for antiviral response mechanisms11. The function of PKR dimerization is not entirely understood. Most likely, the PKR subunits
in the dimer phosphorylate each other25. The type I IFN system is tightly regulated on a transcriptional level, and IRF-3 represents one central
transcription factor for the induction of IFN and ISGs38. Central hallmarks of activation are phosphorylation, dimerization, and translocation to the
nucleus, where it recruits the transcriptional co-activators p300 and CREB-binding protein (CBP) to initiate IFN mRNA synthesis21,39. Analysis of
IRF-3 dimerization is a widely used tool to monitor activation of the type I IFN response38. Therefore, we used the detection of IRF-3 oligomeric
complexes as a proof of principle for the oligomerization assays of RIG-I and PKR oligomerization. Indeed, allowing separation of protein lysates
under non-denaturing conditions, we were able to detect IRF-3 dimerization in Cl 13 infected samples.
Undoubtedly, each lab will need to optimize the protocols of limited protease digestion and native PAGE. If confronted with no detection of
any resistant proteins or too many resistant fragments, one might shorten or prolong the time of digestion, respectively. Differences can also
be due to the specific TPCK-trypsin stock, as preparations slightly differ. Therefore, various TPCK-trypsin concentrations should be tested for
optimization. Cell lysates can be prepared from other cell lines than A549, but adaptations of the protocol might be required. It is recommended
to adjust the amount of total proteins for trypsin digestion and native PAGE according to the expression level of the protein of interest in this
specific cell type. Moreover, limited detection or weak separation of oligomeric complexes by native PAGE can have several reasons and can be
addressed as followed: make sure that the equipment is cleaned to remove remaining denaturing agents, keep all samples and the gel during
the PAGE at 4 °C, and do not extend the time between sample preparation and loading onto the gel. Limited protease digestion and native PAGE
have also been employed to monitor the activation of another important, closely related PRR, MDA540-42. Monitoring of MDA5 activation required
different experimental conditions compared to RIG-I and PKR, and was therefore not included here.
In summary, point-by-point protocols for two useful and sensitive methods to measure activation of RIG-I and PKR are presented. Limited
protease digestion and native PAGE, both coupled to Western blot analysis, permit monitoring of conformational changes and oligomerization,
respectively. Using these methods, we had previously shown that RIG-I can be activated by nucleocapsids of various viruses directly after their
entry into the cells32.
The exact nature and origin of the RNA species relevant for RIG-I and PKR activation in infected cells are still not entirely solved. Furthermore,
many viruses interfere with the functions of PRRs by a wide variety of strategies12,43-46. The presented techniques enlarge the spectrum
of methods by allowing an easy and direct measurement of RIG-I and PKR activation, are quick to perform, and do not require expensive
equipment.
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SUMMARY
Host defense to RNA viruses depends on rapid intra-
cellular recognition of viral RNA by two cytoplasmic
RNA helicases: RIG-I and MDA5. RNA transfection
experiments indicate that RIG-I responds to naked
double-stranded RNAs (dsRNAs) with a triphos-
phorylated 50 (50ppp) terminus. However, the identity
of the RIG-I stimulating viral structures in an
authentic infection context remains unresolved. We
show that incoming viral nucleocapsids containing
a 50ppp dsRNA ‘‘panhandle’’ structure trigger anti-
viral signaling that commences with RIG-I, is
mediated through the adaptor protein MAVS, and
terminates with transcription factor IRF-3. Indepen-
dent of mammalian cofactors or viral polymerase
activity, RIG-I bound to viral nucleocapsids, under-
went a conformational switch, and homo-oligo-
merized. Enzymatic probing and superresolution
microscopy suggest that RIG-I interacts with the
panhandle structure of the viral nucleocapsids.
These results define cytoplasmic entry of nucleocap-
sids as the proximal RIG-I-sensitive step during
infection and establish viral nucleocapsids with a
50ppp dsRNA panhandle as a RIG-I activator.
INTRODUCTION
Host defenses to RNA viruses are dependent on rapid detection
by pathogen recognition receptors (PRRs). Intracellular recogni-
tion of virus infection is mediated by two cytoplasmic RNA heli-
cases: RIG-I and MDA5 (termed RIG-like receptors, RLRs) (Kato
et al., 2011). The binding of an RNA ligand to these PRRs leads to
phosphorylation and dimerization of interferon regulated factor 3
(IRF-3), which subsequently activates genes for type I interferons
(IFN-a/b) (Hiscott, 2007). These cytokines trigger the expression
of IFN-stimulated gene (ISG) products that have antiviral and
immunomodulatory activities (Randall and Goodbourn, 2008).
The infection cycle of RNA viruses consists of the phases
attachment, entry, messenger RNA (mRNA) transcription,
genome replication, assembly, and exit. Negative-strand RNA
viruses carry an RNA-dependent RNA polymerase (RdRp) within
their particles and immediately start transcribing their genome
after entering the cell. The protein products of this so-called
primary transcription then drive the replication of the genome
via a positive-sense intermediate. Positive-strand RNA viruses
do not carry an RdRp in their particles and directly translate their
genome after entry. The newly synthesized RdRp then produces
a negative-sense intermediate, mRNA, and progeny genome.
Usually, the genome of both negative- and positive-strand
RNA viruses is packaged by a viral nucleocapsid protein (often
called N).
Most studies on activation of RLRs were based either on
infection with RNA viruses undergoing a full replication cycle
or on transfection of cells with naked viral or synthetic RNAs.
The infection experiments established that RIG-I and MDA5
recognize mostly nonoverlapping subsets of viruses (McCartney
and Colonna, 2009). The RNA transfection experiments re-
vealed that RIG-I responds to long double-stranded RNA
(dsRNA) molecules, short dsRNAs with a triphosphorylated
50 (50ppp) terminus, and poly-U/UC-rich sequences, whereas
MDA5 activation is more dependent on branched dsRNA struc-
tures (Binder et al., 2011; Hornung et al., 2006; Kato et al., 2008;
Pichlmair et al., 2006, 2009; Saito et al., 2008; Schlee et al., 2009;
Schmidt et al., 2009). Despite these achievements, the question
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of the natural RLR ligands (i.e., which viral structures are stimu-
lating the RLRs in the authentic infection context) is largely
unsolved. Two recent RNA fractionation studies showed that
full-length and shortened RNAs arising during genome replica-
tion of 50ppp-RNA viruses are natural stimulators of RIG-I
(Baum et al., 2010; Rehwinkel et al., 2010). However, it remained
open whether these RIG-I ligands were naked RNA side
products of viral genome replication or whether RIG-I could
also recognize nucleoprotein-encapsidated RNA, the main
viral structure in the infected cell. Our study presented here
addresses this problem and indicates that RIG-I is capable of
reacting to incoming, encapsidated RNA virus genomes. This
immediate early IFN response requires the viral 50ppp dsRNA
‘‘panhandle’’ structure but is independent of viral RNA synthesis.
RIG-I thereby directly interacts with the panhandle on the viral
nucleocapsids, switches conformation, oligomerizes, and trig-
gers the activation of IRF-3.
RESULTS
Our first aim was to identify the earliest infection step that trig-
gers IFN induction. In the hope of drawing conclusions on the
responsible viral determinant, we employed a set of RNA viruses
with different genomic features. Dependent on the particular
virus, a block of viral mRNA translation by cycloheximide (CHX)
has different effects on primary transcription and genome repli-
cation (Table S1 available online).
Entry of Negative-Sense RNA Viruses Can Activate IFN
Induction in the Absence of Replication
Influenza A virus (FLUAV) and vesicular stomatitis virus (VSV) are
negative-strand RNA viruses. Application of CHX allows particle
attachment, entry of nucleocapsids, and primary transcription,
but not genome replication (Figure S1). We measured the
virus-inducible genes for IFN-b and ISG56 in human A549 cells
by real-time RT-PCR. Figure 1A shows that both FLUAV and
VSV are strongly activating these genes, even when CHX was
applied. Thus, an IFN response can occur before the viruses start
replicating their genome.
To narrow down the IFN-relevant infection step, we repeated
the experiment using Rift Valley fever virus (RVFV) and La Crosse
virus (LACV). These bunyaviruses are peculiar in that their tran-
scription depends on concurrent translation (Raju et al., 1989).
CHX treatment arrests viral primary transcription at a very early
step, but had only a minor influence on IFN-b and ISG56 induc-
tion (Figure 1B). Apparently, not even a fully operating primary
transcription is required for triggering an IFN response.
Recent reports suggested that particle attachment or mem-
brane fusion can activate an antiviral response (Holm et al.,
2012; Noyce et al., 2011), although other groups did not observe
this in their systems (Handke et al., 2009; Spiropoulou et al.,
2007; Stoltz and Klingstro¨m, 2010). We employed several
methods to study the involvement of particle attachment. First,
we pretreated cells with NH4Cl, an agent that inhibits bunyaviral
entry into the cytoplasm (Filone et al., 2006) but does not impede
the IFN response (Figure S2A). As shown in Figure 1C, NH4Cl
almost entirely abrogated the host response to RVFV. Similarly,
three other bunyavirus entry inhibitors (de Boer et al., 2012) (Fig-
ure S2B–S2D), as well as virus inactivation by b-propiolactone
(Figure S2E) or UV irradiation (Figure S2F), all led to a reduction
of IFN induction. In a complementary approach, we employed
two types of virus-like particles (VLPs) of RVFV. Complete
VLPs contain nucleocapsids with a reporter minigenome,
whereas ‘‘ghost’’ VLPs have just the N protein inside (Fig-
ure S2G). The complete VLPs, also called transcriptionally
competent (tc-) VLPs (Hoenen et al., 2011), are capable of
Figure 1. IFN Response to Incoming Negative-Strand RNA Viruses
(A–D) Cells were treated with inhibitors, infected, incubated for 24 hr, and then
assayed for mRNA levels of IFN-b (left panels) and ISG56 (right panels) using
real-time RT-PCR. Here and in all following figures, mean values and SDs from
three independent experiments are shown. (A and B) IFN response in the
absence of viral genome replication. Cells were treated for 1 hr with 0 or
50 mg/ml CHX and then infected either with FLUAVDNS1 (FLUAV) and VSV (A)
or with RVFVDNSs::GFP (RVFV) and LACVdelNSs (LACV) (B). (C and D)
Requirement for virus entry. (C) Cells were treated for 1 hr with 0 or 50 mM
NH4Cl and then infected with RVFVDNSs::GFP. (D) Infection with different
types of VLPs. Cells were CHX treated and infected with tc-VLPs or the
equivalent amount of ghost VLPs. See also Figures S1–S2H.
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primary transcription, but not of replication (Habjan et al., 2009a).
tc-VLPs triggered IFN-b and ISG56 expression, even under
CHX (Figure 1D). Ghost VLPs, however, did not elicit any IFN
response, although they bind equally well to the cells (Fig-
ure S2H). These data indicate that, in our system, virus entry
or primary transcription is necessary and sufficient for IFN
induction.
The Immediate Early IFN Response Requires Viral
50Triphosphate RNA and RIG-I
All viruses used so far contained the RIG-I-activating 50ppp
group on their RNA genome (Habjan et al., 2008a; Hornung
et al., 2006; Pichlmair et al., 2006). To clarify the contribution of
the genome end, we employed two RNA viruses that lack this
feature (see Table S1). Prospect Hill virus (PHV; family Bunyavir-
idae) has a monophosphate at the 50 end (Garcin et al., 1995;
Habjan et al., 2008a). Semliki Forest virus (SFV; family Togaviri-
dae) has a 50 cap structure (McInerney et al., 2005). CHX inhibits
PHV in the same way as the related RVFV or LACV (Figure S1).
SFV is a positive-strand RNA virus (i.e., its genome is directly
translated after entry). In the absence of CHX, PHV minimally
activated the IFN-b promoter and moderately activated ISG56
transcription, as expected (Prescott et al., 2005), whereas the
IFN response to SFV was similar to LACV (Figure 2A). Strikingly,
application of CHX completely abrogated the IFN response to
both PHV and SFV. In line with this, the transcription factor
IRF-3 was activated under CHX-restricted infection with VSV
or LACV, but not PHV or SFV (Figure S3A–S3F). Thus, IFN
responses to incoming RNA virus nucleocapsids occur only if
the genome contains a 50ppp.
To pin down the responsible RLR, we evaluated the influence
of specific knockdowns. Cells were transfected with small inter-
fering RNAs (siRNAs) forMDA5, RIG-I, or a control (Figure S3G),
treated with CHX, and infected with VSV or LACV. Knockdown of
RIG-I, but not ofMDA5, impaired IFN induction by VSV and LACV
nucleocapsids (Figure 2B). To bolster these findings, we utilized
mouse embryo fibroblasts (MEFs) deficient in RIG-I or MDA5.
Because these cells were extremely sensitive to CHX (data not
shown), we employed tc-VLPs as a virus system halted at the
stage of primary transcription. MEFs lacking MDA5 displayed
similar host responses to tc-VLPs as WT MEFs (Figure 2C).
MEFs lacking RIG-I, by contrast, completely lost their ability to
respond (Figure 2D). Knockout of MAVS (Seth et al., 2005), the
adaptor common to MDA5 and RIG-I, had a similar impact (Fig-
ure S3H). Taken together, these data suggest that nucleocap-
sids of 50ppp RNA viruses activate an IFN response via the
RIG-I-MAVS signaling cascade.
Activation of RIG-I
Binding of a target RNA to RIG-I triggers a conformational switch
(Saito et al., 2007; Takahasi et al., 2008) and oligomerization
(Binder et al., 2011; Saito et al., 2007). The conformational switch
is indicated by partial resistance to trypsin digestion. We
observed that the full infection cycle of SFV, VSV, and LACV
leads to the emergence of trypsin-resistant fragments of RIG-I
(Figure 3A). When cells had been pretreated with CHX, VSV
and LACV still triggered the conformational switch of RIG-I,
whereas SFV infection had no effect (Figure 3B). The oligomeri-
zation of RIG-I was assayed by native PAGE. In uninfected cells,
only monomers of RIG-I were detected (Figure 3C). Curiously,
also in SFV-infected cells only monomeric RIG-I is present (Fig-
ure 3D), although RIG-I switches conformation (see Figure 3A).
For the 50ppp RNA viruses VSV and LACV, both the full and
the CHX-aborted replication cycle resulted in RIG-I oligomeriza-
tion (Figures 3E and 3F). The 50-monophosphorylated PHV, by
contrast, only weakly activated the conformational switch (Fig-
ure 3G) and not the oligomerization (Figure 3H). Taken together,
these results suggest that RIG-I is rapidly and strongly activated
by viral nucleocapsids in the absence of genome replication,
provided the genome is carrying a 50ppp group.
Interaction between RIG-I and Incoming Nucleocapsids
We wondered whether RIG-I could form a complex with viral
50pppRNAnucleocapsids. As an experimental system,we chose
the setup closest to the immediate early phase (arrested primary
transcription), namely infection with bunyaviruses such as LACV
under CHX treatment. The N protein thereby served as a marker
for viral nucleocapsids. Using confocal immunofluorescence
Figure 2. Influence of the Viral 50ppp Group and of RIG-I
(A) Cells were CHX treated; infected with LACVdelNSs, PHV, or SFV; and
assayed as described in Figure 1.
(B) Innate response to VSV or LACVdelNSs by cells treated with CHX and with
siRNAs targeting MDA5 or RIG-I.
(C and D) MEFs lacking MDA5 (C) or RIG-I (D), and the corresponding
WT MEFs, were tested for their innate response to tc-VLPs. See also Figures
S3A–S3H.
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microscopy, we detected the nucleocapsids of incoming LACV
particles as individual dots in the cytoplasm (Figure 4A). These
LACV N dots colocalize with RIG-I (Figure S4A), as indicated by
overlay pictures and intensity profiles of the fluorescence signals.
Quantitative analysis revealed that LACV nucleocapsids colocal-
ize with RIG-I in 51% of the cases but with the cytoplasmic
control protein glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) in 33% of the cases (data not shown). N/RIG-I colocal-
ization was also observed in cells undergoing a full replication
cycle (data not shown), in agreement with observations on
FLUAV (Onomoto et al., 2012). The incoming LACV nucleocap-
sids also colocalized with peroxisomes (Figure S4B), cyto-
plasmic organelles involved in immediate early activation of
RIG-I (Dixit et al., 2010). Coimmunoprecipitation demonstrated
that RIG-I was capable of binding the incoming LACVnucleocap-
sids (Figure 4B). The same RIG-I/LACV nucleocapsid interaction
was observedwhen a full replication cycle was allowed, whereas
Figure 3. Activation of RIG-I
(A and B) Conformational switch. A549 cells were
treated with 0 (A) or 50 mg/ml CHX (B), infected
with the indicated viruses, and lysed 6 hr later. Cell
extracts were subjected to limited trypsin diges-
tion (right panels) or left untreated (left panels).
Upper panels show western blot analysis with
an anti-RIG-I antibody, and lower panels show
Ponceau S staining as loading control.
(C–F) Oligomerization. A549 cells were left
untreated (UT) or treated with 50 mg/ml CHX. Then,
cells were either mock infected (C) or infected with
SFV (D), VSV (E), or LACVdelNSs (F). At the
indicated time points, RIG-I was analyzed by
native PAGE and western blotting. As positive
and negative controls, VSV-infected cells at 6 hr
postinfection (CTRL) and mock-infected cells,
respectively, were used.
(G and H) PHV and RIG-I. A549 cells infected with
LACVdelNSs or PHV were monitored for the RIG-I
conformation at 6 hr postinfection (G) or for RIG-I
oligomerization over a time course (H). The ratio of
oligomers to monomers (normalized to the actin
signal and in relation to mock cells) is indicated
below the blots (fold induction).
MDA5 did not interact under any condi-
tion (data not shown). Overexpressed N
protein, by contrast, could not be precip-
itated via RIG-I (Figure S4C). We per-
formed similar experiments with RVFV.
Again, incoming nucleocapsids triggered
the conformational switch and oligomeri-
zation of RIG-I and activated IRF-3 (Fig-
ure S4D). Moreover, the nucleocapsids
of RVFV colocalized (Figure S4E) and
coprecipitated with RIG-I (Figure S4F).
Strikingly, incoming nucleocapsids could
be forced into a high-molecular-weight
RIG-I complex. TheATPanalogADP,AlF3
traps RIG-I in an RNA-bound closed
conformation unable to cycle between
the different states (Kowalinski et al.,
2011). When CHX-treated and infected cells were incubated
with ADP,AlF3, the oligomers of RIG-I shifted from a smear into
a single high-molecular-weight band (Figure 4C, upper panels).
Probing of the lysates for the viral Nprotein revealed a similar shift
from an oligomeric state to a high-molecular-weight complex
(Figure 4C, lower panels). This was true for LACV as well as for
RVFV, indicating a general phenomenon. Together, these find-
ings demonstrate that RIG-I is able to associate with nucleocap-
sids of 50ppp RNA viruses directly after entry into the cell, leading
to RIG-I activation and innate immune signaling.
Nucleocapsid Binding and Activation of RIG-I Are
Independent of Mammalian Cofactors
The RIG-I/nucleocapsid interaction could either be direct or
mediated by one of the cellular cofactors of RIG-I (Kato et al.,
2011; Kok et al., 2011; Miyashita et al., 2011). To distinguish
between these possibilities, we employed an insect cell system.
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Drosophila melanogaster cells are a useful tool to reconstitute
mammalian signaling complexes in a background-free setting
(Yang and Reth, 2012) and are infectable with RVFV (Kortekaas
et al., 2011). When human RIG-I was expressed in Drosophila
D.mel-2 cells, conformational switching and oligomerization
were observed after infection with RVFV (Figures 5A and 5B).
RIG-I was also activated in vitro by mixing of lysates from RIG-
I-transfected D.mel-2 cells with lysates of infected D.mel-2 cells
(Figure 5C). Coimmunoprecipitation experiments demonstrated
binding of RIG-I to viral nucleocapsids in the Drosophila system
(Figure 5D). Again, this nucleocapsid interaction was indepen-
dent of whether RIG-I contacted RVFV during authentic virus
infection or whether lysates containing either RIG-I or RVFV
nucleocapsids were mixed in vitro. Thus, activation and nucleo-
capsid interaction of RIG-I occur in a direct manner and without
the contribution of a mammalian cofactor.
Nucleocapsid-Borne 50ppp-dsRNA Is Necessary and
Sufficient for RIG-I Activation
Our experiments with bunyaviruses and CHX implicated that the
transcriptional activity of nucleocapsids may not be relevant for
RIG-I activation. However, CHX still allows some abortive tran-
scription (Raju et al., 1989). To clarify whether RIG-I requires
this residual RNA synthesis, we performed several experiments.
First, we depleted the cellular NTP pool with the compounds
Brequinar (BRQ; inhibits pyrimidine synthesis), mycophenolic
acid (MA; reduces GTP levels), pyrazofurin (PYF; reduces CTP
and UTP levels), or cyclopentenylcytosine (CPEC; depletes the
CTP pool) (Linke et al., 1996; Qing et al., 2010). Each of these
inhibitors affected viral RNA synthesis (Figure S5A). Nonethe-
less, even when combinedwith CHX, neither inhibitor diminished
RIG-I activation by LACV (Figure 6A). In fact, some of the com-
pounds slightly increased RIG-I activation and enhanced the
activation of IRF-3 (Figure 6A). Second, we depleted Drosophila
D.Mel-2 cell lysates containing either RIG-I or nucleocapsids
from NTPs by dialysis. When these dialyzed lysates were mixed
with each other, the conformational switch of RIG-I still occurred
and was enhanced by adding back ATP (Figure 6B). Third, we
employed nucleocapsids that had been isolated from purified
virus particles. Dialyzed RIG-I-containing D.Mel-2 extracts
were incubated with nucleocapsids of RVFV or LACV. The nucle-
ocapsids clearly induced the conformational switch of RIG-I
in vitro (Figure 6C). We conclude from these experiments that
viral transcription is not necessary for triggering RIG-I. As out-
lined above, the genomic RNA of bunyaviruses forms a
panhandle structure that has remarkable similarity with the
optimal 50ppp dsRNA ligand identified by transfection and
in vitro binding experiments (Figure S5B). Indeed, destroying
the dsRNA structures with RNase III or cleaving the triphos-
phates with a phosphatase abolished the ability of viral nucleo-
capsids to activate RIG-I (Figures 6D and 6E). Treatment with
the single-stranded RNA-specific RNase A, by contrast, had
no effect. Thus, a 50ppp dsRNA structure is indeed necessary
for the activation of RIG-I by nucleocapsids.
Figure 4. Interaction of RIG-I with LACV Nucleocapsids
(A) Colocalization analysis. CHX-treated A549 cells were infected with LACVdelNSs and analyzed 5 hr later by double immunofluorescence using antisera against
LACV N (green channel) or RIG-I (red channel). Cell nuclei were counterstained with DAPI (blue channel). The square area of the inset is digitally magnified on the
right hand side. Three fluorescence intensity profiles are shown on the bottom.
(B) Coimmunoprecipitation. CHX-treated A549 cells were infected with LACVdelNSs (moi 10), lysed 5 hr later, and subjected to IP and western blot analysis using
antibodies against p21 (negative control), LACV N, and RIG-I. As input control, 10% of the cell lysate were analyzed in parallel (left lanes).
(C) ADP-aluminum fluoride trapping. CHX-treated A549 cells were infected with LACVdelNSs (left panels) or RVFVDNSs::REN (right panels). At 5 hr postinfection,
lysates were incubated with ADP,AlF3 and analyzed by native PAGE andwestern blot using antibodies against RIG-I (upper panels) or viral N (lower panels). Lines
indicate oligomers, arrowheads monomers, and arrows point toward high-molecular-weight complexes. See also Figures S4A–S4F.
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ASingle Site on theNucleocapsids Is Contacted by RIG-I
We employed ground state depletion (GSD) microscopy to
visualize the RIG-I/LACV nucleocapsid complex at 20 nm
resolution. This technique allows the display of individual nucleo-
capsids in their characteristic pseudocircular shape (Figure 7,
green channel), which is caused by the dsRNA panhandle for-
mation between the 50 and 30 genome ends (Obijeski et al.,
1976). Strikingly, accumulations of RIG-I are contacting nucleo-
capsids at a single site, lending the cocomplexes a ‘‘diamond
ring’’-like appearance (Figure 7, red channel). The negative
control GAPDH, by contrast, appeared to be more distant and
not accumulated at the nucleocapsids (Figure S6). These ob-
servations add additional weight to our hypothesis that RIG-I
binds the nucleocapsids via the terminal 50ppp dsRNA
panhandle.
DISCUSSION
The aim of our study was to clarify whether RIG-I is capable of
recognizing the RNA contained within incoming viral nucleocap-
sids. Our results indicate that this is indeed the case. RIG-I was
rapidly activated by viruses with the prototypical 50ppp dsRNA
panhandle structure, even when viral RNA synthesis was abol-
ished. Moreover, we detected a direct, single-site interaction
between RIG-I and nucleocapsids that was dependent on
50ppp dsRNA. Thus, viral nucleocapsids containing a 50ppp
panhandle represent a pathogen-associated molecular pattern
(PAMP) for RIG-I. These findings advance the proximal RIG-I-
sensitive step of the viral infection cycle from the late stage
of genome replication (Baum et al., 2010; Rehwinkel et al.,
2010) to the immediate early step of nucleocapsids entering
the cytoplasm.
Erroneous, nonencapsidated replication products appear
during infection with FLUAV (Vreede et al., 2004). It is quite likely
that such naked replication products (Rehwinkel et al., 2010;
Vreede et al., 2004), along with defective interfering RNAs
(Baum et al., 2010; Killip et al., 2011; Strahle et al., 2006) and
newly formed nucleocapsids (this study), are responsible for
RIG-I induction under a full viral multiplication cycle. Previous
reports already demonstrated that genome replication is not an
absolute requirement for IFN induction (Killip et al., 2012; Marcus
and Sekellick, 1980) and that transfected nucleocapsids of the
50ppp viruses measles and VSV can activate IRF-3 even if they
are transcriptionally inactive (tenOever et al., 2002, 2004).
None of these studies, however, had addressed the involvement
of RIG-I or the requirement for a specific 50 genome end. Our
work extends their conclusions by showing that incoming viral
nucleocapsids can directly activate RIG-I, thus triggering a rapid
innate immune response.
It remains to be shown how RIG-I manages to access the
encapsidated viral RNA. Although the dsRNA-panhandle struc-
ture is covered by the viral polymerase (Resa-Infante et al.,
2011), some cytoplasmic exposure is necessary (e.g., to initiate
mRNA transcription). The global presence of RIG-I in the
Figure 5. Activation of RIG-I and Binding to Viral Nucleocapsids in Insect Cells
(A and B) D.Mel-2 cells expressing human RIG-I were infected for 72 hr with RVFVDNSs::REN (RVFV) and then tested for RIG-I conformation (A) and oligo-
merization (B).
(C) In vitro activation of RIG-I. Lysates of RIG-I-expressing D.Mel-2 cells weremixed with lysates of naive or RVFVDNSs::REN-infected D.Mel-2 cells and assayed
for RIG-I conformation.
(D) Coimmunoprecipitation. D.Mel-2 cells were either left naive (mock), or only infected with RVFVDNSs::REN (RVFV), only expressing RIG-I (RIG-I), or were both
expressing RIG-I and superinfected with RVFVDNSs::REN (RIG-I / RVFV). Combinations of lysates were subjected to IP and western blot analysis using anti-
bodies against RVFV N or RIG-I. As input control, 10% of the cell lysate were analyzed in parallel (left lanes).
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cytoplasm and its high affinity for 50ppp dsRNA may allow to
rapidly entrap a panhandle, even if it is only briefly exposed.
Our observation of an early and substantial formation of RIG-I
oligomers in response to incoming nucleocapsids supports this
hypothesis.
The standard model of RIG-I activation implies that ligand
binding induces a conformational change followed by oligomer-
ization (Kowalinski et al., 2011; Saito et al., 2007; Takahasi et al.,
2008). Interestingly, oligomerization seems not to be a strict
consequence of the conformational switch. While infection with
the negative-stranded 50ppp-RNA viruses VSV, LACV, and
RVFV triggers both the conformational switch and the oligomer-
ization, infection with the positive-strand 50capped RNA virus
SFV triggers only the conformational switch. It is known that
innate immune recognition of SFV occurs mainly through
MDA5 with a modest contribution from RIG-I (Schulz et al.,
2010). VSV, LACV, and RVFV are mainly recognized by RIG-I
(Habjan et al., 2008a; Kato et al., 2006; Verbruggen et al.,
2011). Thus, a weak RIG-I trigger like SFV may only cause the
conformational switch, whereas stronger RIG-I triggers continue
to the subsequent oligomerization.
We have introduced Drosophila cells as a tool to establish that
RIG-I activation occurs independent of mammalian cofactors. In
mammalian cells, RIG-I is fine-tuned by inhibitors and cofactors.
The Drosophila cells, which can coexpress up to 12 different re-
combinant proteins (Yang and Reth, 2012), hold promise as
a system to reconstitute the RIG-I signaling complex for studying
the details of its regulation.
The classical studies on PRRs and PAMPs involved the usage
of purified RNA ligands. However, as we and others (Baum and
Garcı´a-Sastre, 2011; Kato et al., 2011) have pointed out, viral
RNAs in their physiological context are complexed with host
cell or viral proteins. Recent reports on the PRRs PKR and
TLR3 provide increasing evidence that protein-bound RNA
ligands are comparable or even more powerful PRR ligands
than naked RNAs (Dauber et al., 2009; Lai et al., 2011). It would
be interesting to test other PRRs for activation by physiological
nucleic acid-protein complexes.
In summary, our results indicate that RIG-I, the major intracel-
lular PRR for viral pathogens, is capable of recognizing the
50ppp-dsRNA of viral nucleocapsids. This enables a cytoplasmic
response to incoming negative-strand RNA viruses at the earliest
possible time point of infection.
EXPERIMENTAL PROCEDURES
Cells, Viruses, Plasmids, and Reagents
A549, 293T, and MEFs deficient in RIG-I, MDA5 (Kato et al., 2006), or MAVS
(Seth et al., 2005) were cultivated in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (FCS) at 37C and 5%
CO2. D.Mel-2 cells (GIBCO) were cultivated in Spodopan (Pan Biotech)
at 28C with no additional CO2. VSV, SFV, FLUAVDNS1 (Garcı´a-Sastre
et al., 1998), RVFVDNSs::GFP (Habjan et al., 2008b; Kuri et al., 2010),
Figure 6. Activation of RIG-I Solely
Depends on the Nucleocapsid-Borne
Panhandle Structure
(A) Effect of NTP withdrawal on activation of RIG-I
and IRF-3. Pretreated A549 cells were infected
with LACVdelNSs for 5 hr. Pretreatment with CHX
(50 mg/ml) was for 1 hr and with BRQ (10 mM,
stocks dissolved in DMSO), MA (10 mM, stocks
dissolved in methanol), PYF (10 mM, stocks dis-
solved in DMSO), or CPEC (5 mM, stocks dissolved
in DMSO) for 24 hr. RIG-I conformation (upper
two panels), RIG-I oligomerization (upper middle
panel), and IRF-3 phosphorylation (lower middle
panel) were monitored. Immunoblot for actin
served as loading control.
(B) RIG-I activation in dialyzed samples. Lysates
from D.Mel-2 cells expressing RIG-I (RIG-I) or in-
fected with RVFVDNSs::REN (RVFV) were dia-
lyzed against PBS, mixed with each other, and
incubated with or without ATP. After 1 hr incuba-
tion, mixes were subjected to the RIG-I confor-
mational switch assay.
(C) RIG-I activation by purified viral nucleocap-
sids (RNPs). Lysates from D.Mel-2 cells ex-
pressing RIG-I were dialyzed against PBS and
mixed with purified nucleocapsids from particles
of LACV (left panels) or RVFV (right panels).
Incubation with ATP and conformational switch
assay were performed as described for (B).
Equivalent fractions of gradient-purified super-
natants from mock-infected cells were used as
negative control (CTRL).
(D and E) Structural requirements for viral nucleocapsids to activate RIG-I. Lysates from RVFV-infected D.Mel-2 cells (D) or purified RVFV nucleocapsids (E) were
incubated with ATP and one of the indicated enzymes, namely RNase A (A), RNase III (III), or SAP. After mixing and incubation with dialyzed lysates from RIG-I-
expressing D.Mel-2 cells, the RIG-I conformational switch assay was performed. Negative controls (CTRL) were performed as described for (C). See also Figures
S5A and S5B.
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RVFVDNSs::REN (Habjan et al., 2008b; Kuri et al., 2010), and LACVdelNSs
(Blakqori et al., 2007) were propagated on Vero cells. Plasmids pI.18_RVFV_N,
pI.18_RVFV_L, pI.18_RVFV_M, and pHH21_RVFV_vMGFP were described
previously (Habjan et al., 2008b, 2009a). Plasmid pRmHA3-RIG-I was con-
structed by cloning a PCR-generated RIG-I complementary DNA (cDNA) frag-
ment into pRmHA3 (Bunch et al., 1988) using engineered 50 KpnI and 30 SalI
restriction sites. Primer sequences are available upon request. CHX, NH4Cl,
CuSO4, BRQ, and MA were from Sigma. PYF (NSC-143095) and CPEC
(NSC-375575) were kindly obtained from the Drug Synthesis and Chemistry
Branch of the National Cancer Institute.
Production of VLPs
RVFV VLPs were generated as described previously (Habjan et al., 2009a).
Briefly, subconfluent monolayers of 293T cells in 90 mm dishes were
transfected with 3 mg each of pI.18_RVFV_N, pI.18_RVFV_L, pI.18_RVFV_M,
and pHH21_RVFV_vMGFP (tc-VLPs), or pI.18_RVFV_N and pI.18_RVFV_M
only (ghost VLPs) usingNanofectin (PAALaboratories). At 5hr posttransfection,
medium was changed and 48 hr later supernatants collected and clarified
fromcell debris by centrifugation (6,0003g, 10min at 4C). VLPswere concen-
trated with Amicon Ultra-15 (Millipore) Ultracel-100 kDa filter devices.
Infection of Cells
Cells grown to 90% confluency were inoculated for 1 hr with viruses or
VLPs dissolved in 200 ml OptiMEM (Invitrogen; for mammalian cells) or Spodo-
pan (for insect cells) at a multiplicity of infection (moi) of 5. FLUAVDNS1 was
washed off with PBS, whereas for all other infections the inoculumwas directly
replaced with DMEM 5% FCS (mammalian cells) or Spodopan (insect cells). If
required, cells were pretreated with inhibitors dissolved in complete medium
for 1 hr (CHX, NH4Cl) or 24 hr (BRQ, MA, PYF, CPEC). The inhibitors were
also added to the virus inoculum and the incubation medium.
Real-Time RT-PCR
Cellular RNA was isolated with the NucleoSpin RNA II kit (Macherey-Nagel).
A total of 600 ng was used for cDNA synthesis and PCR employing the
QuantiTect SYBR Green RT-PCR Kit (QIAGEN) and a LightCycler II (Roche).
mRNAs of human and murine IFN-b and ISG56 were detected with specific
QuantiTect primers (see Supplemental Information) and normalized against
g-actin (human cells) or GAPDH (murine cells) using the ddCT method (Livak
and Schmittgen, 2001). Upregulation of inducible genes is depicted in relation
to nonstimulated, noninfected (mock) cells.
siRNA Knockdown
Knockdown of gene expression was achieved by 2-fold reverse transfection of
siRNAs. siRNAs (25 nM each; see Supplemental Information) were diluted in
100 ml DMEM, mixed with 3 ml HiPerFect (QIAGEN), incubated for 10 min at
room temperature, and dropped onto a 12-well plate. Then, 1.5 3 105 cells
in DMEM 10% FCS were seeded on top. After 48 hr at 37C, cells were
harvested, counted, and 1.5 3 105 cells were again reverse transfected as
described.
Activation State of RIG-I
To assay the conformation of RIG-I, cells were lysed in PBS/0.5% Triton X-100
and incubated on ice for 10 min. Then, samples were sonified in a Branson
3200 Ultrasonic cleaner at 4C for 10 min and centrifuged at 4C for 10 min
at 10,000 3 g. An aliquot of 25 mg of total protein in 10 ml PBS was digested
for 25 min with 0.2 mg/ml L-1-tosylamido-2-phenylethyl chloromethyl ketone-
treated trypsin (Sigma-Aldrich) at 37C. Reaction was stopped by adding 53
sample buffer (250 mM Tris-HCl [pH 6.8], 10% SDS, 50% glycerol, 25%
b- mercaptoethanol [b-ME], 0.5% bromphenol blue) and heating at 95C for
5 min. Samples were subjected to 12% SDS-PAGE and western blot analysis
using mouse monoclonal anti-RIG-I antibody (ALME-1; Enzo Life Sciences) at
1:1,000. Staining of the blot with 0.1% Ponceau S in 5% acetic acid served as
a loading control.
To investigate the oligomerization of RIG-I, 50 mg of sonified cell lysate in
native loading buffer (50 mM Tris-HCl [pH 6.8], 10% glycerol, 0.1% bromphe-
nol blue) was loaded onto a nondenaturing 8% polyacrylamide gel. Proteins
were separated by electrophoresis with 50 mM Tris-NaOH (pH 9.0), 384 mM
glycin as anode buffer and 50 mM Tris (pH 8.3), 384 mM glycin, 1% sodium
deoxycholate as cathode buffer. Western blot analysis was performed as out-
lined above.
Immunofluorescence Assays
Cells were grown on coverslips to 30%–50% confluency, infected, and incu-
bated for the indicated time. Cells were fixed with 3% paraformaldehyde, per-
meabilized with 0.5% Triton X-100 in PBS, and washed three times with PBS.
Primary antibodies were diluted in PBS/1% FCS. Primary antibodies were
either rabbit polyclonal anti-LACV N (1:1,000) (Blakqori et al., 2007) or rabbit
polyclonal anti-RVFV N (1:1,000) (Lorenzo et al., 2008) combined with mouse
polyclonal anti-human RIG-I (1:200) (Baum et al., 2010). After 1 hr incubation at
room temperature, coverslips were washed three times in PBS then treated
with goat anti-rabbit Cy2 and goat anti-mouse Cy3 at a dilution of 1:200. After
washing three times in PBS, coverslips were mounted with Fluorsave solution
(Calbiochem) and examined using a Leica SP5 confocal microscope.
For the superresolution microscopy, a Leica SRGSDmicroscope was used.
Samples were prepared as described for confocal microscopy except that
goat anti-rabbit Alexa Fluor 488 (LACV N) and goat anti-mouse Alexa Fluor
647 (RIG-I) were employed as secondary antibody antibodies. Samples
were embedded in freshly prepared 100 mM b-mercaptoethylamine in PBS
(pH 7.4) directly before imaging.
Coimmunoprecipitation Assays
Cells grown in two T175 flasks were scraped off in 10 ml PBS, centrifuged at
low speed, and the pellets lysed in 1,050 ml RIPA buffer (prepared with
DEPC-treated H2O) containing protease inhibitors, incubated on ice for
30 min and centrifuged at 4C for 10 min at 10,000 3 g. Supernatants were
transferred to fresh tubes and 10% kept as input control. The remaining
90% of the lysates were subjected to immunoprecipitation (IP) using Dyna-
beads (Invitrogen). In parallel, 1.5 mg beads per IP were coupled with the
appropriate antibodies using the Dynabeads antibody coupling kit (Invitrogen).
For the anti-p21 and anti-RIG-I IPs, beads were coupled with rabbit polyclonal
anti-mouse antibody (DAKO); for the anti-LACV N IP, beads were coupled
with rabbit polyclonal anti-LACV N (each at a 1:200 dilution per IP); and for
Figure 7. Superresolution Immunofluorescence Microscopy of RIG-
I/LACV Nucleocapsid Complexes
CHX-treated A549 cells were infected with LACVdelNSs and analyzed 5 hr
later by GSD double immunofluorescence using antisera against LACV N
(green channel) or RIG-I (red channel). Four example areas with nucleocapsids
are shown. Scale bar represents 200 nm. See also Figure S6.
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the anti-RVFV N IP, beads were coupled with mouse polyclonal anti-N serum
(Habjan et al., 2009b) for 20 hr at 37C. After antibody coupling, beads were
washed two times with RIPA buffer, and the anti-mouse antibody beads
were further incubated with mouse monoclonal anti-p21 (Santa Cruz Biotech-
nology) or mousemonoclonal anti-RIG-I antibody ALME-1 at a 1:200 dilution in
RIPA buffer for 2 hr at 4C. The beads were then incubated with the lysates for
2 hr at 4C and the immunoprecipitates washed three times with RIPA buffer
and then eluted with sample buffer (50 mM Tris-HCl [pH 6.8], 2% SDS, 10%
glycerol, 5% b-ME, 0.1% bromphenol blue) for 5 min at 95C. Eluates were
analyzed by western blotting using rabbit polyclonal anti-LACV N or anti-
RVFV N antisera (1:1,000), mouse monoclonal anti-RIG-I antibody ALME-1
(1:1,000), or mouse monoclonal anti-p21 (1:500). Protein A horseradish perox-
idase conjugate (Millipore; 1:10,000) was used for detection.
ADP-Aluminum Fluoride Trapping
ADP,AlF3 trapping was performed essentially as described elsewhere
(Chaney et al., 2001). Briefly, 50 mg cell protein was prepared in STA buffer
(25 mM Tris-acetate [pH 8.0], 8 mM Mg-acetate, 10 mM KCl, 3.5% w/v PEG
6000, 1 mM DTT) with 0.2 mM ADP and 10 mM NaF and incubated at 37C
for 5 min. After addition of 0.4 mM AlCl3, the reactions were incubated for
further 10 min and then supplemented with native loading buffer (50 mM
Tris-HCl [pH 6.8], 10% glycerol, 0.1% bromophenol blue). Native gel electro-
phoresis and western blot analysis were performed as described above.
Expression of RIG-I in Drosophila Cells
D.Mel-2 cells (13 107) resuspended in 10 ml Spodopan were transfected with
16 mg pRmHa3-RIG-I plasmid mixed with 48 ml Cellfectin (Invitrogen) and
incubated at 28C in T75 flasks. RIG-I expression was induced 48 hr later
with 1 mM CuSO4, and 24 hr later cells were scraped off in 10 ml PBS. Cells
were pelleted by 5 min centrifugation at 100 3 g and resuspended in 800 ml
RIPA buffer (for IPs) or in 150 ml 0.5% Triton X-100 in PBS (for RIG-I assays).
The suspensions were incubated for 10 min at 4C and centrifuged at
10,000 3 g, and the supernatants were kept at 4C.
Dialysis and ATP Supplementation of Cell Lysates
Visking dialysis tubing 27/32 with a diameter of 21 mm (Serva Electrophoresis)
was used to deplete cell lysates from low-molecular-weight compounds. The
membrane tubes were activated by submerging in H2O and boiling for 1 min in
the microwave oven, followed by a transfer into H2O at room temperature. For
cell lysates, 100 ml was dialyzed at 4C against PBS in 1 ml Eppendorf tubes
covered with the dialysis membrane. For nucleocapsids, 10 ml was dialyzed
using 200 ml PCR tubes. The buffer was exchanged after 1 hr, 12 hr, and
then again 1 hr later. To test the contribution of ATP, lysates or nucleocapsids
were first mixed and then incubated with or without 1 mM ATP for 1 hr at 37C.
The RIG-I conformational switch assay was performed as indicated above.
Purification of Viral Nucleocapsids
BHK cells seeded in ten T175 flasks were infected with virus at an moi of 0.01.
Cell supernatants were harvested at 3 days later and virions purified by centri-
fugation through a 30% glycerol cushion at 25,000 rpm for 1.5 hr at 4C in
a SW-32 rotor. Pellets were resuspended in hypotonic lysis buffer (10 mM
Tris/HCl [pH 7.8], 150 mM NaCl, 1 mM EDTA, 1% NP40) in the presence of
complete protease inhibitors (Roche). Nucleocapsids were purified in a CsCl
gradient as described elsewhere (Mavrakis et al., 2002), with minor modifica-
tions. Briefly, the cleared lysate was loaded on top of a continuous 20%–40%
CsCl gradient in 20 mM Tris/HCl (pH 7.9), 200 mM NaCl, centrifuged at
52,000 rpm for 2 hr at 12C in a SW60 rotor, and the recovered fraction pelleted
at 45,000 rpm for 1 hr at 4C in a TLA45 rotor. Nucleocapsids were resus-
pended in PBS and dialyzed against PBS to remove residual CsCl. Nucleo-
capsid-containing fractions were identified by SDS-PAGE with Coomassie
blue staining and western blot analysis.
Enzymatic Treatment of Lysates
Dialyzed lysates of RVFV-infected D.Mel-2 cells (50 mg protein in 10 ml) or
nucleocapsids were supplemented with 1 mM ATP and incubated either
with 5 mg RNase A, 1 U RNase III, or 2 U shrimp alkaline phosphatase (SAP)
for 1 hr at 37C. Samples were then mixed 1:1 with dialyzed lysates from
RIG-I-expressing D.Mel-2 cells (50 mg protein in 10 ml) and incubated for 1 hr
at 37C. The RIG-I conformation assay was performed with half of the sample,
whereas the other half was kept as input control.
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Table S1 
 
Viral 
system1 
Genome 
polarity2 
Genome 5’end  Attachment Primary 
transcription 
Genome 
replication / 
secondary 
transcription 
Earliest 
step 
affected by 
CHX3 
FLUAV (-) pppAGCGAAAGCA... 
(Segment 1 of 8) 
yes yes yes Genome 
replication 
VSV 
 
(-) pppACGAAGACAA... yes yes yes Genome 
replication  
RVFV (-) pppACACAAAGAC... 
(3 segments) 
yes yes yes Primary 
transcription 
RVFV tc-
VLPs  
(-) pppACACAAAGAC... 
(M segment ends) 
yes yes no Primary 
transcription 
ghost 
VLPs 
none None yes no no none 
LACV (-) pppACACAAAGAC... 
(3 segments) 
yes yes yes Primary 
transcription 
PHV      
 
(-) pUAGUAGUAGU... 
(3 segments) 
yes yes yes Primary 
transcription 
SFV (+) m7GATGGCGGATG...   
 
yes n.a.4 n.a. Genome 
replication  
1Virus abbreviations: FLUAV, influenza A virus; LACV, La Crosse virus; PHV, Prospect Hill virus; RVFV, Rift 
Valley fever virus; SFV, Semliki Forest virus; VLPs, virus-like particles; VSV, Vesicular stomatitis virus. 2(-): 
negative-strand RNA virus, (+): positive-strand RNA virus. 3CHX, Cycloheximide. 4n.a., not applicable 
 
 
 
Figure S1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Effect of CHX Treatment on Viral RNA Synthesis (related to all figures) 
A549 cells were either left untreated, or pretreated with CHX (50 µg/ml) for 1 h at 37°C, and 
infected with viruses at an MOI of 1. Seven hours (RVFV) or twelve hours (all other viruses) 
post-infection, cells were lysed and the total cell RNA was extracted. Viral RNA levels were 
measured by real-time RT-PCR as indicated in Supplemental Experimental Procedures. 
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Figure S2 
 
 
 
 
 
Figure S2. Control Experiments, Methods, and Tools for Investigating IFN Induction by 
Incoming Virus Particles (related to Figure 1) 
(A) ISG response to IFN is unaffected by NH4Cl. A549 cells were treated for 1 h with 0 or 
50 mM NH4Cl, and then either transfected with 500 ng RNA of RVFV∆NSs::GFP particles 
(vRNA), or treated with 1000 U/ml IFN-α (IFN). IFN-β and ISG56 mRNA levels were 
analyzed 24 h later by real-time RT-PCR. (B, C, and D) RVFV entry inhibitors and the 
IFN response. (B) A549 cells were treated for 1 h either with 8 µl DMSO, or with 100 nM of 
Bafilomycin A (BafA) in DMSO, and infected and analysed as described for Figure 1C. (C) A 
parallel experiment employing 160 µM of Dynasore (DynS), or 40 µM of Chlorpromazine 
(ChPZ), each dissolved in DMSO. (D) Real-time RT-PCR analysis for the RVFV L gene as 
described (Bird et al., 2007). (E and F) IFN response to inactivated virus particles. A549 
cells were infected with RVFV∆NSs::GFP particles inactivated with ß-propiolactone (ß-PL) 
(E) or irradiated with UV (λ=311 nm) for the indicated period of time (F). (G) Production of 
RVFV VLPs. (Upper left panel) Biological activity of GFP-expressing tc-VLPs. BSR-T7/5 
cells were transfected with plasmids for RVFV N and L and 24 h later infected with tc-VLPs. 
At 24 h post infection, GFP-positive cells were observed by fluorescence microscopy. (Upper 
right panel) Concentrated tc-VLPs or ghost VLPs, or cell lysate of RVFV-infected Vero cells 
were loaded on a 12% polyacrylamide gel and tested by immunoblot using pan-specific anti-
RVFV mouse antiserum. (Lower panel) Ghost VLP preparations contain intact particles 
which protect the N from trypsin digestion. Recombinant RVFV nucleoprotein rN (0.2µg) 
containing a His-tag (His-N), as well as RVFV∆NSs::GFP, tc-VLPs, and ghost VLPs purified 
by ultracentrifugation were exposed to trypsin (100 µg/ml), and incubated for 30 min at 37° 
C. Samples were immunoblotted using an anti-RVFV N antibody. Fractions of trypsin-
sensitive N indicate the presence of free N secreted by infected and transfected cells, as 
observed earlier (Kortekaas et al., 2011). (H) Attachment of VLPs. A549 cells were 
incubated with RVFV VLPs that are either complete (tc-VLPs), or for which either the 
polymerase (-L), the glycoproteins (-M), or the polymerase and the minireplicon (ghost 
VLPs) were omitted. RVFV∆NSs::REN infection served as positive control (RVFV). Cells 
were infected for 1 h at 4°C, fixed with 3% paraformaldehyde and analyzed by 
immunofluorescense using rabbit anti-RVFV N antiserum (1:200, green channel) and Hoechst 
33342 (blue channel) as nuclear counterstain. Note that cells were not permeabilized prior to 
analysis. Therefore only particles attached to the cells are detected. Figures S2A to F show 
mean values and standard deviations from three independent experiments. 
  
Figure S3 
 
 
 
 
 
 
 
 
 
 
 Figure S3. Companion Experiments and Controls for the Influence of the 5’ppp Group 
and RIG-I / MAVS Signaling on IFN Induction (related to Figure 2) 
(A to F) Activation of IRF-3 in dependence of viral 5’ genome ends. A549 cells were left 
untreated (UT) or treated with 50 µg/ml CHX. Then, cells were either mock infected (A) or 
infected with SFV (B), VSV (C), or LACVdelNSs (D) as described for Figure 1. At the 
indicated time points post-infection, cells were lysed with RIPA buffer and protein extracts 
cleared from cell debris separated by native PAGE. The presence of phospho-IRF-3 (P-IRF-3) 
and actin, and the oligomerization state of total IRF-3 were analyzed by Western blot using 
specific antisera. As internal controls, lysate from VSV-infected cells at 6 h post-infection 
was used as positive control for the mock infected cells (CTRL), and lysates from mock 
infected cells were used as negative control for the virus-infected cells. (E) Subcellular 
localization of IRF-3 in LACV-infected cells. A549 cells were treated with CHX or left 
untreated, and then mock infected or infected with LACVdelNSs. Upper panel shows 
representative examples of immunofluorescence analyses for IRF-3 (green). Graph shows 
statistics (mean and standard deviations) of the IRF-3 subcellular localization from a total of 4 
independent experiments, in each of which 100 cells were randomly chosen. (F) PHV and 
IRF-3 activation. A549 cells were mock infected or infected with LACVdelNSs or PHV, and 
6 h later monitored for IRF-3 phosphorylation and dimerisation as described for panels A to 
D. (G) Knockdown of intracellular PRRs. A549 cells were transfected with a negative 
control siRNA (CTRL), or with siRNAs directed against MDA5 or RIG-I. After two rounds 
of transfection, cells were either infected as indicated for Figure 2B, or lysed and tested for 
the presence of the siRNA targets by western blot analysis. MDA5 was immunodetected 
using rabbit polyclonal antiserum NBP1-03299 (1:500; Novus Biologicals), actin and RIG-I 
were immunodetected as indicated for A–D and Figure 3, respectively. (H) Host response to 
RVFV primary transcription in MAVS knockout cells. wt MEFs or MEFs lacking the 
MAVS gene were infected with transcriptionally competent RVFV VLPs expressing a GFP 
reporter minireplicon (tc-VLPs). After 24 h of infection, mRNA levels of IFN-β and ISG56 
were determined by real-time RT-PCR. Mean values and standard deviations from three 
independent experiments are shown. 
 
Figure S4 
 
 Figure S4. Companion Experiments and Controls for the Interaction of RIG-I with 
Viral Nucleocapsids (related to Figure 4) 
(A) RIG-I signal in knock-down cells. A549 cells were transfected with a negative control 
siRNA (CTRL), or with an siRNA against RIG-I. After two rounds of transfection, cells were 
tested for the presence of RIG-I by Western blot (upper panel) and immunofluorescence 
analysis (lower panel). (B) Co-localization of LACV nucleocapsids with peroxisomes. 
CHX-treated A549 cells were infected with LACVdelNSs (MOI 5) and 5 h later analyzed by 
immunofluorescence using rabbit and mouse antisera directed against LACV N (green 
channel) or catalase as a marker for peroxisomes (red channel), respectively. Cell nuclei were 
counterstained with DAPI (blue channel). The square area of the inset is digitally magnified 
on the right hand side. Three fluorescence intensity profiles (numbered 1 to 3) are shown on 
the bottom. (C) Only viral nucleocapsids, but not the nucleocapsid protein alone, interact 
with RIG-I. A549 cells were either untreated, transfected for 24 h with plasmid pI.18-LACV 
N, or infected for 5 h with LACVdelNSs (MOI of 5). Cells were lysed in RIPA buffer and 
subjected to immunoprecipitation (IP) for LACV N or RIG-I and analyzed by Western blot. 
As input control, 10% of the cell lysate were analyzed in parallel (left lanes). * indicate 
unspecific bands. (D) Activation of RIG-I and IRF-3 by RVFV. (Upper panel) A549 cells 
were treated with 0 or 50 µg/ml CHX and then infected with RVFV∆NSs::REN at an MOI of 
5. After the indicated incubation periods, cells were lysed in PBS / 0.5% Triton X-100 and 
analysed for oligomerization of RIG-I and IRF-3, and for phosphorylation of IRF-3. (Lower 
panel) RIG-I conformational switch assay of A549 cells treated with CHX and infected for 5 
h with RVFV∆NSs:REN. (E) Co-localization of RIG-I with RVFV nucleocapsids. CHX-
treated A549 cells were infected with RVFV∆NSs::GFP (MOI 5) for 5 h and analyzed by 
immunofluorescence using a rabbit antiserum against RVFV N (1:5000; green channel) and 
mouse polyclonal antiserum against RIG-I (1:200; red channel), respectively. Cell nuclei were 
counterstained with DAPI (blue channel). The square area of the inset is digitally magnified 
on the right hand side. Three fluorescence intensity profiles (numbered 1 to 3) are shown on 
the bottom. (F) Co-immunoprecipitation of RIG-I and RVFV nucleocapsids. CHX-treated 
A549 cells were infected with RVFV∆NSs::GFP (MOI 5) and 5 h later lysed in RIPA buffer. 
Lysates were subjected to immunoprecipitation (IP) using rabbit antiserum against RVFV N 
(1:1000), mouse monoclonal anti-RIG-I antibody ALME-1 (1:1000), or mouse monoclonal 
anti-p21 (1:500). As input control, 10% of the cell lysate were analyzed in parallel (left lanes). 
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Figure S5. Control Experiment and Illustration for the Activation of RIG-I by the Viral 
Panhandle (related to Figure 6). 
(A) Effect of NTP withdrawal on LACV RNA synthesis. A549 cells pretreated with 
different inhibitors were infected with LACVdelNSs for 5 h at an MOI of 5. Before and 
during the infection period, the cell culture medium contained either no additive (-), CHX (50 
µg/ml) added 1 h before infection, or BRQ (10 µM, stocks dissolved in DMSO), MA (10 µM, 
stocks dissolved in methanol), PYF (10 µM, stocks dissolved in DMSO), or CPEC (5 µM, 
stocks dissolved in DMSO) added 24 h before infection. Total cellular RNA was isolated and 
analyzed by real-time RT-PCR using primers specific for the LACV N RNA (Verbruggen et 
al., 2011). (B) LACV panhandle structure. The first 32 nucleotides of the 5’ and 3’ LACV 
M genome segment (Genbank acc # NC_004109) are depicted as an example. Note that the 
non-Watson–Crick base pair G-U (bold face characters) does not disturb the dsRNA structure 
(Holbrook et al., 1991). 
 
Figure S6 
 
 
 
Figure S6. Super-Resolution Immunofluorescence Microscopy of GAPDH and LACV 
Nucleocapsids (related to Figure 7).  A549 cells were treated with 50 µg/ml CHX and 
infected with LACVdelNSs (MOI 5). Cells were analyzed 5 h later by GSD double 
immunofluorescence using antisera against LACV N (green channel) or glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, red channel). The primary antibody anti-GAPDH mouse 
monoclonal 9B3 (HyTest) was diluted 1:100. Four example areas with nucleocapsids are 
shown. Scale bar 200 nm. 
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Supplemental Experimental Procedures 
 
Primers for real-time RT-PCR 
mRNAs of human IFN-β, ISG56, and γ-actin were measured with QuantiTect primers 
QT00203763, QT00201012, and QT00996415, respectively. mRNAs of murine IFN-β, 
ISG56, and GAPDH were measured with QuantiTect primers QT00249662, QT01161286, 
and QT01658692, respectively.   
 
Short interfering RNAs 
AllStar Negative Control siRNA and validated FlexiTube siRNAs (Qiagen) against RIG-I 
mRNA (SI03649037) and MDA5 mRNA (GS23586) were used. 
 
Chemical inactivation of virus particles 
Virus stocks containing 0.05% β-propiolactone (Acros Organics) were incubated at 4° C for 
16 h. β-propiolactone was subsequently hydrolyzed by incubating samples at 37° C for 2 h. 
 
Homodimerisation and phosphorylation of IRF-3  
A549 cells were grown to 80% confluency in T25 flasks. Cell lysis and native-polyacrylamide 
gel electrophoresis (PAGE) were performed as described (Iwamura et al., 2001), with minor 
modifications. Briefly, cells were lysed in 0.5% Triton X-100 dissolved in PBS supplemented 
with protease inhibitor cocktail (Roche) and incubated on ice for 10 min. Lysates were 
sonified in a Branson 3200 Ultrasonic cleaner for 10 min at 4°C and then centrifuged at 4°C 
for 10 min at 10,000×g. Protein concentration was determined by Bradford assay (BioRad) 
and 50 µg of total protein lysate were separated by electrophoresis in a nondenaturing 8% 
polyacrylamide gel, with 1% sodiumdeoxycholate in the cathode buffer. Total IRF-3 and 
phosphorylated IRF-3 monomers and oligomers were detected by Western blot analysis with 
rabbit polyclonal anti-IRF-3 antibody FL-425 (1:500, Santa Cruz Biotechnology) or rabbit 
monoclonal anti-P386-IRF-3 (1:100, IBL), respectively. β-actin, detected by mouse 
monoclonal antibody 8H10D10 (1:1000, Cell signaling) served as a loading control. 
 
Subcellular localization of IRF-3  
Cells were analyzed by immunofluorescence (see Experimental Procedures) using the FL-425 
rabbit polyclonal anti-IRF-3 as primary antibody (1:500, Santa Cruz Biotechnology). And 
goat anti-rabbit Cy2 conjugated as secondary antibody. 
 Real-time RT-PCR for detection of viral sequences 
Total cellular RNA was isolated with the NucleoSpin RNA II kit (Macherey-Nagel) and 
eluted in 30 µl of ddH2O. An aliquot of 600 ng RNA was then used as a template for cDNA 
synthesis. For detection of FLUAV and VSV sequences, reverse transcription was performed 
using the Qiagen QuantiTect Reverse Transcription Kit using the (-) strand specific forward 
primers 5’-GAT AGT ACC GGA GGA TTG ACG ACT A-3’ (VSV) and 5’-GGA CTG CAG 
CGT AGA CGC TT-3’ (FLUAV). PCR was performed using QuantiTect SYBR Green PCR 
Kit and the respective forward primers, combined with the reverse primers 5’- TCA AAC 
CAT CCG AGC CAT TC-3’ (VSV) and 5’- CAT CCT GTT GTA TAT GAG GCC CAT-3’ 
(FLUAV). For detection of LACV, PHV and SFV sequences, the one-step QuantiTect SYBR 
Green RT-PCR Kit was used. Primer sequences were 5’-GGG TAT ATG GAC TTC TGT G-
3’ and 5’-GCC TTC CTC TCT GGC TTA-3’ (LACV S segment forward and reverse 
(Verbruggen et al., 2011)), 5’-CTC AAA ATT GGC AGC TAC A-3’ and 5’-CTT CAC CGG 
CAG GCT G-3’ (PHV S segment forward and reverse, and 5’-GCA AGA GGC AAA CGA 
ACA GA-3’ and 5’-GGG AAA AGA TGA GCA AAC CA-3’ (SFV nsp3 forward and reverse 
(Fragkoudis et al., 2008)). mRNA levels of human γ-actin were detected with QuantiTect 
primers QT00996415. All virus-specific values were normalized against the γ-actin mRNA 
signal using the ddCT method. Up-regulation of viral sequences is depicted in relation to non-
stimulated, non-infected (mock) cells. 
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Summary 
The cytoplasmic RNA helicase RIG-I plays a key role in innate immune-sensing of RNA 1 
viruses and antiviral signaling. We show that RIG-I recognizes incoming nucleocapsids of 2 
influenza A virus (FLUAV) during their short cytoplasmic transit to the nucleus. RIG-I 3 
activation was mediated by 5’-triphosphorylated dsRNA on nucleocapsids and modulated by 4 
polymorphisms at position 627 of polymerase subunit PB2. Avian FLUAV nucleocapsids 5 
possessing PB2-627E were prone to an increased RIG-I recognition as compared to those 6 
with mammalian-adapted PB2-627K. Previously known phenotypes of PB2-627E in 7 
mammals such as delayed onset of infection and reduced nucleocapsid stability were partially 8 
restored in RIG-I-defective cells. The inhibitory effect of RIG-I on PB2-627E nucleocapsids 9 
was independent of antiviral signaling. These results identify RIG-I as a directly acting 10 
mammalian restriction factor for avian FLUAV and highlight nucleocapsid disruption as a 11 
promising target for antiviral therapy. 12 
 13 
14 
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Highlights 15 
► 5’ppp dsRNA panhandle of incoming influenza virus nucleocapsids activates RIG-I 
► Human-adaptive mutation PB2-627K counteracts activation of RIG-I 
► RIG-I directly inhibits incoming nucleocapsids with the avian PB2-627E signature 
► Strength of polymerase binding to NP determines the sensitivity to RIG-I 
- 4 - 
Introduction 
Influenza A viruses (FLUAV; family Orthomyxoviridae) are a significant health threat. 16 
Regular, global outbreaks are occuring due to replenishment from a seemingly unlimited 17 
reservoir of strains in birds (Cauldwell et al., 2014; Klenk, 2014; Manz et al., 2013). FLUAV 18 
virions consist of a lipid envelope with the glycoproteins HA and NA, that also provide the 19 
basis for taxonomic classification, as well as the proton channel M2. The inner leaflet of the 20 
viral envelope is covered by the M1 protein. Inside the particles are eight nucleocapsids 21 
containing the negative-strand RNA genome encapsidated by the nucleoprotein (NP) and 22 
associated with the RNA polymerase complex with subunits PB1, PB2, and PA. The eight 23 
genome segments encode the main structural proteins, auxiliary proteins (NS1, NEP), and 24 
sometimes other, strain-dependent, factors. Gene expression is regulated by partially 25 
complementary 5` and 3` end sequences (the “panhandle”) that pseudo-circularize the single-26 
stranded RNA genome and serve as promoter for transcription and replication. An 27 
outstanding feature of FLUAV is that most parts of the replication cycle occur in the nucleus.  28 
RIG-I (Retinoic acid-inducible gene I) is an RNA helicase that acts as a major host sensor for 29 
virus infections in the cytoplasm (Yoo et al., 2014). RIG-I recognizes non-self RNA 30 
structures and activates a signaling cascade leading to phosphorylation of transcription factor 31 
IRF3 and induction of the antiviral type I interferons (IFN-).  32 
RIG-I contains a central multipartite helicase/ATPase domain flanked by N-terminal caspase 33 
recruitment domains (CARDs) and a C-terminal domain (CTD) (Yoo et al., 2014). 34 
Unstimulated RIG-I is in an auto-repressed, monomeric conformation with the CARDs 35 
confined and the CTD exposed. When the CTD binds a ligand RNA, RIG-I undergoes a 36 
conformational switch enabling it expose the CARDs for interaction with TRIM25 and 37 
MAVS to initiate antiviral signaling (Gack, 2014; Kowalinski et al., 2011; Rawling and Pyle, 38 
2014).  39 
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Synthetic short 5’ppp-dsRNA represents the optimal RIG-I ligand (Schlee et al., 2009; 40 
Schmidt et al., 2009), a structure with remarkable similarity to the panhandle formed by the 41 
annealed 5’ and 3’ genome ends of segmented negative-strand RNA viruses (Schlee, 2013; 42 
Weber and Weber, 2014b). Accordingly, naked genomic RNA of FLUAV and other negative-43 
strand RNA viruses is an excellent activator of RIG-I (Habjan et al., 2008; Hornung et al., 44 
2006; Pichlmair et al., 2006). We recently reported that RIG-I is capable of recognizing 45 
5’ppp-dsRNA panhandles also in the physiological context, when packaged by viral 46 
nucleoprotein and polymerase into nucleocapsids (Weber et al., 2013). That study, however, 47 
had focused on the cytoplasmically replicating bunyaviruses. Therefore, it remained open 48 
whether the panhandles of FLUAV nucleocapsids could also be sensed by the cytoplasmic 49 
RIG-I, and whether this occurs during the passage of the incoming nucleocapsids from the 50 
endosome to the nucleus early in infection. Here, we report that the transiting FLUAV 51 
nucleocapsids are indeed recognized and directly impaired by RIG-I, and that the degree of 52 
RIG-I sensitivity varies depending on adaptive mutations in the polymerase subunit PB2. 53 
 54 
55 
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Results 56 
 57 
Activation of RIG-I by incoming FLUAV nucleocapsids 58 
At the onset of infection, the nucleocapsids of FLUAV are released from endosomes to be 59 
transported through the cytoplasm and into the nucleus. Only there they start primary 60 
transcription, followed by translation and genome replication. To investigate the interaction 61 
between incoming nucleocapsids (and not their RNA products arising later on) and RIG-I in 62 
the cytoplasm, we (i) synchronized infection by incubating the virus inoculum at 4°C for 1 h, 63 
(ii) allowed the subsequent infection at 37°C to proceed for only 1 h, and (iii) added various 64 
inhibitors to ensure restriction to the immediate early infection phase. The inhibitors were 65 
Cycloheximide (CHX; blocks protein synthesis and therefore viral genome replication), 66 
leptomycin B (LMB; inhibits nuclear export of nucleocapsids), and actinomycin D (ActD; 67 
inhibits viral transcription) (Figure S1A). In addition, we tested Ivermectin (IVM) which is 68 
known to block the nuclear import machinery (Wagstaff et al., 2012). Human A549 cells were 69 
pretreated with one or several of the inhibitors, and 1 h-infected with strain A/PR8/34 (H1N1) 70 
at a multiplicity of infection (MOI) of 1 as outlined above. Irrespective of the inhibitor, 71 
incoming FLUAV nucleocapsids triggered two markers of RIG-I activation: the formation of 72 
homo-oligomers (Figure 1A), and the conformational switch reflected by a partial trypsin 73 
resistance (Figure 1B). RIG-I activation by incoming nucleocapsids was comparable to levels 74 
obtained by 1 h-transfection of naked virus particle RNA (vRNA). Quantification by RT-75 
qPCR demonstrated the expected absence of viral RNA synthesis (Figures 1C and S1B). In 76 
line with this, transcription inhibition by various NTP depleting agents also had no influence 77 
on RIG-I activation by FLUAV (Figure S1C). Nonetheless, not only RIG-I, but also its 78 
downstream target IRF3 were activated by the incoming nucleocapsids (Figure 1D). It must 79 
be remarked that in all our experiments, virus stocks were used which were free of defective 80 
interfering particles (data not shown), a known activator of RIG-I (Baum et al., 2010). 81 
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Moreover, in agreement with a previous study (Killip et al., 2014) we noted that addition of 82 
ActD to the mix containing CHX and LMB results in occasional background activation of 83 
antiviral signaling in uninfected cells (data not shown). We therefore conducted the majority 84 
of subsequent experiments with CHX/LMB treatment and within the short, 1 h-period of 85 
synchronized infection, conditions that were optimal for robustly studying interactions of 86 
RIG-I with incoming nucleocapsids. 87 
 88 
RIG-I binds to the panhandle on FLUAV nucleocapsids 89 
Confocal microscopy revealed that the incoming nucleocapsids are co-localizing with RIG-I, 90 
but not with the related helicase MDA5 (Figure S2A and data not shown). Superresolution 91 
microscopy suggests that RIG-I directly attaches on one side of the rod-like nucleocapsids 92 
(Figure 2A). The stability of these co-complexes was tested by pull-down experiments. 93 
Although the viral input was barely detectable as expected for a 1 h infection, the RIG-I 94 
immunoprecipitates contained enriched amounts of NP (Figure 2B), indicating interaction of 95 
RIG-I with incoming nucleocapsids. Again, this was not dependent on viral RNA synthesis 96 
(Figure S2B). When cell lysates were separated in a CsCl gradient, we observed a partial, 97 
virus-induced shift of RIG-I from higher density fractions towards the lower density fractions 98 
which also contained the nucleocapsids (Figure 2C; fractions 7,8,9 in uninfected cells vs 99 
fractions 3,4 and 6 in infected cells). RIG-I was also activated and shifted towards lower 100 
density CsCl fractions when its ATPase activity was inhibited with ADP●AlF3, suggesting 101 
that complex formation is independent of downstream events (Figures S2C-S2E). We also 102 
used our insect cell / in vitro system (Weber et al., 2013). Extracts of Drosophila S2 cells 103 
expressing human RIG-I were dialyzed and supplemented with ATP (to support RIG-I 104 
activation). The recombinant RIG-I reacted to purified and dialyzed FLUAV nucleocapsids 105 
by conformational switching, oligomerization, and a shift of RIG-I fractions in the CsCl 106 
gradient (Figure S2F-S2H). To test the structural determinants of RIG-I activation, purified 107 
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FLUAV nucleocapsids were pretreated in vitro with enzymes. Both destruction of dsRNA by 108 
RNase III as well as cleavage of the 5’ppp by a phosphatase aborted RIG-I stimulation, 109 
whereas the ssRNA-specific RNase A had no such effect (Figure 2D). Importantly, RIG-I 110 
activation did not depend on the specific nucleocapsid preparation method, and was also 111 
observed for nucleocapsids that were affinity-purified via a Strep-tagged PB2 subunit (Figure 112 
S2I-S2K). Also cotransfection experiments demonstrated that the pull-down of NP by RIG-I 113 
is dependent on the genomic RNA, and not on protein-protein interactions (see below). 114 
Together, these data suggest that RIG-I directly interacts with the 5’ppp dsRNA panhandle on 115 
intact FLUAV nucleocapsids and in a manner that is independent of mammalian cofactors or 116 
viral RNA synthesis. 117 
 118 
PB2 is a RIG-I antagonist 119 
Avian FLUAV strains need to acquire adaptive mutations to establish infection in mammals. 120 
A major determinant of host switching and virulence is the polymerase subunit PB2 (Hatta et 121 
al., 2001). PB2 position 627, in particular, carries in avian strains a glutamic acid (E), but in 122 
most mammalian-adapted strains a lysine (K) (Subbarao et al., 1993). The reason for the 123 
mammalian selection pressure towards PB2-627K is not fully understood (Cauldwell et al., 124 
2014; Manz et al., 2013). Interestingly, however, chicken are known to be deficient in RIG-I 125 
(Barber et al., 2010). Using the conformational switch assay, we investigated whether RIG-I 126 
might be involved in the mammalian-specific effects on avian-signature PB2 polymerases. 127 
Human A549 cells were exposed to the immediate early infection phase of variants of four 128 
FLUAV strains, A/quail/Shantou/2061/00 (H9N2), A/Thai/KAN-1/04 (H5N1), pandemic 129 
A/Hamburg/05/2009 (pH1N1), or A/WSN/33 (H1N1). In all cases, those viruses with the 130 
avian signature PB2-627E activated RIG-I much stronger than those with the mammalian 131 
signature PB2-627K (Figure 3A and S3A). These differences were not due to variations in 132 
input RNA or RNA synthesis, as viral RNA levels were comparable and did not increase 133 
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during the 1 h-experiment (Figure 3B and S3B-S3D). Also in CsCl gradient assays, we 134 
observed a more pronounced shift of RIG-I fractions in response to a PB2-627E virus (Fig. 135 
3C, left panels). The PB2-627E virus also relocalized the RIG-I interactors MAVS and 136 
TRIM25 (Fig. 3C, right panels), further supporting the notion of a stronger RIG-I activation 137 
by the avian-signature nucleocapsids. 138 
The A/PR/8/34 strain used for the initial RIG-I activation experiments (see Figures 1 and 2) 139 
contains PB2-627K (Foeglein et al., 2011). A comparison of A/PR/8/34 with PB2-627K and -140 
627E variants of A/WSN/33 (H1N1) demonstrates its relatively weak RIG-I activation 141 
potential (Figure S3E), thus being in line with the correlation between reduced RIG-I 142 
activation and the PB2-627K signature. Virus-like particles containing a A/WSN/33 (H1N1) 143 
reporter minigenome (VLPs) showed the same PB2-627-dependent phenotype, independent 144 
of the particular envelope protein (Figure S3F). This confirms that nucleocapsids are the 145 
critical component. As expected, RIG-I activation by PB2-627E virus was independent of any 146 
viral RNA synthesis (Figure S3G). We also measured IFN induction obtained after overnight 147 
infection by the different FLUAV strains, again under CHX and LMB. Surprisingly, despite 148 
the clear effects on RIG-I activation described above, there were no consistent PB2-627-149 
dependent differences in IFN induction, both in wt and in RIG-I- depleted knockdown cells 150 
(Figure 3D and S3H). Of note, human-adapted PB2-627K has a higher polymerase activity in 151 
mammalian cells (Naffakh et al., 2000), but nonetheless activated RIG-I much weaker than 152 
PB2-627E. This again argues against RNA synthesis as a trigger of RIG-I. Collectively, our 153 
data indicate that the adaptive mutation PB2-E627K represents a viral countermechanism to 154 
RIG-I recognition, even if it has no significant effect on IFN induction. 155 
 156 
157 
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RIG-I influences infection by incoming PB2-627E nucleocapsids 158 
PB2-627E confers reduced polymerase activity in mammalian cells, whereas in avian cells the 159 
activity is similar to PB2-627K (Massin et al., 2001; Paterson et al., 2014). The species-160 
specific differences were attributed to a mammalian restriction factor acting on PB2-627E 161 
only (Mehle and Doudna, 2008). We wondered whether RIG-I could be contributing to PB2-162 
627E suppression in mammalian cells. The classic assay for measuring FLUAV polymerase 163 
activity is the minireplicon reporter system, consisting of plasmid-expressed polymerase 164 
subunits and NP that encapsidate, transcribe and replicate a reporter minigenome bearing 165 
panhandle sequences. Minireplicon activity in human 293 wt cells confirmed the difference 166 
between the two PB2 variants (Figure 4A). We generated knockout 293 cells (Figure S4A) to 167 
test the effect of RIG-I on minireplicon activity, but could not detect major differences to wt 168 
cells or MDA5 knockout cells (see Figure 4A). It needs to be noted, however, that here the 169 
recombinant nucleocapsids are not entering the cytoplasm like in infection, but are artificially 170 
assembled in the nucleus by the plasmid-encoded proteins. Thus, as an alternative closer to 171 
the immediate early infection situation, we employed VLPs containing recombinant FLUAV 172 
nucleocapsids. Reporter activity in the 293 wt cells used to produce VLPs for strain 173 
A/WSN/33 (H1N1) differed between the two PB2 variants, as expected (Figure 4B and S4B). 174 
However, VLPs with PB2-627E re-gained considerable activity upon infection of ΔRIG-I 175 
cells, but not in wt cells or MDA5 cells (Figure 4C). Curiously, in cells that lacked the RIG-I 176 
adaptor MAVS, PB2-627E could also not be rescued, suggesting that signaling may not be 177 
necessary (see below). We also tested the influence of RIG-I on viral multiplication. To 178 
obtain multicycle growth, we infected 293 wt or RIG-I cells for 24 h with MOI 0.0001 of 179 
PB2 variants of strain A/Thai/KAN-1/04 (H5N1). The absence of RIG-I rescued the low 180 
yields of the PB2-627E virus by one order of magnitude, whereas the PB2-627K virus was 181 
slightly reduced (Figure 4D). Overall, the approximately 50.000 fold growth difference 182 
between the PB2 signature viruses in wt cells decreased to 400 fold in RIG-I cells. Since 183 
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RIG-I is activated by nucleocapsid entry, we also monitored the initial establishment of 184 
infection. Wt or RIG-I cells were infected with MOI 1, and the synthesis of NP assayed for 8 185 
h. For PB2-627K viruses, NP was detected from 4 h p.i. on in both cell types (Figures 4E, 186 
S4C and S4D). For the PB2-627E virus, by contrast, NP was detected at 8 h p.i. in wt cells, 187 
but from 6 h on in ΔRIG-I cells. Since viral entry is neither affected by the PB2 signature nor 188 
by the cell genotype (Figure S4E), we conclude that RIG-I targets PB2-627E-type 189 
nucleocapsids during the onset of infection. 190 
 191 
Species- and signaling-independent antiviral effect of RIG-I 192 
An unexpected result of our VLP infection experiments (see figure 4C) was that the 193 
attenuated phenotype of incoming PB2-627E nucleocapsids was not rescued by deleting the 194 
signaling adaptor MAVS. Similarly, also virus with PB2-627E was delayed in ΔMAVS cells 195 
(Figure 5A). To investigate this further, we transcomplemented ΔRIG-I cells with an ATPase-196 
negative RIG-I mutant (K270A) that is unable to signal but still able to bind RNA (Takahasi 197 
et al., 2008). Strikingly, the RIG-I K270A mutant was as potent as wt RIG-I in delaying the 198 
onset of PB2-627E virus and VLP infection (Figures 5B and S5). This is in line with our 199 
observation that chemical ATPase inhibition of RIG-I does not impede activation and 200 
nucleocapsid binding (see Figures S2C to S2E). Transcomplementation with human RIG-I 201 
also endowed chicken cells with the ability to slow down PB2-627E virus infection (Figure 202 
5C). Again, this was independent of antiviral signaling. These data suggest that the binding of 203 
RIG-I to incoming nucleocapsids (see Figs. 2 and S2) is sufficient to delay infection by 204 
FLUAV strains with the avian PB2-627E signature. Thus, RIG-I signaling may not be 205 
required for the restriction of avian strains early in infection. 206 
 207 
Nucleocapsid stability influences RIG-I binding and sensitivity 208 
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The 627K adaptation is known to increase the binding of PB2 to NP (Labadie et al., 2007). 209 
Although this had been disputed as an artefact of the stronger polymerase activity (and hence 210 
nucleocapsid formation) by PB2-627K (Cauldwell et al., 2013), others had shown stronger 211 
NP binding by PB2-627K also in a nucleocapsid-free in vitro system (Ng et al., 2012). In our 212 
immediate-early infection setup, infection occured for 1 h and the formation of daughter 213 
nucleocapsids was impossible due to CHX treatment. Nonetheless, also under these 214 
conditions NP co-precipitated more PB2-627K than PB2-627E, confirming the adaptation-215 
specific differences in binding affinity (Figure 6A). Moreover, NP / PB2-627E interactions 216 
slightly increased in ΔRIG-I cells that were infected (see Figure 6A) or are harbouring 217 
minireplicon systems (Figures S6A and S6B). 218 
RIG-I directly interacts with the panhandles of FLUAV nucleocapsids (see Figures 2D and 219 
S2K). Interestingly, RIG-I pulled down more incoming nucleocapsids of the PB2-627E type 220 
than of the PB2-627K type (Figure 6B). Moreover, the PB2 protein of the 627K type was 221 
found to be co-precipitated, but not PB2 of the 627E type. Similar results were obtained with 222 
recombinant nucleocapids of the minireplicon system, an experimental set-up that also 223 
allowed to demonstrate that RIG-I-NP interactions are depending on the encapsidated genome 224 
RNA (Figure 6C). Thus, nucleocapsids of the PB2-627E type are more efficiently bound by 225 
RIG-I.  226 
The lower affinity of PB2-627E to NP may enable RIG-I to better access the nucleocapsid-227 
borne panhandle RNA. This would implicate that the strength of the polymerase - 228 
nucleocapsid interaction influences RIG-I activity. To directly test this hypothesis, we 229 
disrupted the polymerase complex with a PB1-derived peptide (PB1-T6Y)  (Wunderlich et al., 230 
2011). The inhibitor peptide massively increased RIG-I activation by incoming nucleocapsids, 231 
and independent of the PB2-627 signature (Figures 6D and S6C). Thus, the strength of 232 
polymerase binding, modulated either naturally (by PB2 mutation) or artificially (by 233 
disrupting PB1-PA interactions), sensitizes nucleocapsids to RIG-I. 234 
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 235 
In summary, our results indicate that FLUAV nucleocapids are prone to signaling-236 
independent RIG-I inhibition during their passage through the cytoplasm early in infection. 237 
RIG-I recognizes the panhandle structure on the viral genome RNA, which is normally bound 238 
by the polymerase complex. The sensitivity to RIG-I is determined by the well known host 239 
adaptation at PB2-627, which affects the binding affinity of PB2 to nucleocapsids. Thus, RIG-240 
I apparently represents one of the mammalian restriction factors driving adaption of avian 241 
FLUAV strains towards tighter polymerase binding. 242 
243 
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Discussion 244 
An outstanding feature of influenza viruses is the replication in the nucleus. This allows 245 
access to the cellular transcription and splicing machineries, and - as our results suggest - the 246 
hiding from cytoplasmic RIG-I during most phases of the infection cycle. In fact, since 247 
orthomyxoviruses are also unique with respect to the unusually high number of genome 248 
segments (and hence RIG-I ligands), it is possible that moving into the nucleus initially 249 
evolved as a RIG-I counterstrategy. In line with this, efficient interaction with the nuclear 250 
import machinery was shown to be a determinant of host adaptation (Gabriel et al., 2011; 251 
Hudjetz and Gabriel, 2012; Resa-Infante et al., 2008). However, the virus remains vulnerable 252 
during the transit to the nucleus, since at this stage of infection neither the classic IFN 253 
antagonist NS1 (Hale, 2014) nor the host response suppressors PA-X (Jagger et al., 2012) or 254 
PB1-F2 (Varga et al., 2011) would be expressed. Therefore, it appears plausible that the 255 
nucleocapsids themselfes have to cope with the pathogen recognition system, an assumption 256 
that is in agreement with our data and also with previous reports that FLUAV polymerase 257 
subunits can prevent IFN induction (Marcus et al., 2005; Perez-Cidoncha et al., 2014) and 258 
interact with RIG-I and MAVS (Graef et al., 2010; Iwai et al., 2010; Li et al., 2014; Liedmann 259 
et al., 2014). Moreover, for influenza B virus it was demonstrated that nucleocapsids were 260 
sufficient to induce IFN, whereas for FLUAV RNA synthesis was required (Osterlund et al., 261 
2012). These comparative data again point towards nucleocapsids being able to both induce or 262 
suppress innate immunity, dependent on the genetic background. 263 
The connection between RIG-I activation and IFN induction is not straightforward. Avian 264 
FLUAV strains that strongly activated RIG-I were in fact weaker or equal IFN inducers than 265 
the mammalian strains whose nucleocapsids had inhibited RIG-I. Most likely, the underlying 266 
reason is found in the differences in RNA polymerase activities, which are inseparable from 267 
the RIG-I inhibition capacity. While PB2-627E nucleocapsids have low RNA synthesis rates 268 
but are strong activators of RIG-I, PB2-627K nucleocapsids have a highly active polymerase 269 
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but inhibit RIG-I. Thus, the RIG-I inhibition by PB2-627K might be overwhelmed by the 270 
higher RNA synthesis rate.  271 
It was previously stated that IFN induction by FLUAV occurs exclusively through RNA 272 
synthesis products (Killip et al., 2014; Osterlund et al., 2012). However, we observed IRF3 273 
activation by incoming nucleocapsids even when viral transcription was shut off by ActD 274 
treatment. This appears to contradict the results by Killip et al., who had not seen any such 275 
IRF3 activation (Killip et al., 2014). However, in that study IRF3 was assayed at 8 h post-276 
infection, a time point at which IRF3 activity may have waned, as IRF3 returns to the inactive 277 
state in case of low inducers (Long et al., 2014). We therefore propose that incoming FLUAV 278 
nucleocapsids can activate RIG-I and antiviral signaling, similar to those of influenza B virus 279 
(Osterlund et al., 2012) and the cytoplasmic RNA viruses (Weber et al., 2013). IFN induction 280 
by nucleocapsids is however comparatively weak and the subsequent RNA synthesis becomes 281 
the dominant IFN elicitor once the nucleocapsids have reached the nucleus. 282 
Although PB2-627K had no apparent bearing on IFN induction, for PB2-627E viruses and 283 
VLPs the establishment of infection was slowed down by RIG-I. Strikingly, while deletion of 284 
RIG-I accelerated infection by avian strains, deletion of the downstream adaptor MAVS did 285 
not. Moreover, a signaling-inactive mutant of RIG-I was as potent as wt RIG-I itself in 286 
slowing down PB2-627E viruses. It is therefore likely that the binding of RIG-I to the 287 
panhandle RNA results in a direct (although transient) antiviral effect against avian strains. 288 
The mammalian-adapted nucleocapsids are more efficient in hiding their panhandle, and it 289 
could be speculated this to be due to the stronger binding of the PB2 to the NP. The signaling-290 
independent antiviral effect may also explain why RIG-I follows the nucleocapsids into the 291 
nucleus at the late stage of infection (Li et al., 2014). 292 
Besides PB2-627K, there might be more factors influencing the RIG-I sensitivity of 293 
nucleocapsids. The circulating 2009 pandemic pH1N1 strains have retained the PB2-627E 294 
signature, but acquired compensating second-site mutations (Mehle and Doudna, 2009; 295 
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Yamada et al., 2010). Nonetheless, our direct comparisons between variants of four FLUAV 296 
strains that differed only in position PB2-627 strongly indicate that this major adaptation is in 297 
fact a RIG-I escape mechanism. It will be interesting to see whether other adaptive mutations 298 
in the polymerase or the NP also affect RIG-I. 299 
FLUAV epidemics feed from avian reservoirs. Wild bird species, e.g. ducks, express 300 
functional RIG-I, but domestic chicken do not (Barber et al., 2010; Kowalinski et al., 2011). 301 
Many avian FLUAV strains cause asymptomatic infection e.g. in ducks, but an acute systemic 302 
disease in chicken (Kim et al., 2009). Populations of wild birds are comparatively disperse, 303 
i.e. overt disease would reduce the chance of viral spread. Chicken, by contrast, are held 304 
under crowded conditions and with a constant, non-natural replenishment of susceptible 305 
individuals. A certain RIG-I sensitivity may allow FLUAV to persist in the wild bird 306 
reservoir. In domestic chicken, there is no selection pressure on sparing the host, and the 307 
absence of RIG-I could enable rapid viral spread. In humans, the viral transmission mode 308 
requires replication to levels causing respiratory symptoms. Hence, it could be speculated that 309 
mutations suppressing RIG-I activation are needed for efficient and sustainable infection of 310 
humans, but not in chicken (no RIG-I) or wild birds (RIG-I enables asymptomatic infection). 311 
While RIG-I appears to be acting on incoming nucleocapsids of avian-adapted viruses, other 312 
host cell factors are likely to contribute to the PB2-directed host restriction during later stages 313 
of infection. 314 
Applying a polymerase-disrupting peptide massively increased RIG-I activation by 315 
nucleocapsids. This uncovers the full potential of RIG-I and implies that even for avian-316 
adapted strains only a fraction of the nucleocapsids is actually recognized. Therefore, drugs 317 
targeting the FLUAV polymerase complex will have the secondary benefit of boosting 318 
antiviral host responses.  319 
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In sum, our data implicate that incoming FLUAV nucleocapsids are prone to a direct antiviral 320 
inhibition by RIG-I, and that the degree of RIG-I sensitivity is dependent on nucleocapsid 321 
stability. 322 
 323 
Experimental Procedures 324 
 325 
Cells and viruses 326 
A549, HEK 293, DF-1, MDCK II, and Drosophila S2 cells were cultivated as described 327 
(Weber et al., 2013). FLUAV A/PR/8/34, the recombinant strains of 328 
A/quail/Shantou/2061/2000 (H9N2) (Baron et al., 2013), A/Hamburg/05/2009 (pH1N1), 329 
A/WSN/33 (H1N1), and A/WSN/33 with Strep-tagged PB2 (Rameix-Welti et al., 2009) were 330 
grown on MDCK II cells. A/Thai/KAN-1/04 (H5N1) was grown on chicken DF-1 cells 331 
(Manz et al., 2012). All viruses were entirely sequenced and confirmed to harbor only the 332 
intended mutations.  333 
 334 
Infections 335 
Cells were washed once with phosphate-buffered saline (PBS) and inoculated for 1 h at 4°C 336 
with virus dissolved in OptiMEM (Invitrogen) or 250 µl cell supernatant containing VLPs. 337 
The inoculum was replaced with DMEM containing 0,2% BSA and (except for VSV-G VLP 338 
infections) 1 μg/ml L-1-tosylamido-2-phenylethyl chloromethyl ketone (TPCK)-treated 339 
trypsin (Sigma-Aldrich), and cells were further incubated at 37°C. 340 
 341 
RIG-I activation assays 342 
Analyses of RIG-I conformation and oligomerization were described elsewhere (Weber et al., 343 
2013; Weber and Weber, 2014a). For co-sedimentation assays from mammalian cells, cell 344 
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lysates were prepared as for co-immunoprecipitation (see below). The cleared lysates were 345 
loaded on a discontinuous 5% to 15% CsCl gradient in 20 mM Tris/HCl pH 7.9, 200 mM 346 
NaCl and centrifuged at 52,000 rpm for 2 h at 12°C in a SW60 rotor (Beckman). Altogether 347 
12 fractions were recovered from top to bottom and pelleted at 45,000 rpm for 1 h at 4°C in a 348 
TLA45 rotor (Beckman). Pellets were dissolved in sample buffer, boiled for 5 min and 349 
analyzed by immunoblotting. Proteins were detected with rabbit polyclonal anti-350 
A/quail/Shantou/2061/00 (H9N2) (Baron et al., 2013) at 1:8000, and the mouse monoclonals 351 
anti-RIG-I ALME-1 (Enzo Life Sciences; 1:1000), anti-MAVS (Abcam; 1:500), and anti-352 
human TRIM25 (BD Transduction laboratories, 1:5000). 353 
Co-sedimentation assays with S2 cell samples were performed by a similar procedure. 354 
Briefly, 50 µl dialyzed lysates (containing 100 µg protein) were mixed with 50 µl of dialyzed 355 
PR/8/34 nucleocapsids and supplemented with 1 mM ATP. After 1 h at 37°C the samples 356 
were analyzed using a discontinuous 10% to 30% CsCl gradient.  357 
 358 
Inhibitor treatments 359 
CHX, CuSO4, ActD and IVM were purchased from Sigma Aldrich, and LMB from Biomol. 360 
Cells were pretreated with CHX (50 µg/ml, stocks dissolved in DMSO), LMB (16 nM, stocks 361 
dissolved in ethanol), ActD (1µg/ml, stocks dissolved in DMSO), or IVM (50 µM, stocks 362 
dissolved in DMSO ) for 1 h before infection. Inhibitors were also included in the virus 363 
inoculum and the incubation medium. ADP●AlF3 treatment was performed as described 364 
(Weber et al., 2013). 365 
 366 
Immunofluorescence microscopy 367 
For superresolution immunfluorescence by ground state depletion (GSD) microscopy, 368 
samples were prepared as described for confocal microscopy (see supplemental information) 369 
with minor modifications. As secondary antibodies donkey anti-rabbit Alexa Fluor 555 370 
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(FLUAV) and goat anti-mouse Alexa Fluor 647 (RIG-I) were used and samples were 371 
embedded in 50 mM Tris-HCl pH 8.0 dissolved in 10% Vectashield mounting medium 372 
(VectorLabs) and 90% glycerol. Analysis was performed with the Leica SR GSD microscope. 373 
 374 
Purification of native viral nucleocapsids 375 
MDCK II cells were seeded in 9 T175 cell culture flasks at a confluency of 40% and infected 376 
with FLUAV strain PR/8/34 at an MOI of 0.01 or left uninfected  (control). Supernatants 377 
were harvested at 48 h p.i. and nucleocapsids were purified as described (Weber et al., 2013).  378 
 379 
Co-immunoprecipitation assay 380 
Immunoprecipitations using mouse monoclonals anti-p21 (Santa Cruz Biotechnology) and 381 
anti-RIG-I (ALME-1) were performed as described (Weber et al., 2013).  Mouse monoclonal 382 
anti-NP (HB65) (Wisskirchen et al., 2011) was used at a 1:200 dilution in RIPA buffer. 383 
Mouse monoclonals anti-p21 (1:500), anti-RIG-I ALME-1 (1:1000), and rabbit polyclonal 384 
H9N2 (1:8.000) were used for immunoblotting. 385 
 386 
Enzymatic treatment of nucleocapsids 387 
Dialyzed nucleocapsids were treated with RNase A, RNase III, or SAP and incubated with 388 
dialyzed lysates from RIG-I-expressing S2 cells (supplemented with 1 mM ATP) as described 389 
(Weber et al., 2013). 390 
 391 
Real-time RT-PCR 392 
RNA was isolated from cells using the RNeasy Mini Kit (Qiagen), and 10 ng were analyzed 393 
with the one-step QuantiTect SYBR Green RT PCR kit (Qiagen) in a StepOne Real-Time-394 
PCR-Cycler (Applied Biosystems). Cellular RNA was quantified with specific QuantiTect 395 
primers against IFN-ȕ  (QT00β0γ76γ) and Ȗ-actin (QT00996415). For detection of FLUAV 396 
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segment 7 sequences, reverse transcription was performed using the QiagenQuantiTect® 397 
Reverse Transcription Kit with the (-) strand specific forward (5’-GGA CTG CAG CGT 398 
AGA CGC TT-γ’) and (+) strand specific reverse primer (5’- CAT CCT GTT GTA TAT 399 
GAG GCC CAT-γ’). PCR was performed using QuantiTect® SYBR® Green PCR. Values 400 
were normalized against Ȗ-actin using the ΔΔCT method (Livak and Schmittgen, 2001). Up-401 
regulation of inducible genes is depicted in relation to non-stimulated, non-infected (mock) 402 
cells. 403 
 404 
siRNA knockdown 405 
A549 cells were twice reverse-transfected with predesigned siRNAs from Qiagen (AllStar 406 
Negative Control siRNA and FlexiTube siRNAs against RIG-I (SI03649037) and MDA5 407 
mRNA (GS23586)). For each siRNA, 25 nM were diluted in 100 µl DMEM, supplemented 408 
with 1 µl Lipofectamine RNAiMAX Reagent (Invitrogen) and incubated for 15 min at room 409 
temperature. The siRNA transfection mixes were transferred into a 24 well plate, and 1×10E5 410 
cells dissolved in 900µl DMEM 10% FCS were seeded on top. After 48 h of incubation at 411 
37°C with 5% CO2, cells were harvested, and 1×10E5 cells were again reverse transfected as 412 
described above and incubated for additional 24 h at 37°C with 5% CO2. 413 
 414 
Generation of knockout cell lines 415 
Using GeneJuice reagent (Merck), 2.5×10E4 HEK 293T cells were transfected with plasmids 416 
for either a Zinc finger nuclease targeting the RIG-I gene or for a pair of Transcription 417 
Activator-Like Effectors to Nucleases targeting the genes for MDA5 or MAVS. Two days 418 
later, 0.5 cells per well were seeded into 6 96-well plates. After two weeks, colonies were 419 
trypsinized and seeded into two replica plates. The next day, one of the replicates was lysed 420 
(0.2 mg/ml proteinase K, 1 mM CaCl2, 3 mM MgCl2, 1 mM EDTA, 1% Triton-X-100, 10 421 
mM Tris pH 7.5). Genotypes were obtained by sequencing PCR amplicons covering the target 422 
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site of interest (target sequences and primer sequences available upon request). For each 423 
target gene, a clone was selected that had all alleles disrupted. 424 
 425 
VLP system 426 
HEK293 cells were transiently transfected with plasmids in 2 µl GeneJammer (Agilent) per 1 427 
µg DNA, and medium was changed after 4 h. VLPs for strain A/WSN/33 were generated as 428 
described (Neumann et al., 2000). HEK293 wt cells were transfected with plasmids for VSV-429 
G oder FLUAV HA (1 µg), as well as M1 (2 µg), M2 (100 ng), NEP (1 µg), PB2-627E or 430 
PB2-627K (1 µg), PB1 (1 µg), PA (100 ng), NP (1 µg), a firefly luciferase minigenome 431 
construct (1 µg), and a Renilla luciferase construct (pRL-SV40; 75 ng). As negative control, 432 
PB2 was replaced by additional PB1 plasmid. Two days later supernatants were collected and 433 
treated with 25 U/ml Benzonase (Novagen) for 3 h at 37°C. Cleared cell supernatants were 434 
used for VLP infections of HEK293 cells (pretransfected with NP, PA, PB1 and the matching 435 
PB2) as described above. Luciferase activities were measured 48 h post transfection (VLP-436 
producing cells) or infection (VLP-infected cells). Firefly luciferase activity was normalized 437 
against Renilla activity. Relative polymerase activity is depicted as fold induction with 438 
respect to mock control. 439 
 440 
Peptide inhibitor treatment 441 
A549 cells seeded at 80% confluency in T25 flasks were washed once with PBS and infected 442 
with A/Thai/KAN-1/04 (MOI 1) for 1 h at 4°C. Then, cells were treated with 10 ng/ml Borna-443 
X-Tat or PB11-15 T6Y-Tat (Wunderlich et al., 2011) dissolved in medium with 0,2% BSA. At 444 
1 h post-treatment, cells were lysed and subjected to the RIG-I conformational switch assay. 445 
 446 
447 
- 22 - 
Acknowledgements 448 
We thank Silke Stertz and Jovan Pavlovic for the kind gift of anti-PB2 and anti-NP 449 
antibodies. We are indebted to the Drug Synthesis and Chemistry Branch of the National 450 
Cancer Institute for donating NTP-depleting agents. Work in the FW laboratory is supported 451 
by the DFG grants We 2616/7-1 of SPP 1596, SFB 593 and SFB 1021, by the 452 
Forschungsförderung gem. §2 Abs. 3 Kooperationsvertrag UKGM, and by the Leibniz 453 
Graduate School EIDIS. H-DK is supported by the European Commission (FP7 project 454 
FLUPHARM), and MS by the Bundesministerium für Bildung und Forschung 455 
(FluResearchNet). Work in AG-S laboratories is partly supported by CRIP (Center for 456 
Research on Influenza Pathogenesis), an NIAID funded Center of Excellence for Influenza 457 
Research and Surveillance (CEIRS, contract # HHSN272201400008C), and by NIAD HHSN 458 
272201000054C contract and U19AI083025 grant. The authors declare that there is no 459 
conflict of interest. 460 
 461 
462 
- 23 - 
References 463 
Barber, M.R., Aldridge, J.R., Jr., Webster, R.G., and Magor, K.E. (2010). Association of 464 
RIG-I with innate immunity of ducks to influenza. Proceedings of the National Academy of 465 
Sciences of the United States of America 107, 5913-5918. 466 
Baron, J., Tarnow, C., Mayoli-Nussle, D., Schilling, E., Meyer, D., Hammami, M., Schwalm, 467 
F., Steinmetzer, T., Guan, Y., Garten, W., et al. (2013). Matriptase, HAT, and TMPRSS2 468 
activate the hemagglutinin of H9N2 influenza A viruses. Journal of virology 87, 1811-1820. 469 
Baum, A., Sachidanandam, R., and Garcia-Sastre, A. (2010). Preference of RIG-I for short 470 
viral RNA molecules in infected cells revealed by next-generation sequencing. Proceedings of 471 
the National Academy of Sciences of the United States of America 107, 16303-16308. 472 
Cauldwell, A.V., Long, J.S., Moncorge, O., and Barclay, W.S. (2014). Viral determinants of 473 
influenza A virus host range. The Journal of general virology 95, 1193-1210. 474 
Cauldwell, A.V., Moncorge, O., and Barclay, W.S. (2013). Unstable polymerase-475 
nucleoprotein interaction is not responsible for avian influenza virus polymerase restriction in 476 
human cells. Journal of virology 87, 1278-1284. 477 
Foeglein, A., Loucaides, E.M., Mura, M., Wise, H.M., Barclay, W.S., and Digard, P. (2011). 478 
Influence of PB2 host-range determinants on the intranuclear mobility of the influenza A 479 
virus polymerase. The Journal of general virology 92, 1650-1661. 480 
Gabriel, G., Klingel, K., Otte, A., Thiele, S., Hudjetz, B., Arman-Kalcek, G., Sauter, M., 481 
Shmidt, T., Rother, F., Baumgarte, S., et al. (2011). Differential use of importin-alpha 482 
isoforms governs cell tropism and host adaptation of influenza virus. Nature communications 483 
2, 156. 484 
Gack, M.U. (2014). Mechanisms of RIG-I-like receptor activation and manipulation by viral 485 
pathogens. Journal of virology 88, 5213-5216. 486 
Graef, K.M., Vreede, F.T., Lau, Y.F., McCall, A.W., Carr, S.M., Subbarao, K., and Fodor, E. 487 
(2010). The PB2 subunit of the influenza virus RNA polymerase affects virulence by 488 
interacting with the mitochondrial antiviral signaling protein and inhibiting expression of beta 489 
interferon. Journal of virology 84, 8433-8445. 490 
Habjan, M., Andersson, I., Klingstrom, J., Schumann, M., Martin, A., Zimmermann, P., 491 
Wagner, V., Pichlmair, A., Schneider, U., Muhlberger, E., et al. (2008). Processing of 492 
genome 5' termini as a strategy of negative-strand RNA viruses to avoid RIG-I-dependent 493 
interferon induction. PloS one 3, e2032. 494 
Hale, B.G. (2014). Conformational plasticity of the influenza A virus NS1 protein. The 495 
Journal of general virology. 496 
Hatta, M., Gao, P., Halfmann, P., and Kawaoka, Y. (2001). Molecular basis for high virulence 497 
of Hong Kong H5N1 influenza A viruses. Science 293, 1840-1842. 498 
Hornung, V., Ellegast, J., Kim, S., Brzozka, K., Jung, A., Kato, H., Poeck, H., Akira, S., 499 
Conzelmann, K.K., Schlee, M., et al. (2006). 5'-Triphosphate RNA is the ligand for RIG-I. 500 
Science 314, 994-997. 501 
Hudjetz, B., and Gabriel, G. (2012). Human-like PB2 627K influenza virus polymerase 502 
activity is regulated by importin-alpha1 and -alpha7. PLoS pathogens 8, e1002488. 503 
Iwai, A., Shiozaki, T., Kawai, T., Akira, S., Kawaoka, Y., Takada, A., Kida, H., and 504 
Miyazaki, T. (2010). Influenza A virus polymerase inhibits type I interferon induction by 505 
binding to interferon beta promoter stimulator 1. The Journal of biological chemistry 285, 506 
32064-32074. 507 
Jagger, B.W., Wise, H.M., Kash, J.C., Walters, K.A., Wills, N.M., Xiao, Y.L., Dunfee, R.L., 508 
Schwartzman, L.M., Ozinsky, A., Bell, G.L., et al. (2012). An overlapping protein-coding 509 
region in influenza A virus segment 3 modulates the host response. Science 337, 199-204. 510 
- 24 - 
Killip, M.J., Smith, M., Jackson, D., and Randall, R.E. (2014). Activation of the interferon 511 
induction cascade by influenza A viruses requires viral RNA synthesis and nuclear export. 512 
Journal of virology 88, 3942-3952. 513 
Kim, J.K., Negovetich, N.J., Forrest, H.L., and Webster, R.G. (2009). Ducks: the "Trojan 514 
horses" of H5N1 influenza. Influenza and other respiratory viruses 3, 121-128. 515 
Klenk, H.D. (2014). Influenza viruses en route from birds to man. Cell host & microbe 15, 516 
653-654. 517 
Kowalinski, E., Lunardi, T., McCarthy, A.A., Louber, J., Brunel, J., Grigorov, B., Gerlier, D., 518 
and Cusack, S. (2011). Structural Basis for the Activation of Innate Immune Pattern-519 
Recognition Receptor RIG-I by Viral RNA. Cell 147, 423-435. 520 
Labadie, K., Dos Santos Afonso, E., Rameix-Welti, M.A., van der Werf, S., and Naffakh, N. 521 
(2007). Host-range determinants on the PB2 protein of influenza A viruses control the 522 
interaction between the viral polymerase and nucleoprotein in human cells. Virology 362, 523 
271-282. 524 
Li, W., Chen, H., Sutton, T., Obadan, A., and Perez, D.R. (2014). Interactions between the 525 
Influenza A Virus RNA Polymerase Components and Retinoic Acid-Inducible Gene I. 526 
Journal of virology. 527 
Liedmann, S., Hrincius, E.R., Guy, C., Anhlan, D., Dierkes, R., Carter, R., Wu, G., Staeheli, 528 
P., Green, D.R., Wolff, T., et al. (2014). Viral suppressors of the RIG-I-mediated interferon 529 
response are pre-packaged in influenza virions. Nature communications 5, 5645. 530 
Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression data using 531 
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (San Diego, Calif 532 
25, 402-408. 533 
Long, L., Deng, Y., Yao, F., Guan, D., Feng, Y., Jiang, H., Li, X., Hu, P., Lu, X., Wang, H., 534 
et al. (2014). Recruitment of phosphatase PP2A by RACK1 adaptor protein deactivates 535 
transcription factor IRF3 and limits type I interferon signaling. Immunity 40, 515-529. 536 
Manz, B., Brunotte, L., Reuther, P., and Schwemmle, M. (2012). Adaptive mutations in NEP 537 
compensate for defective H5N1 RNA replication in cultured human cells. Nature 538 
communications 3, 802. 539 
Manz, B., Schwemmle, M., and Brunotte, L. (2013). Adaptation of avian influenza A virus 540 
polymerase in mammals to overcome the host species barrier. Journal of virology 87, 7200-541 
7209. 542 
Marcus, P.I., Rojek, J.M., and Sekellick, M.J. (2005). Interferon induction and/or production 543 
and its suppression by influenza A viruses. Journal of virology 79, 2880-2890. 544 
Massin, P., van der Werf, S., and Naffakh, N. (2001). Residue 627 of PB2 is a determinant of 545 
cold sensitivity in RNA replication of avian influenza viruses. Journal of virology 75, 5398-546 
5404. 547 
Mehle, A., and Doudna, J.A. (2008). An inhibitory activity in human cells restricts the 548 
function of an avian-like influenza virus polymerase. Cell host & microbe 4, 111-122. 549 
Mehle, A., and Doudna, J.A. (2009). Adaptive strategies of the influenza virus polymerase for 550 
replication in humans. Proceedings of the National Academy of Sciences of the United States 551 
of America 106, 21312-21316. 552 
Naffakh, N., Massin, P., Escriou, N., Crescenzo-Chaigne, B., and van der Werf, S. (2000). 553 
Genetic analysis of the compatibility between polymerase proteins from human and avian 554 
strains of influenza A viruses. The Journal of general virology 81, 1283-1291. 555 
Neumann, G., Watanabe, T., and Kawaoka, Y. (2000). Plasmid-driven formation of influenza 556 
virus-like particles. Journal of virology 74, 547-551. 557 
Ng, A.K., Chan, W.H., Choi, S.T., Lam, M.K., Lau, K.F., Chan, P.K., Au, S.W., Fodor, E., 558 
and Shaw, P.C. (2012). Influenza polymerase activity correlates with the strength of 559 
interaction between nucleoprotein and PB2 through the host-specific residue K/E627. PloS 560 
one 7, e36415. 561 
- 25 - 
Osterlund, P., Strengell, M., Sarin, L.P., Poranen, M.M., Fagerlund, R., Melen, K., and 562 
Julkunen, I. (2012). Incoming influenza A virus evades early host recognition, while influenza 563 
B virus induces interferon expression directly upon entry. Journal of virology 86, 11183-564 
11193. 565 
Paterson, D., te Velthuis, A.J., Vreede, F.T., and Fodor, E. (2014). Host restriction of 566 
influenza virus polymerase activity by PB2 627E is diminished on short viral templates in a 567 
nucleoprotein-independent manner. Journal of virology 88, 339-344. 568 
Perez-Cidoncha, M., Killip, M.J., Oliveros, J.C., Asensio, V.J., Fernandez, Y., Bengoechea, 569 
J.A., Randall, R.E., and Ortin, J. (2014). An unbiased genetic screen reveals the polygenic 570 
nature of the influenza virus anti-interferon response. Journal of virology 88, 4632-4646. 571 
Pichlmair, A., Schulz, O., Tan, C.P., Naslund, T.I., Liljestrom, P., Weber, F., and Reis, E.S.C. 572 
(2006). RIG-I-Mediated Antiviral Responses to Single-Stranded RNA Bearing 5' Phosphates. 573 
Science 314, 997-1001. 574 
Rameix-Welti, M.A., Tomoiu, A., Dos Santos Afonso, E., van der Werf, S., and Naffakh, N. 575 
(2009). Avian Influenza A virus polymerase association with nucleoprotein, but not 576 
polymerase assembly, is impaired in human cells during the course of infection. Journal of 577 
virology 83, 1320-1331. 578 
Rawling, D.C., and Pyle, A.M. (2014). Parts, assembly and operation of the RIG-I family of 579 
motors. Current opinion in structural biology 25, 25-33. 580 
Resa-Infante, P., Jorba, N., Zamarreno, N., Fernandez, Y., Juarez, S., and Ortin, J. (2008). 581 
The host-dependent interaction of alpha-importins with influenza PB2 polymerase subunit is 582 
required for virus RNA replication. PloS one 3, e3904. 583 
Schlee, M. (2013). Master sensors of pathogenic RNA - RIG-I like receptors. Immunobiology 584 
218, 1322-1335. 585 
Schlee, M., Roth, A., Hornung, V., Hagmann, C.A., Wimmenauer, V., Barchet, W., Coch, C., 586 
Janke, M., Mihailovic, A., Wardle, G., et al. (2009). Recognition of 5' triphosphate by RIG-I 587 
helicase requires short blunt double-stranded RNA as contained in panhandle of negative-588 
strand virus. Immunity 31, 25-34. 589 
Schmidt, A., Schwerd, T., Hamm, W., Hellmuth, J.C., Cui, S., Wenzel, M., Hoffmann, F.S., 590 
Michallet, M.C., Besch, R., Hopfner, K.P., et al. (2009). 5'-triphosphate RNA requires base-591 
paired structures to activate antiviral signaling via RIG-I. Proceedings of the National 592 
Academy of Sciences of the United States of America 106, 12067-12072. 593 
Subbarao, E.K., London, W., and Murphy, B.R. (1993). A single amino acid in the PB2 gene 594 
of influenza A virus is a determinant of host range. Journal of virology 67, 1761-1764. 595 
Takahasi, K., Yoneyama, M., Nishihori, T., Hirai, R., Kumeta, H., Narita, R., Gale, M., Jr., 596 
Inagaki, F., and Fujita, T. (2008). Nonself RNA-sensing mechanism of RIG-I helicase and 597 
activation of antiviral immune responses. Molecular cell 29, 428-440. 598 
Varga, Z.T., Ramos, I., Hai, R., Schmolke, M., Garcia-Sastre, A., Fernandez-Sesma, A., and 599 
Palese, P. (2011). The influenza virus protein PB1-F2 inhibits the induction of type I 600 
interferon at the level of the MAVS adaptor protein. PLoS pathogens 7, e1002067. 601 
Wagstaff, K.M., Sivakumaran, H., Heaton, S.M., Harrich, D., and Jans, D.A. (2012). 602 
Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to 603 
inhibit replication of HIV-1 and dengue virus. The Biochemical journal 443, 851-856. 604 
Weber, M., Gawanbacht, A., Habjan, M., Rang, A., Borner, C., Schmidt, A.M., Veitinger, S., 605 
Jacob, R., Devignot, S., Kochs, G., et al. (2013). Incoming RNA virus nucleocapsids 606 
containing a 5'-triphosphorylated genome activate RIG-I and antiviral signaling. Cell host & 607 
microbe 13, 336-346. 608 
Weber, M., and Weber, F. (2014a). Monitoring activation of the antiviral pattern recognition 609 
receptors RIG-I and PKR by limited protease digestion and native PAGE. Journal of 610 
visualized experiments : JoVE, e51415. 611 
- 26 - 
Weber, M., and Weber, F. (2014b). Segmented negative-strand RNA viruses and RIG-I: 612 
divide (your genome) and rule. Curr Opin Microbiol 20C, 96-102. 613 
Wisskirchen, C., Ludersdorfer, T.H., Muller, D.A., Moritz, E., and Pavlovic, J. (2011). The 614 
cellular RNA helicase UAP56 is required for prevention of double-stranded RNA formation 615 
during influenza A virus infection. Journal of virology 85, 8646-8655. 616 
Wunderlich, K., Juozapaitis, M., Ranadheera, C., Kessler, U., Martin, A., Eisel, J., Beutling, 617 
U., Frank, R., and Schwemmle, M. (2011). Identification of high-affinity PB1-derived 618 
peptides with enhanced affinity to the PA protein of influenza A virus polymerase. 619 
Antimicrobial agents and chemotherapy 55, 696-702. 620 
Yamada, S., Hatta, M., Staker, B.L., Watanabe, S., Imai, M., Shinya, K., Sakai-Tagawa, Y., 621 
Ito, M., Ozawa, M., Watanabe, T., et al. (2010). Biological and structural characterization of a 622 
host-adapting amino acid in influenza virus. PLoS pathogens 6, e1001034. 623 
Yoo, J.S., Kato, H., and Fujita, T. (2014). Sensing viral invasion by RIG-I like receptors. Curr 624 
Opin Microbiol 20C, 131-138. 625 
 626 
627 
- 27 - 
Figure legends 628 
 629 
Fig. 1. Activation of RIG-I signaling by incoming influenza virus nucleocapsids. 630 
(A and B) RIG-I activity assays. A549 cells were pre-incubated for 1 h with inhibitors, 631 
inoculated with strain A/PR/8/34 (MOI 1) or left uninfected (mock) for 1 h at 4°C, incubated 632 
1 h at 37°C, and analyzed. (A) Oligomerization assay. Lysates of cells treated with CHX (50 633 
µg/ml), LMB (16 nM), ActD (1 µg/ml), or IVM (50 µM) were separated by native PAGE and 634 
immunostained for RIG-I. Actin served as loading control. (B) Conformational switch. 635 
Lysates as in (A) were subjected to limited trypsin digest and analyzed by RIG-I immunoblot. 636 
The Ponceau S protein stain (representative section shown) serves as loading control for the 637 
digested samples. (C) Quantification of total FLUAV segment 7 RNA by RT-qPCR. Input 638 
represents RNA amounts harvested after the 1 h inoculation period at 4°C. (D) IRF3 639 
activation. A549 cells were pretreated with inhibitors, inoculated with strain A/PR/8/34 (MOI 640 
1) or left uninfected (mock) for 1 h at 4°C, and incubated for 1 h under inhibitor treatment. 641 
Lysates from cells were separated by native PAGE and analyzed by immunoblotting for 642 
phosphorylated IRF3 (P-IRF3) and actin as described (Weber et al., 2013). See also Figures 643 
S1A-S1C. 644 
 645 
Fig. 2. RIG-I interacts with incoming influenza virus nucleocapsids and is activated in a 646 
5’ppp-dsRNA-dependent manner. 647 
(A to C) CHX / LMB-treated A549 cells were infected with A/PR/8/34 (MOI 1) for 1 h. (A) 648 
Cells analyzed for RIG-I and FLUAV by 3D GSD superresolution immunofluorescence 649 
microscopy. Scale bar, 1 µm. Insets are digitally magnified and shown below the main image 650 
(taken from one individual cell). (B) Co-immunoprecipitation. Cell lysates were subjected to 651 
immunoprecipitation (IP) using antibodies against p21 (negative control), RIG-I, or FLUAV 652 
NP, and analyzed by immunoblot. Input control: 2% of the lysate. Asterisks (*) indicate 653 
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unspecific bands. (C) Co-sedimentation assay. Cell lysates were separated by a discontinuous 654 
CsCl gradient (2% lysate as input control), and fractions analyzed by immunoblotting. (D) 655 
Conditions for activation of RIG-I by nucleocapsids in vitro. Dialyzed lysate of RIG-I-656 
expressing S2 cells was mixed with nucleocapsids of strain A/PR/8/34 (RNPs) or a control 657 
preparation (CTRL) and supplemented with 1 mM ATP. The nucleocapsids had either been 658 
pretreated with 5 µg RNase A (A), 1 U RNase III (III), or 2 U Shrimp Alkaline Phosphatase 659 
(SAP), or left untreated (-), for 1 h at 37°C. RIG-I conformational switch was assayed after 1 660 
h of nucleocapsid co-incubation at 37°C. See also Figures S2A-S2K. 661 
  662 
Fig. 3. Adaptive mutations in PB2 influence the activation of RIG-I by FLUAV 663 
nucleocapsids.  664 
(A) RIG-I activation by viruses with different PB2-627 signatures. Cells were infected with 665 
strains of A/quail/Shantou/2061/00 (H9N2), A/Thai/KAN-1/04 (H5N1), A/Hamburg/05/2009 666 
(pH1N1), or A/WSN/33 (H1N1) containing avian-signature E or mammalian-signature K at 667 
PB2-627. Infections, CHX/LMB treatment and RIG-I conformational switch testing were 668 
performed as described for 1 and 2. (B) Quantification of virus RNAs by RT-qPCR for 669 
genomic segment 7. Input represents RNA amounts harvested after the 1-h infection period. 670 
(C) Co-sedimentation assay. Lysates of cells infected with PB2 variants of A/WSN/33 671 
(H1N1) using our standard 1 h-protocol were separated by a CsCl gradient and analyzed by 672 
immunoblotting. (D) RIG-I-dependent IFN induction by incoming nucleocapsids. A549 cells 673 
were transfected with the indicated siRNAs or a negative control siRNA (CTRL). A549 cells 674 
siRNA-depleted of RIG-I or MDA5 were pretreated with CHX and LMB, and infected with 675 
FLUAV strains (MOI 1) for 16 h. IFN- mRNA levels were determined by real-time RT-676 
PCR. See also Figures S3A-S3H. 677 
 678 
Fig. 4. RIG-I evasion by PB2-E627K.  679 
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(A) Activity of A/WSN/33-based minireplicon systems containing PB2-627K, -627E, or no 680 
PB2 (-) in HEK293 wt, ΔRIG-I or ΔMDA5 cells. (B) Reporter activities in HEK293 cells 681 
producing VLPs containing nucleocapsids with the indicated PB2 signatures. (C) Reporter 682 
activities in wt and deletion cells infected with VLPs. Cells had been pretransfected with PB1, 683 
PA, NP, and matching PB2. (D) Multicycle virus kinetics. 293 wt or RIG-I cells were 684 
infected with the indicated PB2 variants of strain A/Thai/KAN-1/04 (H5N1) at an MOI 685 
0.0001. Virus yields were determined 24 h later by plaque assay. In all cases, mean and SDs 686 
from 3 independent experiments are shown. (E) Single-cycle virus kinetics. Cells were 687 
infected at an MOI of 1 and monitored for NP expression over time. See also Figures S4A-688 
S4D. 689 
 690 
Fig. 5. Signaling-independent RIG-I effect on early infection 691 
Single-cycle infection kinetics of A/WSN/33 on human cells lacking MAVS (A) or RIG-I (B), 692 
or on chicken DF-1 cells that naturally lack RIG-I (C). The RIG-I and the DF-1 cells were 693 
transiently transfected with plasmids encoding GFP (negative control), FLAG-RIG-I wt, or 694 
FLAG-RIG-I K270A, as indicated. Overexpression was controlled using antibodies against 695 
GFP or the N-terminal Flag tag of the RIG-I constructs. See also Figure S5. 696 
 697 
Fig. 6. Effect of the PB2 627 signature on protein-protein interactions.  698 
(A) NP immunoprecipitation. Cells were CHX / LMB treated and infected with A/WSN/33 699 
strains carrying PB2-627K or 627E as described for 1A. Lysates were immunoprecipitated 1 h 700 
later with anti-NP and immunoblotted as indicated. Normalized quantifications of the 701 
immunoprecipitated proteins are shown below. Note that amounts of viral input proteins are 702 
too low to be detected in the total extracts. (B) RIG-I immunoprecipitations from infected 703 
cells. HEK293 cells were infected with A/WSN/33 PB2 variants as described for 1A. 704 
Immunoprecipations with anti-RIG-I and immunoblotting were performed as indicated for 705 
- 30 - 
2B. (C) RIG-I immunoprecipitations of recombinant nucleocapsids. HEK293 cells were 706 
transfected with A/WSN/33 NP combined with GFP or the PB2 variants (left panel), or with 707 
all A/WSN/33 minireplicon plasmids (right panel). Immunoprecipations with anti-RIG-I were 708 
performed as indicated for (B). (D) Polymerase destabilization. A549 cells were infected with 709 
PB2 variants of strain A/WSN/33 (MOI 1), treated with peptides Borna-X-Tat (CTRL) or 710 
PB11-15 T6Y-Tat (PB1-T6Y), and tested for RIG-I conformational switch 1 h post-infection. 711 
See also Figures S6A-S6C. 712 
 713 
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Figure S1. Immediate-early activation of RIG-I is independent of viral RNA synthesis 
(related to Figure 1). 
(A) Effect of inhibitors on viral RNA synthesis. Cells pretreated with the inhibitors used for 
the experiment in figure 1 were infected with FLUAV strain A/PR/8 for 8 h. The amounts of 
viral (-) sense RNA (segment 7) were then measured by RT-qPCR. (B) Normalization of the 
RNA values shown in Fig.1A. The graph illustrates the absence of RNA synthesis during the 
1 h-infection period. (C) Inhibitors of translation and viral RNA synthesis do not 
influence immediate early activation of RIG-I. Conformational switch assay of infected 
A549 cells pretreated with CHX (50 µg/ml) in combination with either 16 nM LMB, 10 µM 
Brequinar (BRQ; depletes pyrimidine synthesis), 10 µM mycophenolic acid (MA; depletes 
GTP), 10 µM Pyrazofurin (PYF; depletes CTP and UTP), or 5 µM cyclopentenylcytosine 
(CPEC; depletes CTP). 
Supplemental Text and Figures
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 Figure S2. Interaction of RIG-I with FLUAV nucleocapsids (related to Figure 2). 
(A) Colocalization analysis. A549 cells were pretreated for 1 h with CHX and LMB, 
inoculated with strain A/PR/8/34 (MOI 1) for 1 h at 4°C, and incubated for another hour at 
37°C under inhibitor treatment. Cells were fixed and stained for double immunofluorescence 
analysis using antisera against RIG-I (red channel) and FLUAV NP (green channel). Cell 
nuclei were counterstained with DAPI (blue channel). The marked square area is shown 
digitally magnified in the lower left corner. Four fluorescence intensity overlays are shown on 
right. (B) Interaction of RIG-I with FLUAV nucleocapsids is independent of viral RNA 
synthesis. Co-immunoprecipitation analysis as performed for figure 2B, but with 1 µg/ml 
ActD added to the inhibitor mix containing CHX and LMB. Lysates of inhibitor- pretreated 
and 1 h-infected A549 cells were subjected to immunoprecipitation (IP) using antibodies 
against cyclin-dependent kinase inhibitor p21 (negative control), RIG-I, or FLUAV NP, and 
analyzed by immunoblot. Input control: 2% of the lysate. Asterisks (*) indicate unspecific 
bands. (C, D, E) Activation of RIG-I by nucleocapsids in the absence of RIG-I ATPase 
activity. Lysates from cells infected as indicated for (A) were treated with ADP●AlF3 and 
tested for conformational switching (C), oligomerization (D), and fractionation in a 
discontinuous CsCl gradient (2% lysate as input control) (E). Analyses were performed as 
described for figures 1 and 2. (F, G, H) FLUAV nucleocapsids directly activate RIG-I in 
vitro. Cell lysates of RIG-I-expressing Drosophila S2 cells were dialyzed, mixed with 
purified nucleocapsids (A/PR/8 RNPs) or a control preparation (CTRL), supplemented with 1 
mM ATP, and assayed by limited trypsin digestion (F), native PAGE (G), or CsCl 
fractionation (H), coupled to immunoblot analysis. (I, J, K) RIG-I activation does not 
depend on the nucleocapsid preparation method. (I) Nucleocapsids of strain A/PR/8/34 
were prepared and purified using a CsCl gradient (left panel) or a glycerol gradient (right 
panel) , and their composition monitored by PB2 and NP immunoblotting (upper panels) and 
by Coomassie staining (lower panel). The fractions with the subsequently used nucleocapsids 
(RNPs) are indicated. (J) Nucleocapsids prepared using either CsCl or glycerol gradients were 
tested for their ability to activate RIG-I conformational switching in the insect cell / in vitro 
reconstitution system as described for (F). (K) Nucleocapsids of strain A/WSN/33 carrying a 
C-terminal strep-tag on the PB2 protein were (Rameix-Welti et al., 2009) were prepared by 
affinity purification and used to activate RIG-I conformational switching in the insect cell / in 
vitro reconstitution system. The nucleocapsids had either been pretreated with RNase A (A), 
RNase III (III), or Shrimp Alkaline Phosphatase (SAP), or left untreated (-) as described for 
Fig. 2D. 
Figure S3 
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Figure S3. RIG-I activation by PB2-627E signature virus is mediated by nucleocapsids 
and independent of viral RNA synthesis (related to Figure 3). 
(A) Quantification of RIG-I conformational switch provoked by different FLUAV 
strains. Cells were treated and infected as described for figure 3A. Signals for the trypsin 
resistant RIG-I fragment were quantified and normalized to the mock control. Data of the 
experiment shown in Figure 3A and of two other independent experiments were used to 
calculate values of mean and SD. (B) Normalization of the RNA values shown in Figure 
3B. The quantification illustrates that nucleocapsids of avian and human strains contain 
similar amounts of RNA and that no RNA synthesis occurs during the 1 infection period. (C 
and D) Systematic comparison of RNA amounts from input and 1 h-infections. Mean 
values and standard deviations from 3 independent experiments are shown (C) and 
normalized (D). P values were determined by Student’s t-test. (E) RIG-I activation by 
nucleocapsids of strain A/PR8/34 is in the range expected for a virus with a PB2-627K 
signature. Cells pretreated with CHX and LMB were infected for 1 h with the indicated 
viruses and tested for RIG-I conformational switching. (F) RIG-I activation is independent 
of the viral envelope. Cells pretreated with CHX and LMB were infected for 1 h with VLPs 
derived from strain A/WSN/33 (H1N1) that either contain the viral HA protein or that are 
pseudotyped with VSV-G, and tested for RIG-I conformational switching. (G) RIG-I 
activation by PB2-627 variant viruses is independent of viral RNA synthesis. RIG-I 
conformational switch assay for cells infected with A/WSN/33 (H1N1) which had been 
pretreated with CHX and LMB (left panel), or in addition with ActD (right panel). (H) 
Control of siRNA treatment efficiency. A549 cells were transfected with the indicated 
siRNAs or a negative control siRNA (CTRL). After two rounds of transfections, cells were 
tested for the presence of the target proteins by immunoblot. 
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Figure S4. Onset of FLUAV infection in dependency of RIG-I (related to Figure 4). 
(A) Characterization of knockout cells. Immunoblot analysis of HEK293 cells which had 
been engineered to disrupt the coding sequences of RIG-I, MDA5, and MAVS respectively 
(see Materials and Methods). (B) PB2 of VLP-producing cells. Immunoblot analysis of 
HEK293 wt cells transfected to produce VSV-G pseudotyped VLPs. (C, D) Onset of 
infection kinetics. HEK293 wt or ΔRIG-I cells were infected with PB2 variants of strain 
A/quail/Shantou/2061/2000 (H9N2) (C) or A/WSN/33 (H1N1) (D) at an MOI of 1, and tested 
by immunoblotting for the presence of NP at the indicated time points. (E) Systematic 
comparison of RNA amounts from input and 1 h-infections of different PB2 signature 
viruses. Mean values and standard deviations from 3 independent experiments are shown. P 
values were determined by Student’s t-test. 
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Figure S5. Signaling-independent RIG-I effect on infection with PB2-627E VLPs 
(related to Figure 5) 
Activities of PB2 variant VLPs of strain A/WSN/33 (VSV-G pseudotyped) in DRIG-I cells 
transcomplemented with GFP, wt RIG-I, or RIG-I K270A as described for Figure 5. Cells had 
been additionally pretransfected with PB1, PA, NP, and matching PB2. Mean and SDs from 3 
independent experiments are shown. 
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Figure S6. Protein-protein interactions in dependency of RIG-I (related to Figure 6). (A 
and B) NP-PB2 co-immunoprecipitation assay for strains WSN (H1N1) and H9N2. 293 
wt, ΔRIG-I or ΔMDA5 cells were transfected with plasmids for NP, PA, PB1, and a firefly 
luciferase minigenome (vRNA-FF) in combination with either GFP or PB2-627K or PB2-
627E. The viral expression plasmids were either derived from strain A/WSN/33 (H1N1) (A) 
or strain A/quail/Shantou/2061/00 (H9N2) (B). At 24 h post-transfection, cell lysates were 
immunoprecipitated with a mouse monoclonal antibody recognizing NP and tested by 
Western blotting for the presence of NP and PB2. (C) Influence of polymerase 
destabilization on RIG-I activation by strain H5N1. A549 cells were pretreated with 10 
ng/ml of peptides Borna-X-Tat (CTRL) or PB11-15 T6Y-Tat (PB1-T6Y) and infected with 
A/Thai/KAN-1/04 (H5N1) strains of the specified PB2 types. At 1 h post-infection, cells were 
lysed and subjected to limited trypsin digestion. 
 
 Supplemental Experimental Procedures 
 
Inhibitor treatments 
Brequinar (BRQ) and mycophenolic acid (MA) were purchased from Sigma Aldrich. 
Pyrazofurin (PYF, NSC-143095) and cyclopentenylcytosine (CPEC, NSC-375575) were 
kindly obtained from the Drug Synthesis and Chemistry Branch of the National Cancer 
Institute.  
Cells were pretreated for 24 h before infection with CHX (see main text) combined with BRQ 
(10 µM, stocks dissolved in DMSO), MA (10 µM, stocks dissolved in methanol), PYF (10 
µM, stocks dissolved in DMSO) or CPEC (5 µM, stocks dissolved in DMSO). Inhibitors were 
also included in the virus inoculum and the incubation medium. 
 
Preparation and transfection of virus particle RNA 
MDCK II cells grown in a T175 flask were infected with A/PR/8/34 (MOI 0,001). At 38 h 
post infection, supernatants were collected and centrifuged at 1,500 rpm for 7 min at 4°C in a 
JA-12 rotor (Beckman). The cleared supernatant was supplemented with 5 M NaCl and 30% 
PEG800 in NTE buffer (10 mM Tris-HCl pH 6.5, 1 mM EDTA, 100 mM NaCl) to a final 
concentration of 0.44 M NaCl and 15% PEG800 in NTE buffer, respectively. The suspension 
was incubated on ice for 30 min under constant shaking and centrifuged at 6,000 rpm for 1 h 
at 4°C. Subsequently, the pellet was resuspended in 1.5 ml peqGOLDTriFAST (Peqlab). 
After 5 min incubation at room temperature, 300 µl chloroform were added and the 
suspension was incubated for another 10 min at room temperature. After centrifugation at 
4,600 rpm for 11 min at 4°C, the aqueous phase was collected and supplemented with 30 µg 
glycogen (Roche Diagnostics) and one volume of isopropanol. The RNA was precipitated for 
16 h at -20°C and then pelleted at 4,600 rpm for 30 min at 4°C. The pellet was washed twice 
by adding 2 ml 70% ethanol followed by centrifugation at 12,000 × g for 10 min at 4°C. After 
the remaining ethanol had evaporated completely, the pellet was resuspended in TE buffer (10 
mM Tris-HCl pH 8.0, 1 mM EDTA) and stored at -80°C. 
For transfection, 500 ng virus particle RNA was incubated for 10 min at room temperature 
with 2 µl/µg RNA jetPRIME (PolyPlus Transfection) according to the manufacturer’s 
instructions. The transfection mix was added dropwise onto human A549 cells grown in a T25 
flask to 80% confluency and the cells incubated for 1 h at 37°C before lysis. 
 
Immunofluorescence microscopy 
For immunfluorescence analysis, human A549 cells were grown on coverslips and infected 
for 1 h as outlined above. Then, cells were fixed with 4% paraformaldehyde dissolved in PBS, 
permeabilized with 0.5% Triton X-100 dissolved in PBS for 15 min, and blocked with 2% 
bovine serum albumine (BSA), 5% glycerol, 0.2% Tween 20 dissolved in PBS for 1 h at room 
temperature. Primary antibodies, rabbit polyclonal recognizing A/quail/Shantou/2061/00 
(H9N2) and mouse polyclonal anti-human RIG-I (1:200; Baum et al., 2010), were diluted in 
blocking solution and cells were stained for 1 h at room temperature. After three times 
washing with PBS, cells were incubated with Alexa Fluor 555 donkey anti-mouse (1:200) and 
Alexa Fluor 488 donkey anti-rabbit (1:200) secondary antibodies supplemented with 4,4-
diamidino-2-phenylindole (DAPI, 1:10.000) for 45 min at room temperature. Cells were 
washed three times with PBS and coverslips were mounted using Fluorsave solution 
(Calbiochem). Stained cell samples were examined using a Leica SP5 confocal microscope.  
 
Expression of RIG-I in S2 cells  
D. mel. S2 cells were transfected with 1 μg of pRmHa3-RIG-I plasmid, induced with CuSO4, 
lysed and extracts dialyzed as described (Weber et al., 2013). 
 
Purification of recombinant viral nucleocapsids 
For purification of recombinant nucleocapsids via Strep-affinity tag, MDCK II cells in a 10 
cm dish were infected with A/WSN/33 carrying a C-terminal Strep-tag on the PB2 protein 
(Rameix-Welti et al., 2009) at an MOI of 1. After 16 h the cells were washed with PBS, 
scraped off in PBS, pelleted by centrifugation at 100 × g for 5 min at 4°C. Pellets were then 
resuspended in Strep-lysis buffer (50 mM Tris/HCl pH 7.5, 150 mM NaCl, 2 mM MgCl2, 
2mM CaCl2, 1% PMSF, 1 mM DTT, 0.7% NP40 and 50 U/ml DNase I (Fermentas)) and 
incubated on ice for 20 min. Lysates were then centrifuged at 16.200 x g for 10 min at 4°C 
and the cleared lysates were incubated for 1 h at 4°C with Strep-Tactin beads (IBA 
Goettingen). Beads were then pelleted by centrifugation at 100 × g for 1 min at 4°C, 
supernatant was removed and the beads were resuspended with wash buffer (50 mM Tris/HCl 
pH 7.5, 150 mM NaCl, 2 mM MgCl2, 2mM CaCl2, 1% PMSF, 1 mM DTT). Washing was 
performed three times and nucleocapsids were eluted by incubating the beads for 15 min on 
ice with wash buffer supplemented with 2.5 mM desthiobiotin (IBA Goettingen) Suspension 
was centrifuged at 100 × g for 1 min at 4°C and the eluate was transferred in a fresh tube and 
nucleocapsids were dialyzed against PBS. 
Co-immunoprecipitation assay of recombinant nucleocapsids 
For immunoprecipitations of recombinant nucleocapsids produced in minireplicon systems of 
strains A/WSN/33 (Neumann et al., 2000) or H9N2 (Baron et al., 2013), cells were seeded in 
T25 flasks and transiently transfected with expression plasmids encoding GFP (1 µg) or 
strain-specific PB2-627K or 627E (1 µg) together with NP (1 µg) alone or additionally with 
strain-specific PB1 (1 µg), PA (100 ng) and the firefly luciferase reporter minigenome 
construct (1 µg). At 24 h post-transfection, cell lysates were prepared and subjected to co-
immunoprecipitation assay. Thereby, beads were directly coupled with mouse monoclonal 
HB65 antibody recognizing NP (Wisskirchen et al., 2011) or RIG-I (ALME-1). Coupled 
beads were incubated with the lysates for 2 h at 4°C and eluted as described. Co-
immunoprecipitations were validated by immunoblotting using rabbit polyclonal H9N2, 
mouse monoclonal anti-PB2 JG6 (Marazzi et al., 2012) and mouse monoclonal anti-RIG-I 
antibody ALME-1. 
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4.4. Intergenic region of incoming nucleocapsid activate PKR 
 -Lassa virus nucleoprotein provides a PKR evasion strategy-  
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Intergenic region of incoming nucleocapsid activate PKR 
 -Lassa virus nucleoprotein provides a PKR evasion strategy- 
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Abstract 
Surveillance of non-self RNA by receptors of the innate immune system is a crucial first line of defense 
against viral infection. A rapid detection is thereby required for initiating an antiviral response to 
ensure survival of the host. Protein kinase R (PKR) represent one immune sensor able to recognize 
dsRNA and specific RNA secondary structures. Despite recognizing viral replicative dsRNA 
intermediates, we identified in this study the hairpin-structured intergenic region (IGR) of viral 
ambisense genomes as natural PKR agonists. Thus, the IGR seems to be exposed from nucleoprotein 
protection within the nucleocapsid complex allowing PKR to interact. Upon IGR recognition, PKR 
undergoes conformational switching and phosphorylation, identifying IGRs of RVFV S segment, New 
World arenavirus Tacaribe (TCRV) and Junin virus (JUNV) and Old World arenavirus Lassa virus (LASV) 
nucleocapsids as natural PKR agonists. To antagonize antiviral activity of PKR, TCRV, JUNV and LASV 
induce proteasomal degradation of activated PKR. In case of LASV, the newly synthesized 
nucleoprotein interacts with PKR and promotes its degradation. Hence, we identified the IGR as part 
of the viral nucleocapsid as an immediate PKR agonist. Furthermore, we pin down LASV nucleoprotein 
as a PKR antagonist by promoting its proteasomal degradation. This highlights PKR as an immune 
sensor of immediate infection and that arenaviruses have adapted to rapidly and efficiently avert 
antiviral PKR activity. Furthermore, IGRs play an essential role in the control of viral protein synthesis 
indicating the necessity to conserve this structure despite the presence of antiviral defense 
mechanisms. This suggests targeting of the IGR to block virus replication a promising target for drug 
development. 
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Introduction 
Virus infection is a constant threat to human mankind. Thus, to rapidly control virus infection an 
immediate recognition of the viral intruder is required. Several groups of innate immune receptors, 
including Toll-like receptors (TLR), RIG-I like receptors (RLR), NOD-like receptors (NLR), C-type lectin 
receptors (CLR), and other cytosolic RNA and DNA sensors  are thereby crucial to distinguish between 
host cell (self) and pathogen associated structures (non-self) (Pandey et al., 2014).  
RLR have a central role to detect RNA virus infection in the cytoplasm of the infected cell. The family 
of RLR is formed by retinoic acid inducible gene 1 (RIG-I), melanoma differentiation association factor 
5 (MDA5) and laboratory of genetics and physiology 2 (LGP2). Studies have demonstrated that RIG-I 
and MDA5 recognize mostly distinct RNA structures. MDA5 is known to sense longer double-stranded 
RNA (dsRNA) molecules, ideally with higher order RNA structures (Pichlmair et al., 2009, Schlee, 2013). 
RIG-I mainly responds to 5′ ppp blunt-ended dsRNA of a minimal length of 10 base pairs (Kohlway et 
al., 2013, Schmidt et al., 2009, Schlee et al., 2009). Recently, dsRNA stretches bearing a 5`diphosphate 
were identified to stimulate a RIG-I dependent response (Goubau et al., 2014). Interestingly, also in 
the encapsidated state, RIG-I can sense short 5`ppp dsRNA panhandle structures of incoming 
nucleocapsids (Weber et al., 2013). Ligand-mediated activation of RIG-I stimulates a signaling reaction 
that culminates in the induction of type I interferon (IFN-alpha/beta), proinflammatory cytokines and 
eventually numerous interferon stimulated genes (ISGs) (Goubau et al., 2013, Reikine et al., 2014, 
Ivashkiv and Donlin, 2014, Hertzog and Williams, 2013). ISG represent viral restriction factors that 
directly inhibit all steps of virus replication and furthermore co-stimulatory molecules, cytokines and 
chemokines which favor the initiation of adaptive immune responses (Schoggins, 2014, Schneider et 
al., 2014, Loo and Gale, 2011).  
Viruses have evolved to impair or evade RIG-I recognition. Further immune sensors are thus required 
to ensure a rapid detection and response to the viral intruder. However, whether other immune 
sensors recognize like RIG-I incoming protein-associated viral RNA and stimulate an antiviral response 
remained elusive. Here, we addressed the question whether protein kinase R (PKR) contributes to an 
immediate immune recognition.  
PKR represents an RNA sensor which is expressed at a low constitutive level mainly in the cytoplasm. 
Despite being upregulated upon virus induced IFN response, PKR expression can also be increased 
upon other cellular stress signals like disturbances of calcium homeostasis (Williams, 1999). PKR 
represents a multifunctional protein involved in the regulation of cap-dependent translation by 
phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (eIF2α). Furthermore, PKR is 
crucial for the virus induced formation of stress granules required for IFN-signaling (Onomoto et al., 
2012). To stimulate PKR activation there is a minimal dsRNA length requirement of approximately 33 
base pairs, but also specific structural modalities like bulges and loops and nucleotide modifications 
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like a 5`ppp support PKR stimulation (Nallagatla et al., 2007, Dzananovic et al., 2013, Bevilacqua and 
Cech, 1996). Thereby, replicative intermediates of negative-strand RNA viruses can form PKR activating 
dsRNA stretches. PKR thus senses virus replication, but involvement of PKR as an immediate immune 
sensor and inducer of antiviral defense mechanisms remains to be resolved. An interaction of PKR with 
viral RNA secondary structures like the hepatitis C virus IRES or dimerized stem-loop structures of 
transactivation (TAR) RNA of human immunodeficiency virus 1 was previously reported (Shimoike et 
al., 2009, Heinicke et al., 2009). Whether PKR would however recognize viral RNA in the encapsidated 
state was not addressed so far. 
In this study, we report the hairpin-structured intergenic region (IGR) of two distinct virus families as 
PKR agonists. Thereby, the IGR seems to be exposed from nucleoprotein protection within the 
nucleocapsid complex allowing PKR to interact. Upon IGR recognition, PKR undergoes conformational 
switching and phosphorylation identifying IGRs of RVFV S segment, New World arenavirus Tacaribe 
(TCRV) and Junin virus (JUNV) and Old World arenavirus Lassa virus (LASV) nucleocapsids as natural 
PKR activators. To antagonize antiviral activity of PKR, TCRV, JUNV and LASV induce proteasomal 
degradation of activated PKR. In case of LASV, the newly synthesized nucleoprotein interacts with PKR 
and promotes its degradation. Hence, we identified the IGR as part of the viral nucleocapsid as an 
immediate PKR agonist. LASV nucleoprotein counteracts antiviral PKR activity by promoting its 
proteasomal degradation. Furthermore, this seems to be a common mechanism within the arenavirus 
family although the responsible TCRV and JUNV protein could not be identified so far. This highlights 
PKR as an immune sensor of immediate infection and that arenaviruses have adapted to rapidly and 
efficiently avert antiviral PKR activity.  
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Experimental Procedures 
Cells, Viruses and Transfection 
Human A549 and HEK293T cells were cultivated in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal calf serum (FCS) at 37°C and 5% CO2. Recombinant La Crosse virus lacking 
the virulence factor NSs (LACV; (Blakqori and Weber, 2005)) and recombinant Rift Valley fever virus 
expressing Renilla luciferase instead of NSs (RVFV; (Habjan et al., 2009a)), Junin virus (JUNV), Tacaribe 
virus (TCRV) and Lassa virus (LASV) were propagated on Vero E6 cells. All work with LASV and JUNV 
was performed in the BSL-4 laboratories at the Philipps University Marburg, Germany.  
For transient overexpression, HEK293T cells were transfected by standard calcium phosphate 
transfection method with either 0.25, 0.5, 1 or 2 µg of pCAGGS_GP-HA, pCAGGS_NP-HA, pCAGGS_Z-
HA or pcDNA3.1_ΔMX combined with 1 µg of pcDNA5_PKR.  
Rift Valley Fever virus like particle (RVF VLP) production 
Generation of RVF VLPs was carried out as previously described (Habjan et al., 2009a), with minor 
alterations. Briefly, 1x10e6 HEK293T cells were transfected with 1 μg each of plasmid pI.18_RVFV_N, 
pI.18_RVFV_L, pI.18_RVFV_M, and a reporter minigenome using Nanofectin transfection reagent (PAA 
Laboratories). Therefore, a minigenome with Renilla luciferase in negative sense flanked by 5’ and 3’ 
untranslated regions (UTRs) from either RVFV middle (M) or small (S) segment was used 
(pHH21_RVFV_vM and pHH21_RVFV_vS, respectively). In case of the S segment, the minigenome 
contained the full-length RVFV S segment and the NSs replaced by Renilla luciferase. For production of 
empty VLPs (no minigenome), 1 μg each of plasmid pI.18_RVFV_N, pI.18_RVFV_M and for DNA amount 
normalization pcDNA3.1_ΔMX was used for transfection. At 4 h post-transfection, the medium was 
exchanged and 48 h later supernatants were collected and clarified from cell debris by centrifugation 
at 500xg for 5 min. Subsequentially, VLPs were treated with 25 U/ml benzonase (Novagen) for 3 h at 
37°C and then stored at -80°C. 
Infection and Inhibitor treatment  
A549 cells were inoculated for 1 h with viruses or RVF VLPs. Infection medium was replaced with 
DMEM containing 2% FCS thereafter. If indicated, cells were pretreated with 50 µg/ml cycloheximide 
(CHX) dissolved in complete medium for 1 h. CHX was also added to the virus inoculum and to the 
medium added afterwards. MG132 dissolved in media at the final concentration of 20 µM was added 
immediately after the virus inoculum was removed. In case of transfected cells, 20 µM MG132 
containing complete media was added 8 h post-transfection and cells were incubated for additional 
16 h at 37°C with 5% CO2. CHX and MG132 were purchased from Sigma-Aldrich. Cells were lysed or 
fixed at the indicated time points. 
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Limited protease digestion 
Limited protease digestion to monitor RIG-I and PKR conformational switching was essentially 
performed as described elsewhere (Weber and Weber, 2014a). Briefly, cells of one well of a six well 
plate were lysed in 25 µl 0.5% Triton X-100 in PBS supplemented with Phosphatase Inhibitor Cocktail 
set II (Calbiochem). After an incubation on ice for 10 min, the samples were centrifuged for 10 min at 
10,000×g at 4°C and 10 µl of the cleared lysate were kept as input and the other 10 µl were digested 
for 20 min with 0.2 µg/µl L-1-tosylamido-2-phenylethyl chloromethyl ketone (TPCK)-treated trypsin 
(Sigma-Aldrich) at 37°C. Reaction was stopped by adding 4-fold sample buffer (200 mM Tris-HCl pH 
6.8, 8% SDS, 40% glycerol, 25% β-Mercaptoethanol, 0.4% Bromphenol Blue) and boiling for 10 min at 
100°C according to BSL4 safety procedures. Samples were subjected to SDS-PAGE and Western Blot 
analysis using mouse monoclonal anti-RIG-I antibody (ALME-1, Enzo Life Sciences) at 1:1,000; mouse 
monoclonal anti-PKR B10 (Santa Cruz) at 1:500 and rabbit monoclonal against phosphorylated PKR at 
position threonine 446 (p-PKR Thr 446; Epitomics) at 1:500.  
Co-immunoprecipitation 
Cells grown in a T75 tissue culture flask (infection) or in two wells of a six well plate (transfection) were 
scraped off in PBS, centrifuged at low speed, and the pellets were lysed in 50 mM Tris-HCl pH 7.5, 
150 mM NaCl and 1% NP40 supplemented with phosphatase inhibitor and Protease inhibitor cocktail 
Complete (Roche), incubated on ice for 10 min and centrifuged for 10 min at 10,000×g at 4°C. Cleared 
cell lysates were transferred to fresh tubes and 2% were kept as input control. The remaining lysate 
was subjected to immunoprecipitation (IP) using magnetic beads (Dynabeads, Invitrogen). The 
coupling of the beads with the corresponding antibody was performed according to the 
manufacturer’s instructions with minor modifications. For each IP, 1.5 mg of beads were incubated 
with rabbit polyclonal anti-mouse antibody (DAKO) at a dilution of 1:200 for 16 h at 37°C. After the 
first antibody coupling, beads were washed three times with lysis buffer, and the anti-mouse antibody 
beads were further incubated with mouse monoclonal anti-p21 (Santa Cruz Biotechnology), mouse 
monoclonal anti-RIG-I or mouse monoclonal anti-PKR B10 at a 1:200 dilution in lysis buffer for 24 h at 
4°C. Beads were washed three times with lysis buffer and then incubated with the lysates for 2 h at 
4°C. The immunoprecipitates were washed three times with lysis buffer and eluted by adding 1-fold 
sample buffer (50 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 6.25% β-Mercaptoethanol, 0.1% 
Bromphenol Blue). Western blot analysis was performed with mouse monoclonal anti-RIG-I at 1:1000, 
mouse monoclonal anti-PKR B10 at 1:500, rabbit monoclonal anti-p-PKR Thr 446 at 1:500, mouse 
monoclonal anti-p21 (Santa Cruz) at 1:500, rabbit polyclonal anti-HA (abcam) at 1:1000, rabbit 
polyclonal anti-LACV N at 1:1000, mouse polyclonal anti-RVFV N serum (Habjan et al., 2009b) at 1:1000 
and rabbit monoclonal anti LASV NP at 1:3000. As a secondary antibody protein A-horseradish 
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peroxidase (HRP) conjugate (Millipore) at a dilution of 1:10,000 was used to avoid detection of heavy 
and light antibody chains. 
Co-sedimentation assay 
For co-sedimentation assays, cell lysates were prepared as described for co-IP. The cleared lysate was 
loaded on top of a discontinuous 50% to 70% glycerol gradient in 50 mM Tris-HCl pH 7.5, 150 mM NaCl 
and centrifuged at 52.000 rpm for 2 h at 12°C in a SW60 rotor (Beckman). Twelve fractions were 
recovered from top to bottom and pelleted at 45,000 rpm for 1 h at 4°C in a TLA45 rotor (Beckman). 
Pellets were dissolved in 1-fold sample buffer, boiled for 5 min at 100°C and validated by SDS-PAGE 
followed by Western Blot analysis. Proteins were detected with mouse monoclonal anti-RIG-I antibody 
at 1:1000, mouse monoclonal anti-PKR B10 at 1:500, rabbit polyclonal anti-LACV N at 1:1000, and 
mouse polyclonal anti-RVFV N serum at 1:1000. 
GSDIM 
For immunfluorescence analysis via ground state depletion microscopy followed by individual 
molecule return (GSDIM), 4x10e5 A549 cells were grown on coverslips and infected for 1 h as outlined 
above. Then, cells were fixed with 4% paraformaldehyde dissolved in PBS for 20 min, permeabilized 
with 0.5% Triton X-100 in PBS for 15 min, and blocked with 2% bovine serum albumine, 5% glycerol, 
0.2% Tween 20 in PBS for 1 h. Primary antibodies, rabbit anti-RVFV MP12 hyperimmune serum C2, 
mouse polyclonal anti-human RIG-I (Baum et al., 2010) and mouse monoclonal anti-PKR B10, were 
diluted 1:200 in blocking solution and cells were stained for 1 h. After three times washing with PBS, 
cells were incubated with secondary antibody Alexa Fluor 555 donkey anti-mouse at 1:200 and Alexa 
Fluor 647 donkey anti-rabbit at 1:200 supplemented with 4,4-diamidino-2-phenylindole (DAPI) at 
1:10,000 for 45 min at room temperature. Cells were washed three times with PBS and samples were 
embedded in freshly prepared 100 mM β-mercaptoethylamine in PBS pH 7.4 directly before imaging. 
Analysis was performed with the Leica SR GSD microscope. Quantification was performed of three 
independent experiments. Student’s T-test was carried out for statistical analysis. 
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Results 
RIG-I and PKR differ in their agonist specificity 
It was recently described by our group that the 5’ppp panhandle structure of incoming viral 
nucleocapsids serve as a natural RIG-I agonist to promote an immediate antiviral IFN response (Weber 
et al., 2013). To test whether other immune receptors would contribute to an immediate virus 
recognition, cells were infected with either La Crosse virus (LACV) or Rift valley fever virus (RVFV) 
(Bunyaviridae), both lacking the virulence marker NSs. Bunyavirus are peculiar since their transcription 
is dependent on an on-going translation (Elliott, 1990). Hence, treatment with the translation inhibitor 
cycloheximide (CHX) aborts viral transcription and allows analysis of immune receptor activation by 
incoming nucleocapsids in the physiological context of virus infection. 
By performing limited protease digestion to monitor RIG-I activation status (Weber and Weber, 2014a), 
stimulated RIG-I undergoes conformational rearrangements leading to detection of trypsin resistant 
fragments. RIG-I activation is thereby independent whether viral replication occurs (Fig. 1A, left panel) 
or if only incoming nucleocapsids are present (Fig. 1A, right panel).  
PKR is another well-known cytoplasmic pattern recognition receptor able to detect dsRNA stretches of 
at least 33 nucleotides or RNA secondary structures (Dabo and Meurs, 2012). PKR is composed of two 
amino-terminal dsRNA binding domains (dsRBD), a carboxy-terminal serine/threonine kinase domain 
and both domains are linked by a flexible linker (VanOudenhove et al., 2009). In absence of a stimulus, 
PKR is present as a monomer with an extended open conformation where the dsRBD are impeding 
kinase domain activity. Agonist recognition induces conformational rearrangements to a closed 
conformation allowing dimerization and auto-phosphorylation (Dabo and Meurs, 2012, Clemens, 
1997, VanOudenhove et al., 2009, Lemaire et al., 2006). Like RIG-I, also PKR conformational changes 
can be measured by limited protease digestion (Weber and Weber, 2014a). Upon agonist recognition, 
PKR reorganizes its domains leading to partial protease resistance. Surprisingly, LACV and RVFV differ 
in their ability to promote PKR resistance to trypsin treatment and induction of PKR phosphorylation 
at threonine 446. LACV full viral replication only poorly and incoming LACV nucleocapsids even fail to 
induce these two markers of PKR activation (Fig. 1B). However, RVFV full infectious cycle and incoming 
nucleocapsids lead to a robust induction of PKR resistant fragments and detection of PKR 
phosphorylation. Since strongest differences between LACV and RVFV induced PKR activation were 
observed by stimulating with incoming nucleocapsids, we focused on the immediate pathogen 
recognition.  
By performing co-sedimentation assay the migration pattern in a discontinuous glycerol gradient of 
RIG-I and PKR upon stimulation with LACV or RVFV nucleocapsids was analyzed. In mock infected cells, 
RIG-I was mainly distributed from fraction 6 to 8 (Fig. 1C, upper panel). LACV and RVFV nucleocapsids 
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induced a shift of RIG-I up to fraction 4 confirming the previous observation that RIG-I is able to 
recognize these two bunyaviruses (Fig. 1C, middle and lower panel). PKR distribution upon LACV 
nucleocapsid stimulation showed a comparable distribution pattern from fraction 7 to 10 as mock 
infection (Fig. 1C, upper and middle panel). In contrast, RVFV nucleocapsids induced a concentration 
of total PKR in fraction 7 (Fig. 1C, lower panel). The observed shift of nucleocapsids can hence be 
associated to recognition of LACV and RVFV nucleocapsids by RIG-I or RIG-I and PKR, respectively. 
Noteworthy, migration of RIG-I and PKR was dependent on RNA since overexpression of the 
nucleoprotein alone did not induce a change in the distribution pattern (Suppl. 1). 
To further validate an interaction between PKR and incoming bunyavirus nucleocapsids co-
immunoprecipitation (co-IP) assays were performed. As reported before, RIG-I interacted with LACV 
as well as RVFV nucleocapsids (Fig 1D). However, with a PKR specific co-IP only RVFV, but not LACV 
nucleocapsids could be co-precipitated.  
In summary, these data indicate that LACV and RVFV nucleocapsids can be both recognized by RIG-I 
and mediate its activation. RVFV nucleocapsids, on the contrary, serve also as PKR agonist.  
Presence of an intergenic region within viral nucleocapsids determines PKR 
recognition and activation 
Since the observed differences of LACV and RVFV nucleocapsid recognition by PKR seemed to be 
dependent on viral RNA, we wondered whether this could be due to the different LACV and RVFV 
coding strategies. Bunyavirus particles comprise three genome segments with negative polarity which 
are named according to their size large (L), middle (M) and small (S). RVFV L and M segment contain 
only a single transcriptional unit in negativesense orientation, whereas the S segment uses ambisense 
coding strategy (Giorgi et al., 1991). Thereby, two open reading frames are separated by a highly 
conserved non-coding intergenic region (IGR). RVFV IGR forms a hairpin structure with a central dsRNA 
stem with internal loops and peculiar poly-C (viral sense) and poly-G (viral anti-sense) repeats (Fig. 2A) 
(Lara et al., 2011, Ikegami, 2012). Members of the Orthobunyavirus family like LACV do not use 
ambisense coding strategy (Elliott, 2014). During the replication cycle, each genome segment is 
transcribed into mRNA and then translated to allow genome replication and generation of progeny 
viruses (Fig. 2B). Amplification of the viral genome (vRNA) involves the synthesis of an exact copy of 
the vRNA, called complementary RNA (cRNA). In case of the RVFV S segment, the cRNA serves also as 
a template for mRNA synthesis (Ikegami, 2012, Walter and Barr, 2011). Since it was described that the 
RVFV IGR is accessible for other proteins (Moy et al., 2014) we wondered whether PKR would also use 
this structure to gain access to RVFV nucleocapsids. 
To validate the importance of the IGR for PKR activation, virus like particles (VLPs) were generated 
containing nucleocapsids either with the RVFV M or S genome segment. PKR activation status was 
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monitored by detection of protease resistance. As a control we included RIG-I activation since 5`ppp 
panhandle structures of M and S segmented nucleocapsids should activate RIG-I to the same extend. 
Indeed, infection with RVF VLPs regardless which genome segment is packaged within the particle as 
well as nucleocapsids from RVFV infection stimulated RIG-I conformational rearrangements (Fig. 2C). 
Likewise, stimulation with RVF VLPs with S segmented nucleocapsids induce PKR resistant fragments 
whereas VLPs containing an encapsidated RVFV M genome segment failed to promote PKR activation.  
To visualize the interaction of RIG-I and PKR with the RVF VLP M or S nucleocapsids super-resolution 
microscopy was employed. As previously reported, RVFV nucleocapsids are displayed as 
pseudocircular structures with RIG-I attached via a single site (Fig 2D). Thereby, interaction of RIG-I 
with RVFV nucleocapsids was independent of which genome segment was packaged in the viral 
particle. Also PKR co-localized with nucleocapsids of RVFV infection presenting all genome segments. 
This interaction was significantly reduced if only M segmented nucleocapsids were present. In case of 
RVF VLPs enclosing S segmented nucleocapsids almost 80% of the viral nucleocapsids co-localized with 
PKR. Like RIG-I also PKR contacts the nucleocapsids only via a single position, most likely the IGR. This 
indicates that PKR recognizes the IGR of incoming RVFV nucleocapsids which promotes PKR activation.  
Arenavirus nucleocapsids promote PKR activation in absence of translation 
In comparison to RVFV, representatives of the Arenaviridae contain two genome segments and each 
uses ambisense coding strategy with an IGR separating the open reading frames (McLay et al., 2014). 
Arenavirus IGR represents like RVFV IGR a hairpin structure composed of a dsRNA stem with internal 
loops and sporadic mismatches (Fig. 3a). Therefore, we hypothesized that during arenavirus infection 
nucleocapsids would present strong stimulators of PKR activation. New World Junin virus (JUNV) and 
Tacaribe virus (TCRV) and Old World Lassa virus (LASV) were chosen as representatives of the 
arenavirus family to validate the potential of their nucleocapsids to promote PKR activation. 
Surprisingly, full infectious cycle of TCRV, JUNV and LASV did not stimulate PKR phosphorylation and 
conformational switching (Fig. 3b). An abort of the infectious cycle at primary transcription due to CHX 
treatment, however, partially rescued PKR activation. These results could be confirmed by a time-
course experiment (Suppl. 2). LACV full replication cycle induced a robust PKR activation whereas LACV 
nucleocapsids did not stimulate a detectable amount of phosphorylated PKR. Furthermore, 24 h post-
infection total PKR gets degraded indicating the induction of a negative feedback loop to control PKR 
signaling. In contrast, RVFV infection and incoming nucleocapsids induced phosphorylation of PKR. 
Therefore, only incoming nucleocapsids containing an IGR are able to promote PKR activation as 
observed in Fig. 1B. Full infectious cycle of TCRV, JUNV and LASV did not stimulate PKR phosphorylation 
though translation inhibition did partially rescue PKR activation. This indicates on the one hand, that 
arenavirus nucleocapsids are indeed able to stimulate PKR activation. On the other hand, PKR 
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activation by arenaviruses can only be detected in absence of protein synthesis. This raises the 
question whether newly synthesized arenavirus proteins prevents PKR activation during the full viral 
life cycle.  
LASV nucleoprotein induces proteasomal degradation of phosphorylated PKR  
To gain further insights into an arenavirus PKR antagonist, the focus was put on LASV. By performing 
co-IPs, an interaction of PKR with nucleocapsids which are just entering the cell (CHX), but also with 
nucleocapsids generated during viral replication (UT) could be observed (Fig. 4A). However, 
phosphorylated PKR could only be detected if translation was blocked. Furthermore, a weak 
interaction of RIG-I with LASV nucleocapsids could only be detected, when full viral replication was 
allowed. This is confirm with the observation that 5` overhangs of arenavirus nucleocapsids hinder RIG-
I recognition (Marq et al., 2010) and that RIG-I might rather interact with arenavirus dsRNA replicative 
intermediates generated during virus replication.  
To identify the responsible protein able to impair PKR activation, LASV nucleoprotein (NP), 
glycoprotein (GP) and matrix protein (Z) were overexpressed with increasing concentrations together 
with PKR at a constant concentration. PKR overexpression alone was able to promote PKR 
phosphorylation (Fig. 4B). Thus, in case of excessive PKR within the cytoplasm of the transfected cells 
two PKR molecules are able to promote each other’s phosphorylation due to proximity. PKR activation 
status was further supported with increasing amounts of LASV GP and Z. However, overexpression of 
LASV NP results in a reduction of phosphorylated PKR in a dose-dependent manner, without having 
major effects on the total PKR amount. By performing co-IP, phosphorylated PKR is reduced in LASV 
NP expressing cells and also total PKR seems to be slightly decreased (Fig 4C). With a PKR specific co-
IP, LASV NP, but not GP or Z, could be co-precipitated indicating an interaction between PKR and LASV 
NP. 
As described above, RVFV and arenavirus nucleocapsids are likewise recognized by PKR. Due to this 
first similarity between the representatives of these two distinct virus families argues whether they 
would also share similar PKR antagonistic mechanisms. Hence, since RVFV NSs promotes the 
proteasomal degradation of PKR (Ikegami et al., 2009, Habjan et al., 2009b) we wondered whether the 
proteasome would also be involved in reduction of activated PKR during the course of arenavirus 
infection. Thus, cells were transfected with the individual LASV proteins together with PKR and 
analyzed for PKR phosphorylation status in absence or presence of the proteasomal inhibitor MG132. 
In untreated (UT) cells LASV NP overexpression reduces PKR phosphorylation in comparison to LASV 
GP and Z, and GFP control (Fig. 4D, left panel). However, if proteasomal degradation is blocked PKR 
phosphorylation is rescued in LASV NP transfected cells (Fig. 4D, right panel). However, LASV GP and Z 
do not affect PKR activation status in absence or presence of MG132. Also under infectious conditions, 
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in untreated cells (UT) TCRV, JUNV and also LASV infection failed to promote PKR activation which 
could be restored by MG132 treatment (Fig. 4E). This indicates that LASV NP specifically induces the 
proteasomal degradation of activated PKR. Additionally, since inhibition of the proteasomal pathway 
also rescues phosphorylated PKR in case of TCRV and JUNV suggests a similar mechanism to prevent 
antiviral PKR activity throughout the arenavirus family.  
Taken together, after LASV entry the viral nucleocapsids are released into the cytoplasm of the infected 
cell for viral transcription and replication (Fig. 5). The IGR of the viral nucleocapsids is recognized by 
PKR, which leads to PKR conformational rearrangements and phosphorylation. Activated PKR initiates 
translation block via phosphorylation of eIF2α and type I IFN and proinflammatory cytokine response 
via NF-κB to impair LASV replication. Once inside the cytoplasm however transcription and viral protein 
synthesis is rapidly initiated. With an increasing concentration within the cell, LASV NP interacts with 
PKR and induces its proteasomal degradation. This identifies nucleocapsids bearing an IGR as natural 
PKR agonists and that arenaviruses have evolved to rapidly counteract immediate immune recognition. 
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Discussion 
Surveillance of non-self RNA by receptors of the innate immune system is a crucial first line of defense 
against viral infection. A rapid detection is thereby required to efficiently control or even eliminate the 
viral intruder. Our group has recently shown, that RIG-I is able to recognize the 5`ppp dsRNA panhandle 
structure of incoming viral nucleocapsids to induce an immediate antiviral type I IFN response (Weber 
et al., 2013). However, whether other host receptors would likewise be able to recognize viral 
structures immediately after virus entry remained unresolved.  
Thus, PKR activation by incoming nucleocapsids of two representatives of the Bunyaviridae was 
validated. Surprisingly, PKR recognizes and gets activated by RVFV but not LACV nucleocapsids. 
Considering the differences of PKR activation between the two related viruses let us conclude that the 
diverse coding strategies and hence different RNA structures play a role. All three genome segments 
of LACV and RVFV L and M segment are in negative polarity with only one transcriptional unit. RVFV S 
segment, however, uses ambisense coding strategy to direct synthesis of two proteins in an opposite 
direction, separated by a non-coding IGR (Giorgi et al., 1991, Elliott, 2014). By analyzing the predicted 
RVFV IGR, a hairpin structure can be observed with a central dsRNA stem with internal loops and 
peculiar poly-C/G repeats. These repeats were previously described as essential transcription 
termination signals (Albarino et al., 2007). As a minimal requirement for PKR activation serves a hairpin 
with a 16-base pair dsRNA stem flanked by 10 to 15 nucleotides of single-stranded tails (Zheng and 
Bevilacqua, 2004). The dsRNA stem thereby does not have to possess perfect base pairing since PKR 
can tolerate non-Watson-Crick structures and also internal loop structures within the dsRNA stem as 
long as the overall A-form geometry of the RNA is retained (Bevilacqua et al., 1998, Bevilacqua and 
Cech, 1996). 
Thus, RVFV IGR presents all criteria of a potential PKR agonist. It was furthermore reported that PKR 
can interact with structured elements of viral RNA like HCV IRES or dimerized stem-loop structures of 
transactivation (TAR) RNA of HIV (Shimoike et al., 2009, Heinicke et al., 2009). However, whether PKR 
recognizes viral RNA packaged into nucleocapsids in infectious context remained elusive. 
Moy et al. previously reported in this regard that human DDX17 or Drosophila Rm62 specifically 
interacts with RVFV S segment IGR (Moy et al., 2014) indicating that the IGR would also be exposed for 
PKR interaction. PKR contacts the dsRNA mainly via 2`hydroxyl groups of the ribose sugar and oxygen 
residues of the phosphate backbone in a sequence independent manner (Bevilacqua and Cech, 1996). 
Orthobunyavirus, like LACV, RNA is deeply sequestered within the nucleocapsids (Ariza et al., 2013) 
making the RNA highly inaccessible for PKR. RVFV nucleocapsids, however, are less symmetric and with 
few specific protein–protein interactions leaving the phosphate backbone partially exposed (Raymond 
et al., 2010, Raymond et al., 2012). Thus, oxygen groups of the phosphate backbone would be 
accessible for PKR interaction. Indeed, our data demonstrates that PKR is able to engage the IGR within 
13 
 
the viral nucleocapsid in the authentic context of virus infection. Interaction with the IGR promotes 
PKR conformational switching and phosphorylation identifying IGRs as natural PKR agonist. Partial 
exposure of the viral RNA alone, however, is not sufficient for PKR activation. This is indicated by the 
observation that RVFV M or S segmented nucleocapsids with the same packaging grade of the viral 
RNA only activate PKR if the IGR is present. As previously reported, influenza B virus nucleocapsids 
serve as PKR agonists at late stages of infection (Dauber et al., 2009). PKR, thereby, interacts with the 
5`ppp dsRNA panhandle. Here, recognition of incoming nucleocapsids by PKR seems to be independent 
of the panhandle since RVFV M segmented nucleocapsids presenting a 5`ppp dsRNA panhandle failed 
to promote PKR activation. It can be postulated that at an early infectious stage, when low amounts of 
nucleocapsids are present RIG-I outcompetes PKR for 5`ppp panhandle interaction. It seems also 
plausible that PKR is only interacting with the 5`ppp promoter structure at later time-points of infection 
when misencapsidated side product of viral replication occur. Furthermore, PKR might not gain access 
to the panhandle of incoming nucleocapsids covered by the viral polymerase since PKR was not 
associated with the ability to remove proteins from RNA as it was postulated for RIG-I (Schmidt et al., 
2011). 
Interestingly, PKR interaction with the IGR of incoming nucleocapsids is independent on IFN induced 
upregulation of PKR as previously observed (Nallagatla et al., 2007). Already basal PKR levels are 
sufficient to recognize the IGR of viral nucleocapsids. 
Despite RVFV, also representatives of the Arenaviridae use ambisense coding strategy, thus, bearing 
an IGR for transcriptional control. Arenavirus nucleoprotein sequesters the RNA bases like RVFV not 
completely leaving them partially exposed (Hastie et al., 2011b). The predicted IGR of TCRV, JUNV and 
LASV S and L segment represents a similar structure in comparison to RVFV with a hairpin composed 
of a dsRNA stem with internal loops and sporadic mismatches. Therefore, it was not surprising that like 
RVFV, also Old World Lassa virus and New World TCRV and JUNV nucleocapsids are able to promote 
PKR activation. This indicates, that the IGR presented in the nucleocapsids of two distinct virus families 
represent natural PKR agonist to promote an immediate antiviral response. Moy et al. postulated that 
interaction of a protein with the IGR of viral genomes has a negative impact on virus replication (Moy 
et al., 2014). We may, therefore, hypothesize that by interaction with bunyavirus RVFV and arenavirus 
TCRV, JUNV and LASSV IGR, PKR could also impair virus replication independent of its downstream 
signaling activity. However, this was beyond the scope of our study and requires further investigation. 
PKR activation surprisingly could only be detected with incoming arenavirus nucleocapsids, but not if 
full infectious cycle was allowed. This raised the question whether arenaviruses encode for a PKR 
antagonist. By applying a diverse set of molecular biological assays LASV NP was identified as an 
inhibitor of PKR activation. Thereby, LASV NP interacts with PKR and induces its proteasomal 
degradation. It seems that the LASV NP encapsidating the viral genome does not affect the activation 
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status of PKR, which suggests that only free LASV NP acts as a PKR antagonist. LASV NP comprises 
dsRNA binding properties (Hastie et al., 2011a), hence, RNA could serve as a scaffold for PKR 
interaction. However, data supports rather a viral RNA independent interaction of LASV NP with PKR. 
Nevertheless, it cannot be excluded that LASV NP forms a complex with cellular RNA. It was reported 
in this regard that recombinant nucleoproteins of NSV can associate with cellular RNA into 
nucleocapsid like structures (Ruigrok et al., 2011). 
Interestingly, LASV NP comprises the ability to oligomerize (Lennartz et al., 2013). It remains to be 
resolved, whether NP monomers or LASV oligomeric complexes promote PKR antagonism. It was 
previously demonstrated that interference with the IFN response is not strictly dependent on NP 
oligomerization (Lennartz et al., 2013). Besides, Hastie et al. reported that rather the dsRNA specific 3` 
to 5` exonuclease activity of LASV NP is essential for inhibiting IFN signaling (Hastie et al., 2011a). Since 
incoming nucleocapsids do not present long dsRNA stretches to the host immune system, degradation 
of dsRNA might play a distinct immune evasion strategy during later infectious stages.  
Arenavirus NP is well conserved between Old and New World arenaviruses (Hastie et al., 2011b), 
suggesting that an IFN antagonistic activity may be a shared feature (Hastie et al., 2011a). Indeed, Old 
World arenavirus LCMV and New World arenaviruses Whitewater Arroyo virus, Pichinde virus, JUNV, 
Machupo virus and Latino virus, but not TCRV were able to impair IFN and proinflammatory response 
(Martinez-Sobrido et al., 2006, Martinez-Sobrido et al., 2007, Rodrigo et al., 2012). However, the 
underlying mechanism still needs to be clarified. Likewise, arenaviruses use proteasomal degradation 
as a common PKR antagonism. However, the responsible viral protein could not be identified so far. 
TCRV unable to impair IFN signaling (Martinez-Sobrido et al., 2007) was surprisingly able to inhibit PKR 
activation. This highlights the requirement to prevent early recognition by PKR to ensure efficient virus 
propagation even in the case of apathogenic viruses like TCRV.  
Conclusively, we identified the hairpin-structured IGR of RVFV S segment, New World arenavirus TCRV 
and JUNV and Old World arenavirus LASV nucleocapsids as natural PKR agonists. To prevent the 
antiviral PKR activity, TCRV, JUNV and LASV induce proteasomal degradation of activated PKR. In case 
of LASV, the newly synthesized nucleoprotein interacts with PKR and promotes its degradation via the 
proteasomal pathway. Hence, we identified the IGR as part of the viral nucleocapsid as an immediate 
PKR agonist in the authentic context of virus infection. Addtionally, LASV NP was pinned down as a 
novel PKR antagonist. In addition to antagonizing immediate PKR recognition, arenavirus also impair 
early detection of viral nucleocapsids by RIG-I via an unpaired 5`ppp (Marq et al., 2010). Therefore, 
arenaviruses have evolved an efficient strategy to counteract immediate recognition and activation of 
antiviral defense mechanisms. Interestingly, IGRs play essential roles in the control of viral protein 
synthesis and hence virus replication (Lopez and Franze-Fernandez, 2007, Emery and Bishop, 1987, 
Geerts-Dimitriadou et al., 2012, Albarino et al., 2007), indicating the necessity to conserve this 
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structure despite the presence of antiviral defense mechanisms. This makes targeting of the IGR to 
block virus replication a promising target for drug development.  
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Figure Legend 
Fig. 1: RIG-I and PKR differ in their agonist specificity 
A549 cells were either left untreated (UT) or were treated with 50 µg/ml cycloheximide (CHX) and 
mock infected or infected with LACVΔNSs or RVFVΔNSs at an multiplicity of infection (MOI) of 5. After 
5 h, cells were lysed and subjected to limited protease digestion (A and B), co-sedimentation (C) or co-
immunoprecipitation assay (D). (A and B) Conformational switch. Cell lysates were treated with trypsin 
(+) and untreated cell lysates (-) served as input control. Western Blot analysis was performed with 
anti-RIG-I antibody (A) and with antibodies recognizing PKR and phosphorylated PKR (P-PKR) (B). (C) 
Co-sedimentation assay. Cell lysates were loaded on a 50-70% discontinuous glycerol gradient, 
centrifuged and collected fractions were concentrated. Samples were subjected to Western Blot 
analysis using antibodies directed against RIG-I, PKR and LACV or RVFV N as a marker for viral 
nucleocapsids. (D) Co-immunoprecipitation. Cell lysates were mixed with anti-p21 (negative control), 
anti-RIG-I or anti-PKR coupled magnetic beads and incubated for 2 h at 4°C. As input control 2% of the 
lysates were kept. Input and eluates were analyzed by Western Blotting using anti-RIG-I, anti-PKR, anti-
LACV or RVFV N and anti-p21 antibodies. 
Fig. 2: Intergenic region of incoming RVFV nucleocapsids serve as PKR agonists. 
(A) RVFV intergenic region. Secondary structure prediction of RVFV S segment (data base entry 
EU312104.1) intergenic region via free energy minimization (mFold). (B) RVFV coding strategy. Viral 
particles contain three genome segments in negative polarity (vRNA) which are named large (L), middle 
(M) and small (S). L and M segment contain only a single transcriptional unit whereas the S segment 
uses ambisense coding strategy. Thereby, two open reading frames are separated by an intergenic 
region (IGR). During replication, each genome segment is first transcribed to allow protein synthesis of 
essential proteins for genome replication. Amplification of the viral genome (vRNA) involves the 
synthesis of an exact copy of the vRNA, called complementary RNA (cRNA). In case of the S segment, 
the cRNA serves also as a template for mRNA synthesis. (C) Conformational switch. A549 cells were 
treated with 50 µg/ml CHX and then infected for 5 h with RVF VLPs containing either M or S segmented 
nucleocapsids. Limited protease digestion and analysis of the samples was performed as for Fig. 1A 
and B. (D) Super-resolution Immunofluorescence Microscopy of RIG-I and PKR nucleocapsid 
complexes. Cells were treated and infected as described for C and then fixed and stained against RVFV 
N (green channel) and RIG-I (upper panel; red channel) or PKR (lower panel; red channel). 
Quantification was performed of three independent experiments. Student’s T-test was carried out for 
statistical analysis. Significant differences are indicated by asterisks (** p<0.01). 
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Fig. 3: Arenavirus replication products prevent nucleocapsid promoted PKR 
activation. 
(A) Secondary structure prediction of TCRV S segment (data base entry NC_004293.1), TCRV L segment 
(data base entry NC_004292.1), JUNV S segment (data base entry JF799984.1), JUNV L segment (data 
base entry JF799980.1), LASV S segment (data base entry HQ688673.1) and LASV L segment (data base 
entry HQ688674.1) intergenic region via free energy minimization (mFold). (B) PKR activation status. 
A549 cells were either left untreated (UT) or were treated with 50 µg/ml CHX and mock infected or 
infected with RVFVΔNSs, TCRV, JUNV or LASV at an MOI of 1. Infection was stopped 5 h post-infection 
and cell lysates were prepared with 0.5% Triton X-100 in PBS. Limited protease digestion and analysis 
of the samples was performed as for Fig. 1B. 
Fig. 4: LASV nucleoprotein promotes proteasomal degradation of PKR. 
(A) Interaction of RIG-I and PKR with LASV nucleocapsids. A549 cells were left untreated (UT) or were 
treated with 50 µg/ml CHX and either mock or LASV infected at an MOI of 5. After 5 h, cell lysates were 
prepared and co-immunoprecipitation was performed as described for Fig. 1D. For Western Blot 
analysis anti-RIG, anti-PKR, anti-P-PKR, anti-LASV NP and anti-p21 antibodies were used. (B) 
Overexpression analysis. HEK293T cells were transfected with either 0.25, 0.5, 1 or 2 µg of HA-tagged 
expression constructs for LASV NP, GP or Z together with 1 µg PKR plasmid. Normalization of 
transfected plasmid amount was done with ΔMx plasmid. Expression was allowed for 24 h and then 
cell lysates were prepared. Samples were analyzed by Western Blotting using anti-P-PKR, anti-PKR and 
anti-HA antibodies. (C) Co-immunoprecipitation. HEK293T cells were transfected with 1 µg of LASV NP, 
GP or Z together with 1 µg PKR plasmid. Lysates were prepared 24 h post-transfection and subjected 
to co-immunorprecipitation with anti-PKR coupled beads as described in Fig. 1D. Input samples and 
eluates were validated as described for B. (D and E) Influence of proteasomal degradation. (D) HEK293T 
cells were transfected like C and 8 h post-transfection either left untreated or treated with 20 µM 
MG132. After additional 16 h, cells were lysed and analyzed as described for B. (E) Conformational 
switch. A549 cells were infected with RVFVΔNSs, TCRV, JUNV or LASV at an MOI of 1 and after the 
inoculum was removed the cells were left either untreated (UT) or were treated with 20 µM MG132. 
After 5 h, cells were lysed and limited protease digestion and Western Blotting was performed as 
described for Fig. 1B. 
Fig. 5: Mechanism of LASV NP mediated PKR antagonism 
Arenavirus IGR exposed from the viral nucleocapsid can be recognized by PKR. Once activated, PKR 
blocks cap-dependent translation of viral and host cell proteins by phosphorylation of the alpha 
subunit of eukaryotic initiation factor 2 (eIF2α). Additionally, PKR induces an antiviral type I interferon 
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(IFN) and proinflammatory response. However, to circumvent PKR activation, LASV NP interacts with 
PKR and promotes its proteasomal degradation 
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Supplemental information 
Supplemental Experimental Procedure 
Co-sedimentation assay of recombinant LCV and RVFV nucleoprotein 
For co-sedimentation assays, A549 cells grown in two wells of a 6 well plate were transiently 
transfected with 1 µg pI.18_RVFV N or pTM_LACV N using Nanofectin transfection reagent (PAA 
Laboratories). Cell lysates were prepared 24 h post-transfection and subjected to co-sedimentation 
assay as ascribed above. Western Blot analysis was performed with mouse monoclonal anti-RIG-I 
antibody at 1:1000, mouse monoclonal anti-PKR B10 at 1:500, rabbit polyclonal anti-LACV N at 1:1000, 
and mouse polyclonal anti-RVFV N serum at 1:1000. 
Time-course experiment  
A549 cells were infected with LACVΔNSs, RVFVΔNSs, TCRV, JUNV or LASV at an MOI of 1. If indicated, 
cells were treated with 50 µg/ml CHX 1 h prior, during infection and while the course of the 
experiment. After 2, 5 and 24 h cells were washed and lysed in 1-fold sample buffer. Samples were 
analyzed by SDS-PAGE and Western Blotting using mouse monoclonal anti-PKR B10 at 1:500, rabbit 
monoclonal anti-p-PKR Thr 446 at 1:500, rabbit polyclonal anti-LACV N at 1:1000, mouse polyclonal 
anti-RVFV N serum at 1:1000, rabbit monoclonal anti LASV NP at 1:3000, guinea pig polyclonal anti-
JUNV NP at 1:500 and guinea pig polyclonal anti-TCRV NP at 1:500. Staining with mouse monoclonal 
anti-actin served as a loading control 
Suppl. 1: RIG-I and PKR do not interact with LACV and RVFV nucleoprotein 
Co-sedimentation assay. HEK293T cells were transfected with either LACV or RVFV N and 24 h post-
transfection cell lysates were prepared. Samples were loaded on a 50-70% discontinuous glycerol 
gradient, centrifuged and collected fractions were concentrated. Samples were subjected to Western 
Blot analysis using antibodies directed against RIG-I, PKR and LACV or RVFV N as a marker for viral 
nucleocapsids. 
Suppl. 2: PKR activation during bunyavirus and arenavirus infection 
PKR activation status. A549 cells were either left untreated (UT) or were treated with 50 µg/ml CHX 
and mock infected or infected with LACVΔNSs, RVFVΔNSs, TCRV, JUNV or LASV at an MOI of 1. After 2, 
5 and 24 h cell lysates were prepared with 1-fold sample buffer and samples were analyzed by Western 
blotting using antisera against phosphorylated PKR, PKR and LASV N, RVFV N, TCRV NP, JUNV NP or 
LASV NP, respectively. Staining against actin served as a loading control.   
21 
 
References 
ALBARINO, C. G., BIRD, B. H. & NICHOL, S. T. 2007. A shared transcription termination signal on negative 
and ambisense RNA genome segments of Rift Valley fever, sandfly fever Sicilian, and Toscana 
viruses. J Virol, 81, 5246-56. 
ARIZA, A., TANNER, S. J., WALTER, C. T., DENT, K. C., SHEPHERD, D. A., WU, W., MATTHEWS, S. V., 
HISCOX, J. A., GREEN, T. J., LUO, M., ELLIOTT, R. M., FOOKS, A. R., ASHCROFT, A. E., 
STONEHOUSE, N. J., RANSON, N. A., BARR, J. N. & EDWARDS, T. A. 2013. Nucleocapsid protein 
structures from orthobunyaviruses reveal insight into ribonucleoprotein architecture and RNA 
polymerization. Nucleic Acids Res, 41, 5912-26. 
BAUM, A., SACHIDANANDAM, R. & GARCIA-SASTRE, A. 2010. Preference of RIG-I for short viral RNA 
molecules in infected cells revealed by next-generation sequencing. Proc Natl Acad Sci U S A, 
107, 16303-8. 
BEVILACQUA, P. C. & CECH, T. R. 1996. Minor-groove recognition of double-stranded RNA by the 
double-stranded RNA-binding domain from the RNA-activated protein kinase PKR. 
Biochemistry, 35, 9983-94. 
BEVILACQUA, P. C., GEORGE, C. X., SAMUEL, C. E. & CECH, T. R. 1998. Binding of the protein kinase PKR 
to RNAs with secondary structure defects: role of the tandem A-G mismatch and 
noncontiguous helixes. Biochemistry, 37, 6303-16. 
BLAKQORI, G. & WEBER, F. 2005. Efficient cDNA-based rescue of La Crosse bunyaviruses expressing or 
lacking the nonstructural protein NSs. J Virol, 79, 10420-8. 
CARROLL, K., ELROY-STEIN, O., MOSS, B. & JAGUS, R. 1993. Recombinant vaccinia virus K3L gene 
product prevents activation of double-stranded RNA-dependent, initiation factor 2 alpha-
specific protein kinase. J Biol Chem, 268, 12837-42. 
CLEMENS, M. J. 1997. PKR--a protein kinase regulated by double-stranded RNA. Int J Biochem Cell Biol, 
29, 945-9. 
DABO, S. & MEURS, E. F. 2012. dsRNA-dependent protein kinase PKR and its role in stress, signaling 
and HCV infection. Viruses, 4, 2598-635. 
DAUBER, B., MARTINEZ-SOBRIDO, L., SCHNEIDER, J., HAI, R., WAIBLER, Z., KALINKE, U., GARCIA-SASTRE, 
A. & WOLFF, T. 2009. Influenza B virus ribonucleoprotein is a potent activator of the antiviral 
kinase PKR. PLoS Pathog, 5, e1000473. 
DZANANOVIC, E., PATEL, T. R., DEO, S., MCELENEY, K., STETEFELD, J. & MCKENNA, S. A. 2013. 
Recognition of viral RNA stem-loops by the tandem double-stranded RNA binding domains of 
PKR. Rna, 19, 333-44. 
ELLIOTT, R. M. 1990. Molecular biology of the Bunyaviridae. J Gen Virol, 71 ( Pt 3), 501-22. 
ELLIOTT, R. M. 2014. Orthobunyaviruses: recent genetic and structural insights. Nat Rev Microbiol, 12, 
673-85. 
EMERY, V. C. & BISHOP, D. H. 1987. Characterization of Punta Toro S mRNA species and identification 
of an inverted complementary sequence in the intergenic region of Punta Toro phlebovirus 
ambisense S RNA that is involved in mRNA transcription termination. Virology, 156, 1-11. 
GEERTS-DIMITRIADOU, C., LU, Y. Y., GEERTSEMA, C., GOLDBACH, R. & KORMELINK, R. 2012. Analysis 
of the Tomato spotted wilt virus ambisense S RNA-encoded hairpin structure in translation. 
PLoS One, 7, e31013. 
GIORGI, C., ACCARDI, L., NICOLETTI, L., GRO, M. C., TAKEHARA, K., HILDITCH, C., MORIKAWA, S. & 
BISHOP, D. H. 1991. Sequences and coding strategies of the S RNAs of Toscana and Rift Valley 
fever viruses compared to those of Punta Toro, Sicilian Sandfly fever, and Uukuniemi viruses. 
Virology, 180, 738-53. 
GOUBAU, D., DEDDOUCHE, S. & REIS, E. S. C. 2013. Cytosolic sensing of viruses. Immunity, 38, 855-69. 
GOUBAU, D., SCHLEE, M., DEDDOUCHE, S., PRUIJSSERS, A. J., ZILLINGER, T., GOLDECK, M., SCHUBERTH, 
C., VAN DER VEEN, A. G., FUJIMURA, T., REHWINKEL, J., ISKARPATYOTI, J. A., BARCHET, W., 
LUDWIG, J., DERMODY, T. S., HARTMANN, G. & REIS, E. S. C. 2014. Antiviral immunity via RIG-
I-mediated recognition of RNA bearing 5'-diphosphates. Nature. 
22 
 
HABJAN, M., PENSKI, N., WAGNER, V., SPIEGEL, M., OVERBY, A. K., KOCHS, G., HUISKONEN, J. T. & 
WEBER, F. 2009a. Efficient production of Rift Valley fever virus-like particles: The antiviral 
protein MxA can inhibit primary transcription of bunyaviruses. Virology, 385, 400-8. 
HABJAN, M., PICHLMAIR, A., ELLIOTT, R. M., OVERBY, A. K., GLATTER, T., GSTAIGER, M., SUPERTI-
FURGA, G., UNGER, H. & WEBER, F. 2009b. NSs protein of rift valley fever virus induces the 
specific degradation of the double-stranded RNA-dependent protein kinase. J Virol, 83, 4365-
75. 
HASTIE, K. M., KIMBERLIN, C. R., ZANDONATTI, M. A., MACRAE, I. J. & SAPHIRE, E. O. 2011a. Structure 
of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease activity essential 
for immune suppression. Proc Natl Acad Sci U S A, 108, 2396-401. 
HASTIE, K. M., LIU, T., LI, S., KING, L. B., NGO, N., ZANDONATTI, M. A., WOODS, V. L., JR., DE LA TORRE, 
J. C. & SAPHIRE, E. O. 2011b. Crystal structure of the Lassa virus nucleoprotein-RNA complex 
reveals a gating mechanism for RNA binding. Proc Natl Acad Sci U S A, 108, 19365-70. 
HEINICKE, L. A., WONG, C. J., LARY, J., NALLAGATLA, S. R., DIEGELMAN-PARENTE, A., ZHENG, X., COLE, 
J. L. & BEVILACQUA, P. C. 2009. RNA dimerization promotes PKR dimerization and activation. J 
Mol Biol, 390, 319-38. 
HERTZOG, P. J. & WILLIAMS, B. R. 2013. Fine tuning type I interferon responses. Cytokine Growth Factor 
Rev, 24, 217-25. 
IKEGAMI, T. 2012. Molecular biology and genetic diversity of Rift Valley fever virus. Antiviral Res, 95, 
293-310. 
IKEGAMI, T., NARAYANAN, K., WON, S., KAMITANI, W., PETERS, C. J. & MAKINO, S. 2009. Rift Valley 
fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR 
and inhibits eIF2alpha phosphorylation. PLoS Pathog, 5, e1000287. 
IVASHKIV, L. B. & DONLIN, L. T. 2014. Regulation of type I interferon responses. Nat Rev Immunol, 14, 
36-49. 
KOHLWAY, A., LUO, D., RAWLING, D. C., DING, S. C. & PYLE, A. M. 2013. Defining the functional 
determinants for RNA surveillance by RIG-I. EMBO Rep, 14, 772-9. 
LARA, E., BILLECOCQ, A., LEGER, P. & BOULOY, M. 2011. Characterization of wild-type and alternate 
transcription termination signals in the Rift Valley fever virus genome. J Virol, 85, 12134-45. 
LEMAIRE, P. A., TESSMER, I., CRAIG, R., ERIE, D. A. & COLE, J. L. 2006. Unactivated PKR exists in an open 
conformation capable of binding nucleotides. Biochemistry, 45, 9074-84. 
LOO, Y. M. & GALE, M., JR. 2011. Immune signaling by RIG-I-like receptors. Immunity, 34, 680-92. 
LOPEZ, N. & FRANZE-FERNANDEZ, M. T. 2007. A single stem-loop structure in Tacaribe arenavirus 
intergenic region is essential for transcription termination but is not required for a correct 
initiation of transcription and replication. Virus Res, 124, 237-44. 
MARQ, J. B., KOLAKOFSKY, D. & GARCIN, D. 2010. Unpaired 5' ppp-nucleotides, as found in arenavirus 
double-stranded RNA panhandles, are not recognized by RIG-I. J Biol Chem, 285, 18208-16. 
MARTINEZ-SOBRIDO, L., GIANNAKAS, P., CUBITT, B., GARCIA-SASTRE, A. & DE LA TORRE, J. C. 2007. 
Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J Virol, 81, 
12696-703. 
MARTINEZ-SOBRIDO, L., ZUNIGA, E. I., ROSARIO, D., GARCIA-SASTRE, A. & DE LA TORRE, J. C. 2006. 
Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus 
lymphocytic choriomeningitis virus. J Virol, 80, 9192-9. 
MCLAY, L., LIANG, Y. & LY, H. 2014. Comparative analysis of disease pathogenesis and molecular 
mechanisms of New World and Old World arenavirus infections. J Gen Virol, 95, 1-15. 
MOY, R. H., COLE, B. S., YASUNAGA, A., GOLD, B., SHANKARLING, G., VARBLE, A., MOLLESTON, J. M., 
TENOEVER, B. R., LYNCH, K. W. & CHERRY, S. 2014. Stem-loop recognition by DDX17 facilitates 
miRNA processing and antiviral defense. Cell, 158, 764-77. 
NALLAGATLA, S. R., HWANG, J., TORONEY, R., ZHENG, X., CAMERON, C. E. & BEVILACQUA, P. C. 2007. 
5'-triphosphate-dependent activation of PKR by RNAs with short stem-loops. Science, 318, 
1455-8. 
23 
 
ONOMOTO, K., JOGI, M., YOO, J. S., NARITA, R., MORIMOTO, S., TAKEMURA, A., SAMBHARA, S., 
KAWAGUCHI, A., OSARI, S., NAGATA, K., MATSUMIYA, T., NAMIKI, H., YONEYAMA, M. & 
FUJITA, T. 2012. Critical role of an antiviral stress granule containing RIG-I and PKR in viral 
detection and innate immunity. PLoS One, 7, e43031. 
PANDEY, S., KAWAI, T. & AKIRA, S. 2014. Microbial Sensing by Toll-Like Receptors and Intracellular 
Nucleic Acid Sensors. Cold Spring Harb Perspect Biol. 
PICHLMAIR, A., SCHULZ, O., TAN, C. P., REHWINKEL, J., KATO, H., TAKEUCHI, O., AKIRA, S., WAY, M., 
SCHIAVO, G. & REIS E SOUSA, C. 2009. Activation of MDA5 requires higher-order RNA 
structures generated during virus infection. J Virol, 83, 10761-9. 
RAYMOND, D. D., PIPER, M. E., GERRARD, S. R., SKINIOTIS, G. & SMITH, J. L. 2012. Phleboviruses 
encapsidate their genomes by sequestering RNA bases. Proc Natl Acad Sci U S A, 109, 19208-
13. 
RAYMOND, D. D., PIPER, M. E., GERRARD, S. R. & SMITH, J. L. 2010. Structure of the Rift Valley fever 
virus nucleocapsid protein reveals another architecture for RNA encapsidation. Proc Natl Acad 
Sci U S A, 107, 11769-74. 
REIKINE, S., NGUYEN, J. B. & MODIS, Y. 2014. Pattern Recognition and Signaling Mechanisms of RIG-I 
and MDA5. Front Immunol, 5, 342. 
RODRIGO, W. W., ORTIZ-RIANO, E., PYTHOUD, C., KUNZ, S., DE LA TORRE, J. C. & MARTINEZ-SOBRIDO, 
L. 2012. Arenavirus nucleoproteins prevent activation of nuclear factor kappa B. J Virol, 86, 
8185-97. 
ROMANO, P. R., ZHANG, F., TAN, S. L., GARCIA-BARRIO, M. T., KATZE, M. G., DEVER, T. E. & 
HINNEBUSCH, A. G. 1998. Inhibition of double-stranded RNA-dependent protein kinase PKR by 
vaccinia virus E3: role of complex formation and the E3 N-terminal domain. Mol Cell Biol, 18, 
7304-16. 
RUIGROK, R. W., CREPIN, T. & KOLAKOFSKY, D. 2011. Nucleoproteins and nucleocapsids of negative-
strand RNA viruses. Curr Opin Microbiol, 14, 504-10. 
SCHLEE, M. 2013. Master sensors of pathogenic RNA - RIG-I like receptors. Immunobiology, 218, 1322-
35. 
SCHLEE, M., ROTH, A., HORNUNG, V., HAGMANN, C. A., WIMMENAUER, V., BARCHET, W., COCH, C., 
JANKE, M., MIHAILOVIC, A., WARDLE, G., JURANEK, S., KATO, H., KAWAI, T., POECK, H., 
FITZGERALD, K. A., TAKEUCHI, O., AKIRA, S., TUSCHL, T., LATZ, E., LUDWIG, J. & HARTMANN, G. 
2009. Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded 
RNA as contained in panhandle of negative-strand virus. Immunity, 31, 25-34. 
SCHMIDT, A., SCHWERD, T., HAMM, W., HELLMUTH, J. C., CUI, S., WENZEL, M., HOFFMANN, F. S., 
MICHALLET, M. C., BESCH, R., HOPFNER, K. P., ENDRES, S. & ROTHENFUSSER, S. 2009. 5'-
triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc 
Natl Acad Sci U S A, 106, 12067-72. 
SCHNEIDER, W. M., CHEVILLOTTE, M. D. & RICE, C. M. 2014. Interferon-stimulated genes: a complex 
web of host defenses. Annu Rev Immunol, 32, 513-45. 
SCHOGGINS, J. W. 2014. Interferon-stimulated genes: roles in viral pathogenesis. Curr Opin Virol, 6, 40-
6. 
SHIMOIKE, T., MCKENNA, S. A., LINDHOUT, D. A. & PUGLISI, J. D. 2009. Translational insensitivity to 
potent activation of PKR by HCV IRES RNA. Antiviral Res, 83, 228-37. 
TAYLOR, D. R., SHI, S. T., ROMANO, P. R., BARBER, G. N. & LAI, M. M. 1999. Inhibition of the interferon-
inducible protein kinase PKR by HCV E2 protein. Science, 285, 107-10. 
VANOUDENHOVE, J., ANDERSON, E., KRUEGER, S. & COLE, J. L. 2009. Analysis of PKR structure by small-
angle scattering. J Mol Biol, 387, 910-20. 
WALTER, C. T. & BARR, J. N. 2011. Recent advances in the molecular and cellular biology of 
bunyaviruses. J Gen Virol. 
WEBER, M., GAWANBACHT, A., HABJAN, M., RANG, A., BORNER, C., SCHMIDT, A. M., VEITINGER, S., 
JACOB, R., DEVIGNOT, S., KOCHS, G., GARCIA-SASTRE, A. & WEBER, F. 2013. Incoming RNA virus 
24 
 
nucleocapsids containing a 5'-triphosphorylated genome activate RIG-I and antiviral signaling. 
Cell Host Microbe, 13, 336-46. 
WEBER, M. & WEBER, F. 2014a. Monitoring Activation of the Antiviral Pattern Recognition Receptors 
RIG-I And PKR By Limited Protease Digestion and Native PAGE. J Vis Exp. 
WEBER, M. & WEBER, F. 2014b. RIG-I-like receptors and negative-strand RNA viruses: RLRly bird 
catches some worms. Cytokine Growth Factor Rev. 
WILLIAMS, B. R. 1999. PKR; a sentinel kinase for cellular stress. Oncogene, 18, 6112-20. 
ZHENG, X. & BEVILACQUA, P. C. 2004. Activation of the protein kinase PKR by short double-stranded 
RNAs with single-stranded tails. Rna, 10, 1934-45. 
 
RIG-I
30 kDa resistant
RIG-I fragment
tr
yp
si
n
-
+
UT
1A
CHX
1C
1D
LACV
input
anti-p21 anti-RIG-I anti-PKR
IP
RIG-I
PKR
N
p21
- + - + - + - +
50% 
glycerol
70% 
glycerolmock
RIG-I
PKR
1 2 3 4 8 9 10 115 6 7 12
P-PKR
PKR
30 kDa resistant
PKR fragment
tr
yp
si
n
-
+
1B
UT CHX LACV N
50% 
glycerol
70% 
glycerolLACV
RIG-I
PKR
1 2 3 4 8 9 10 115 6 7 12
RVFV N
50% 
glycerol
70% 
glycerolRVFV
RIG-I
PKR
1 2 3 4 8 9 10 115 6 7 12
RVFV
input
anti-p21 anti-RIG-I anti-PKR
IP
- + - + - + - +
RIG-I
PKR
N
p21
+ ΔMx
RVFV_M
RVFV_L
+ -
-
-
+
+
+
+
M segment
(-IGR)
S segment
(+IGR)
+ + -
-
-
+
+
+
+
tr
yp
si
n
-
+
-
+
RIG-I
30 kDa resistant
RIG-I fragment
PKR
30 kDa resistant
PKR fragment
2C
2D
RVF VLP
2B
negative (-) sense genome segment
mRNA
vRNA
Cap AAA
-/+ (ambisense) genome segment
Cap AAA
Cap AAA mRNA
vRNA
mRNA
RVFV particle
L and M segment
S segment
nucleocapsids coding strategy
cRNA
2A
RVFV M segment S segment
RVF VLP
RIG-I
PKR
RVFV N
RVFV N
0
20
40
60
80
100
120
RVFV  M  S RVFV  M  S
Co
-
lo
ca
liz
at
io
n
 
w
ith
 
n
u
cl
eo
ca
ps
id
s
(%
)
RVF VLP RVF VLP
**
**
**
3a
P-PKR
PKR
tr
yp
si
n
PKR resistant
fragment
-
+
UT CHX3b
TCRV S segment TCRV L segment
JUNV S segment JUNV L segment
LASV S segment LASV L segment
4B
LASV NP-HA LASV  Z-HALASV GP-HA
PKR+ + ++ + + ++ + + ++
P-PKR
HA
PKR
4E
P-PKR
PKR
tr
yp
si
n
PKR resistant
fragment
-
+
UT Mg132
4D
P-PKR
LASV NP-HA
LASV GP-HA
LASV Z-HA
delMX
+
+
+
MG132
+
+ + + + PKR
+
+
+
UT
+
+ + + +
NP
Z
GP
PKR
4C
LASV NP-HA
LASV GP-HA
LASV Z-HA
delMX
+
+
+
in
pu
t
+
+ + + + PKR
P-PKR
NP
Z
GP
PKR
P-PKR
NP
Z
GP
PKR
IP
: 
an
ti-
PK
R
LASV
anti-p21 anti-RIG-I anti-PKR
- + - + - + - +
RIG-I
PKR
NP
p21
P-PKR
*
input IP
CHX
p21
LASV
input
anti-p21 anti-RIG-I anti-PKR
IP
RIG-I
PKR
NP
- + - + - + - +
P-PKR
UT
*
4A
LASV
eIF2α
translation block
p
p p
N
proteasome
cytoplasm
nucleocapsid
Cap AAA
vRNA
mRNA
transcription
translation
PKR
5
NF-κB
I-κB
IFN and proinflammatory
cytokine response
Virus replication
Suppl. 1
RIG-I
PKR
50% 
glycerol
70% 
glycerolRVFV N
1 2 3 4 8 9 10 115 6 7 12
RVFV N
RIG-I
PKR
LACV N
50% 
glycerol
70% 
glycerolLACV N
1 2 3 4 8 9 10 115 6 7 12
Suppl. 2
time pi (h)
UT
2 5 24 2 5 24
CHX
P-PKR
PKR
actin
m
o
ck
LA
CV
time pi (h)
UT
2 5 24 2 5 24
CHX
P-PKR
PKR
actin
N
R
VF
V
time pi (h)
UT
2 5 24 2 5 24
CHX
P-PKR
PKR
actin
N
TC
R
V
UT
2 5 24 2 5 24
CHX
P-PKR
PKR
actin
NP
time pi (h)
JU
N
V
UT
2 5 24 2 5 24
CHX
P-PKR
PKR
actin
NP
time pi (h)
LA
SV
UT
2 5 24 2 5 24
CHX
P-PKR
PKR
actin
NP
time pi (h)
  
 Original publications and manuscripts 
40 
4.5. REVIEW: RIG-I-like receptors and negative-strand RNA viruses: 
RLRly bird catches some worms 
 
Own contribution:  
I contributed to writing of the manuscript.  
 
 
Michaela Gerlach 
  
Mini review
RIG-I-like receptors and negative-strand RNA viruses: RLRly bird
catches some worms
Michaela Weber, Friedemann Weber *
Institute for Virology, Philipps-University Marburg, D-35043 Marburg, Germany
1. Introduction
Viruses with a single-stranded (ss) RNA genome of negative
polarity (negative-strand RNA viruses, NSVs) are responsible for a
wide range of diseases. Members of the NSV group cause
respiratory problems (e.g. influenza, hantavirus pulmonary
syndrome, respiratory syncytial virus), severe childhood diseases
(measles, mumps), neuronal infection (La Crosse virus, Toscana
virus, Borna disease virus), even with up to 100% mortality
(Rabies), as well as multi-organ failure and haemorrhagic fevers
(Rift Valley fever, Severe fever with Thrombocytopenia, Nipah,
Ebola, Lassa, Hanta, Crimean Congo haemorrhagic fever).
NSVs encode highly active polymerases, producing in a typical
case 100,000 RNA copies per cell within 10 h of infection [1]. Quite
expectedly, such numbers of non-self RNAs in the cytoplasm are
highly immunogenic and could trigger massive antiviral responses.
To avoid being defeated by the innate immune system, NSVs have
evolved strategies against recognition, antiviral signalling, and the
launched antiviral mechanisms. In this review article, we will
attempt to provide an update on the principles of cytoplasmic virus
recognition and viral escape. For deeper insights into specific
aspects and into the extracellular virus recognition which is not
covered here, we refer to the wealth of recent, excellent reviews by
others [2–14].
2. Negative-strand RNA viruses
Taxonomically, the group of NSVs is divided into those having
one, continuous strand of genomic RNA (the Mononegavirales) and
those whose genome is divided into several segments. The
Mononegavirales, also called nonsegmented NSVs (ns-NSVs) have
all genes lined up along the ssRNA genome, separated by
regulatory intergenic regions acting as transcriptional promoters,
and flanked by the regulatory leader and trailer sequences
(Fig. 1A). For segmented NSVs (s-NSVs), by contrast, each RNA
segment contains one promoter (formed by annealing of the 50 and
30 ends) driving expression of one gene (Fig. 1B). The number of
segments differs between s-NSV families. Members of the
Orthomyxoviridae possess mostly 8 segments, whereas Bunyavir-
idae have 3 and Arenaviridae have 2 segments (Table 1). Some
bunyaviruses and all arenaviruses enlarge the genetic capacity of
their segments by transcribing an additional gene from the copy of
the genome RNA (the cRNA), the so-called ambisense strategy.
3. Intracellular virus recognition by RIG-I like receptors
A rapid and efficient antiviral response is essential to limit virus
replication and ensure survival of the host. The cytoplasmic
RIG-I-like receptors (RLRs) are able to detect viral RNA species and
to trigger an intracellular signalling cascade that eventually results
in the release of specific cytokines and chemokines [2,10]. Type I
interferons (IFN-a/b) represent the most important antiviral
cytokines, inducing expression of more than 300 IFN-stimulated
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genes (ISGs) [12]. ISGs act in a variety of ways to inhibit virus
replication, to elevate antiviral alertness in the infected and
surrounding cells, and to modulate the adaptive immune system.
3.1. RLR structure
The group of RLRs consists of RIG-I (retinoic acid inducible gene
1), MDA5 (melanoma differentiation association factor 5) and LGP2
(laboratory of genetics and physiology 2) [10]. RLRs are members
of the DExD/H box RNA helicase family and consist of a carboxy-
terminal domain (CTD), a central DExD/H box RNA helicase domain
(composed of Hel1, Hel2 with the insertion domain Hel2i in
between) and, in the case of RIG-I and MDA5, two additional
amino-terminal caspase recruitment domains (CARDs) (Fig. 2)
[15,16]. For RIG-I, the CTD and the helicase domain are conducting
ligand recognition, whereas in case of MDA5 this function seems to
be performed by the helicase domain. The terminal CARDs are
required for signal transduction. LGP2 does not signal by itself but
can bind double-stranded RNA (dsRNA) and acts as a positive
regulator of MDA5 [17,18].
3.2. RLR signalling
RIG-I has in non-infected cells an auto-repressed conformation
in which the CARDs are masking the RNA binding site of the
helicase domain [16]. The CTD is exposed to the cytosol and
connected by a flexible linker. When the CTD binds to a specific
ligand, RIG-I switches its conformation to wrap around the RNA
ligand (via CTD and helicase domain) and expose the CARDs
instead of the CTD [9]. Stabilization of the active conformation and
homo-oligomerization of RIG-I are facilitated by post-translational
modifications like dephosphorylation, covalent K63 ubiquitinyla-
tion via TRIM25, and association of unanchored ubiquitin chains
[4,19–23]. Activated RIG-I can form helical tetramers, but – similar
to MDA5 – also longer oligomers along dsRNA [21,24,25].
The oligomers of RIG-I and MDA5 serve as platforms to recruit
the adaptor protein MAVS (mitochondrial antiviral signalling) via
multiple CARD-CARD interactions [2]. Activated MAVS associates
with TRAF3/6 to promote activation of the kinases TBK1/IKKe
which are responsible for the phosphorylation of the transcription
factors IRF3 and IRF7 [2]. In parallel, the kinases IKKa and IKKb can
activate NF-kB. IRF3/7 and NF-kB translocate into the nucleus to
initiate expression of IFN-a/b and proinflammatory cytokines. The
basics of RLR signalling are outlined in Fig. 3 (middle panel).
Fig. 1. Differing coding strategies of nonsegmented and segmented NSVs. Symbolized virus particles are shown on top, followed by a sketch of the unencapsidated viral
genome with the individual genes as grey boxes. By convention the ssRNA genomes of NSVs are drawn from 30–50 . (A) The genome of ns-NSVs consists of one continuous
stretch of ssRNA from which all mRNAs are synthesized. Intergenic regions contain stop/start signals regulating termination and initiation of transcription. Note the uncapped
50ppp RNA transcribed from the leader region. Basic set-up of a Rhabdovirus is shown as example. (B) s-NSVs transcribe mostly one mRNA per genome segment (with the
exception of ambisense segments which express another gene transcribed from the opposite direction). n = number of segments. Not all s-NSVs have mRNAs with a polyA,
which is therefore shown in brackets.
Table 1
Negative-strand RNA viruses.
Family Genome
organization
Representative membersa
Filoviridae Nonsegmented Ebola virus (EBOV), Marburg virus
(MARV)
Paramyxoviridae Nonsegmented Nipah virus (NiV), measles virus (MeV),
Parainfluenza virus (PIV), Respiratory
syndrome virus (RSV), Sendai virus
(SeV)
Rhabdoviridae Nonsegmented Rabies virus, vesicular stomatitis virus
(VSV)
Bornaviridae Nonsegmented Borna disease virus (BDV)
Arenaviridae 2 Segments Lassa virus (LASV)
Bunyaviridae 3 Segments Bunyamwera virus (BUNV;
Orthobunyavirus)
La Crosse virus (LACV;
Orthobunyavirus)
Rift Valley fever virus (RVFV;
Phlebovirus)
Toscana virus (TOSV; Phlebovirus)
Severe fever with thrombocytopenia
virus (SFTSV; Phlebovirus)
Hantaan virus (HTNV; Hantavirus)
Crimean-Congo haemorrhagic fever
virus (CCHFV; Nairovirus)
Orthomyxoviridae 6–8 Segments Influenza A virus (FLUAV), Thogoto
virus (THOV)
aVirus acronyms and genera shown in brackets
Fig. 2. RIG-I like receptors and their domains. Domain structure of RIG-I, MDA5
and LGP2. CARD, caspase activation recruitment domains; HEL, DExD/H-box
helicase domain; HEL2i, insertion domain of helicase domain 2; CTD, carboxy-
terminal domain.
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3.3. RLR agonists
Despite their structural and functional similarity, RIG-I and
MDA5 recognize different RNA ligands (see below), and are
activated by distinct but overlapping subsets of viruses [13].
Ligand-wise, RIG-I is strongly activated by blunt-ended dsRNAs of
at least 10 base pairs length bearing a 50triphosphate (50ppp)
group [15,26,27], by long dsRNA molecules of more than 200
base pairs (irrespective of the 50 end) [24,28], but also by
30-monophosphorylated ssRNAs [29] and poly U/UC rich stretches
of ssRNA [30]. MDA5 detects long dsRNA molecules, ideally with
higher order RNA structures [31], and can be activated by
particular stretches of NSV RNAs [32,33]. Both RLRs also show
preference for AU-rich ssRNAs which seems independent of
structure [33,34].
While these activating molecules had mostly been identified
and characterized by transfections and manipulations of naked
RNAs, they nonetheless allowed conclusions on the nature of the
physiological RLR agonists present in infected cells (summarized in
Fig. 3, left and right panels). NSVs encapsidate their ssRNA genome
and its template (and copy), the antigenome, with nucleocapsid
proteins [35]. Therefore, NSVs do not produce detectable amounts
of RLR-critical dsRNA [36]. However, synthesis of the NSV genome
is initiated with an unprimed nucleoside triphosphate, resulting in
a 50ppp terminus. For ns-NSVs, nucleocapsids are linear [35],
suggesting that the 50ppp ssRNA end does not meet the 30
counterpart and hence cannot activate RIG-I [13]. For s-NSVs, by
contrast, the promoter structure which is formed by annealing of
the genome termini (‘‘panhandle’’, see Fig. 1B) bears hallmarks of a
RIG-I agonist. Indeed, we recently showed that the 50ppp dsRNA
panhandle structures packaged into nucleocapsids of two mem-
bers of the Bunyaviridae (La Crosse virus (LACV) and Rift Valley
Fever virus (RVFV)) act as RIG-I agonists in the natural context of
infection [37]. Therefore, RIG-I can recognize the nucleocapsids of
s-NSVs directly after their entry into the cytoplasm. In the case of
ns-NSVs, only RNA synthesis products (e.g. 50ppp leader RNA) can
act as triggers of RIG-I [6,20,33,38–41]. Moreover, particular
stretches of viral mRNA can activate MDA5 [32,33]. During
replication of the RNA genome, the viral polymerase occasionally
jumps template, resulting in RNA products with internal deletions,
the defective interfering (DI) RNAs, named so because they
strongly compete with the full-length genomes for resources
[42]. One particular class, the copy-back DI RNAs, contain
complementary 50 and 30 ends. It is thought that a percentage of
DI RNAs is incompletely encapsidated [43]. For the ns-NSV Sendai
virus (SeV), it was shown that copyback DI RNAs form panhandle-
like dsRNA structures which can accommodate RIG-I oligomers
and activate IFN induction [20,43]. Also for s-NSVs, products of
viral RNA synthesis (including internally deleted genomes) can
activate RIG-I and innate immune signalling [34,44–46]. Thus,
taken together, for s-NSVs incoming nucleocapsids can be detected
by RIG-I, and also later RNA synthesis products trigger innate
immunity. For ns-NSVs, by contrast, the RLRs have to await the
appearance of regular and irregular products of viral RNA
synthesis.
4. Pros and cons of genome segmentation
s-NSVs are schlepping a bundle of genome segments, each with
a RIG-I-sensitive 50ppp dsRNA promoter. This clearly represents a
Fig. 3. Agonists of RIG-I like receptors produced by NSV infection. Left panel: Upon infection with ns-NSVs, RNAs and DI particles are produced which activate RIG-I and MDA5.
Right panel: RNA synthesis by s-NSVs similarly generates regular and aberrant RLR agonists. In contrast to ns-NSVs, the incoming nucleocapsids of s-NSVs can directly
activate RIG-I independent of RNA synthesis. Middle panel: Ligand-bound RLRs switch conformation and homo-oligomerize (not depicted) to recruit the signalling adapter
MAVS on mitochondria. MAVS triggers antiviral type I IFN responses through a signalling cascade involving the kinases TBK1/IKKe and their substrates IRF3 and IRF7. TC,
transcription; RP, replication.
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disadvantage with respect of immune activation. Moreover,
segmentation requires sophisticated packaging mechanisms to
ensure each virion contains the full set of genes. On the other hand,
the segments can easily be exchanged between different virus
variants (reassortment), allowing rapid emergence of new viral
strains with altered antigenic or replicatory properties [5,47].
Dividing the genome in separate units is also considered an
insurance against sequence degeneration in systems with high
error rates, such as RNA-dependent polymerases [48], and
packaging several shorter segments instead of one large genome
was recently shown to increase the physical stability of virus
particles [49]. One evolutionary trade-off of genome segmentation,
however, is the elevated number of RLR agonists presented to the
innate immune system. It is therefore conceivable that s-NSVs
have to express early-hitting IFN evasion strategies which may also
be stronger than those of ns-NSVs.
5. RLR evasion strategies of NSVs
To our knowledge, all NSVs investigated so far have evolved
countermechanisms of RLR signalling, acting to prevent recogni-
tion by RLRs, to interfere with RLR signalling, and/or to suppress
Table 2
Mechanisms of NSVs to counteract RLR signalling.
Interference with Viral protein or function Virus Mechanism References
RLR sensing ssRNA encapsidation all NSVs Prevents dsRNA formation [35,36]
dsRNA unwinding by cellular
helicases UAP56 and URH49
FLUAV, VSV Prevents dsRNA formation [50,51]
Recruitment of La ns-NSVs Prevents RIG-I recognition of viral leader RNA [39]
Regulation of RNA synthesis
by viral proteins or promoter
sequences
ns-NSVs, FLUAV Prevents formation of aberrant RNAs [45,52–57]
Nuclear replication FLUAV Hiding from cytoplasmic RLRs [44]
VP35 EBOV, MARV dsRNA binding [60,61]
NS1 FLUAV dsRNA binding [59,62]
Cleavage of the 50ppp RNA
end to 50p
Bornaviridae,
Hantaviruses, CCHFV
Prevents RIG-I activation [67,68]
Genome RNA 50overhang Arenaviridae Disturbs RIG-I function [71]
dsRNA degradation by
nucleocapsid protein
Lassa virus Removes dsRNA [72,73]
RLR signalling NS2 RSV Interacts with RIG-I to prevent association with MAVS [75]
Z New World Arenaviruses Interacts with RIG-I to prevent association with MAVS [74]
OTU domain Nairoviruses
(Bunyaviridae)
De-ubiquitinylates RIG-I [76,77]
V Paramyxoviruses Wedges into MDA5 structure to prevent formation of
signalling-competent filaments
[78,79]
VP35 EBOV Sequesters the RIG-I cofactor PACT [64]
V Paramyxoviruses Assemble RIG-I and LGP2 into a refractory complex [80]
NS1 FLUAV Interacts with TRIM25 to counteract ubiquitinylation of
RIG-I
[63]
Upregulation of Siglec-G by
unknown mechanism
VSV, SeV (NSVs in
general?)
Ubiquitin-mediated RIG-I degradation [81]
NSs TOSV Ubiquitin-mediated RIG-I degradation [82]
N and P RSV Recruitment of MDA5, MAVS, and RIG-I into inclusion
bodies
[83]
NSs SFTSV Relocalization of RIG-I, TRIM25, TBK1, IKKe and IRF3 into
inclusion bodies
[84,85]
NS1 and NS2 RSV Formation of degradosome to destroy MAVS and IRFs [86]
PB1, PB2, PA, PB1-F2 FLUAV Impairment of MAVS signalling [87–91]
Nucleocapsid protein Arenaviruses,
hantaviruses
Prevention of TBK1 or IKKe activation [93,96]
Gn Hantaviruses Prevention of TBK1 action [95]
P BDV and Rabies Prevention of TBK1 action [92,97]
V Paramyxoviruses Prevention of TBK1 activation [94]
VP35 EBOV Prevents interactions of TBK1 and IKKe with IRFs [66]
VP35 EBOV Inhibits IRF7 function by enhancing its SUMOylation via the
cellular E3 ligase PIAS1
[98]
ML THOV Blocks IRF3 and IRF7 dimerization and association with CBP,
TRAF6 and the general transcription factor IIB
[99,100]
V Paramyxoviruses Interact with IRF3 and impair nuclear translocation. [101]
W NiV Inhibits activation of the IFN-b promoter [102]
NSs RVFV Recruits repression factor SAP30 to inhibit IFN-b
transcription
[103]
Host cell gene expression Cap-snatching s-NSVs Destruction of host cell mRNAs by viral endonuclease
function
[108]
PA-X FLUAV Separate endonuclease domain, suppresses antiviral host
cell responses
[109]
NS1 FLUAV Interferes with processing, nuclear export and translation of
host mRNAs
[8]
M VSV Interferes with nuclear export of host mRNAs [110]
NSs RVFV Disturbs assembly of TFIIH [111]
NSs RVFV Promotes degradation of the TFIIH subunit p62 via the E3
ubiquitin ligase FBXO3.
[112,113]
NSs BUNV Inhibits phosphorylation of the RNA polymerase II subunit
RPB1
[114]
NSs LACV Drives proteasomal degradation of RPB1 [115]
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induction of the type I IFN response. The molecular mechanisms
involved range from a selective interference with key components
of the IFN system to a broad shut-off of the host cell transcription.
Since it has become virtually impossible to summarize all known
mechanisms and factors of viral IFN antagonism, we can only
describe prominent examples to highlight the underlying princi-
ples (Table 2).
5.1. Prevention of RLR sensing
An efficient way of innate immune escape is to avoid the
initiation of RLR signalling directly at its root, i.e. at the level of
detection. As mentioned, NSVs do normally not produce long
dsRNAs [36], first of all because of the packaging of genome and
antigenome RNAs into separate nucleocapsids [35]. For the s-NSV
influenza A virus (FLUAV), depletion of the cellular helicases
UAP56 and URH49, which are known to be involved in RNA
encapsidation [50], resulted in the appearance of long dsRNA [51].
Also for an ns-NSV (vesicular stomatitis virus, VSV) UAP56 and
URH49 are necessary for prevention of dsRNA formation,
suggesting a general mechanism [51]. In addition, ns-NSVs are
recruiting the cellular RNA binding protein La to shield the leader
RNA from RIG-I recognition [39]. The generation of immuno-active
RNAs products can also be avoided by tightly controlling the
processivity of genome transcription and replication. For several
paramyxoviruses (i.e. ns-NSVs) it was described that a loss of
regulatory proteins (dependent on the virus either P, C, V) or a
promoter mutation enhanced viral RNA synthesis but also
facilitated appearance of innate immunity-inducing dsRNA, DI
particles, or other aberrant RNAs [52–57]. A similar control of RNA
synthesis and DI particle formation to avoid IFN induction was
recently reported for FLUAV, suggesting that this is a general
mechanism of NSVs [45].
RLR sensing could also be a reason why members of the
Orthomyxoviridae are replicating in the nucleus. This virus family
contain 6 (Thogoto virus, THOV) to 8 (FLUAV) genome segments,
i.e. the virions contain at least 2 times as many RLR ligands as those
of other s-NSVs. Since RLRs are localized in the cytoplasm, they are
only transiently in contact with orthomyxoviral nucleocapsids,
namely during the initial transport from the endosome to the
nucleus, and during the late step of particle egress. Hiding in the
nucleus could be thus a way by which heavily-segmented NSVs can
minimize RLR sensing. Indeed, innate immunity activation by
FLUAV requires RNA synthesis and RNA nuclear export [44,58].
Thus, the early cytoplasmic passage of nucleocapsids can occur
largely unnoticed by the cell.
On top of the strategies to prevent production or exposure of
RLR-relevant RNAs, both ns-NSVs and s-NSVs exhibit a range of
active mechanisms. The proteins VP35 of Ebola (EBOV) and
Marburg virus (MARV) and NS1 of FLUAV directly  bind dsRNA
[59–62], although it seems that additional host factor interac-
tions are necessary to prevent IFN induction [63–66]. Moreover,
members of the Bornaviridae (ns-NSVs) and Bunyaviridae (s-
NSVs) remove the 50ppp group from their genome to avoid RIG-I
activation [67,68], although some residual activating potential
seems to remain [37,69]. Similarly, for the Arenaviridae (s-NSVs) a
fraction of genome ends [70] can exhibit a single 50overhanging
nucleotide with the potential to disturb RIG-I function [71].
Moreover, Lassa virus (LASV, family Arenaviridae) encodes a
nucleoprotein with 30–50 exoribonuclease activity to degrade
dsRNA [72,73].
5.2. Specific interference with RLR signalling
In addition to masking, processing or degrading RLR agonists,
NSVs can interfere with key components of the RLR signalling
pathway. Several factors of ns-NSVs and s-NSVs are known to act
on the level of RLRs. NS2 of respiratory syncytial virus (RSV) and
the Z protein of New World Arenaviruses directly interact with
RIG-I to prevent the association with MAVS [74,75]. The ovarian
tumour (OTU) domain of Nairoviruses (family Bunyaviridae)
supresses IFN induction and de-ubiquitinylates RIG-I [76,77].
MDA5 was originally discovered as a host interactor and inhibitor
of the paramyxovirus IFN antagonist V [78]. The V proteins are
wedging into the MDA5 structure in a manner that prevents
assembly into signalling-competent filaments [79]. VP35 of EBOV
sequesters the RIG-I activating protein PACT to interfere with RIG-I
activation [64], V proteins of paramyxoviruses assemble RIG-I and
LGP2 into a complex which becomes refractory to activation by
RIG-I ligands [80], and NS1 of FLUAV interacts with TRIM25 to
counteract ubiquitinylation of RIG-I [63]. Interestingly, infections
with VSV or SeV were shown to upregulate the lectin Siglec-G,
resulting in RIG-I degradation via K48-linked ubiquitinylation [81].
A strategy of ubiquitin-dependent RIG-I degradation is also
conducted by Toscana virus (TOSV) via its NSs protein [82].
Some viral factors also sequester key components of RLR
signalling in cellular compartments. RSV N and P proteins recruit
MDA5, MAVS, and less efficiently RIG-I, into virus induced
inclusion bodies [83]. Also Severe fever with thrombocytopenia
syndrome virus (SFTSV) NSs prevents RLR signalling by promoting
relocalization of RIG-I, TRIM25, TBK1, IKKe and IRF3 into virus-
induced cytoplasmic structures [84,85]. NS1 and NS2 of RSV
induce the formation of the so-called degradosome to target
MAVS and IRFs for degradation [86]. MAVS signalling is impaired
by FLUAV polymerase subunits (PB1, PB2 and PA) [87,88] and the
accessory protein PB1-F2 [89–91]. Further downstream, TBK1
activation or action are prevented by N of arenaviruses and
hantaviruses, and Gn proteins of hantaviruses, P proteins of BDV
and Rabies virus, V proteins of paramyxoviruses, and also by EBOV
VP35 [66,92–97].
Finally, at the level of IFN transcription, several viral factors are
known to interfere with IRF or NF-kB activity. EBOV VP35 (a
multifunctional IFN antagonist like FLUAV NS1) enhances
SUMOylation of IRF7 via the cellular E3 ligase PIAS1, thereby
inhibiting its function as an IFN transcription factor [98]. ML of
THOV (family Orthomyxoviridae), acts by blocking IRF3 and IRF7
dimerization and association with CBP, TRAF6 and the general
transcription factor IIB [99,100]. V proteins of several (but not all)
paramyxoviruses interact with IRF3 and impair its nuclear
translocation [101]. In case of the highly pathogenic Nipah virus
(NiV) (family Paramyxoviridae), the W protein translocates into
the nucleus to inhibit activation of the IFN-b promoter [102]. Also
the NSs protein of RVFV specifically inhibits IFN-b mRNA
transcription by forming a promoter-bound complex with the
repression factor SAP30 [103].
5.3. Unspecific interference with RLR signalling
In contrast to the above-described specific mechanisms aiming
at antiviral signalling pathways, some representatives of the NSVs
interfere with the cellular transcription machinery in total. It is
thereby important to distinguish between a primary host cell shut-
off imposed by specific viral mechanisms from the secondary shut-
off caused by translation inhibition due to the dsRNA-activated
host cell kinase PKR. While the primary, ‘‘intended’’ shut-off seems
to be mostly (but not exclusively) the domain of s-NSVs, the
secondary shut-off is in fact an efficient antiviral host reaction. PKR
activation is thus avoided by both s-NSVs and sn-NSVs, either by
tight regulation of RNA synthesis (see above), or by specific anti-
PKR mechanisms [11,104].
A virus-induced, general block of gene expression provides an
efficient mechanism to prevent synthesis of IFN and ISGs, but could
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bear the disadvantage of cutting off from renewable resources.
However, viruses undergoing rapid and lytic infection cycles seem
to care little for such considerations. That the viral host shut-off, a
long-known phenomenon, is often an IFN antagonism in disguise
was revealed by genetic complementation studies showing that the
particular viral shut-off factor is only necessary if the host organism
possesses a functional IFN system [105–107]. In other words, in an
IFN-free host environment the shut-off factors are dispensable for
viral success. Interestingly, all s-NVs (but not ns-NSVs) commit cap-
snatching, an endonuclease-mediated mechanism to degrade host
mRNAs by depriving them of their 50 cap structure. Cap-snatching
spares the s-NSVs to encode their own mRNA capping enzyme, and
could have the convenient side effect of reducing host cell gene
expression, including that of upregulated components of the RLR
and IFN signalling pathways [108]. FLUAV expresses its endonucle-
ase even as a separate domain, called PA-X, which was actually
shown to suppress antiviral host cell responses [109]. FLUAV impairs
host gene expression also by other mechanisms. The multifunctional
protein NS1 interferes with processing, nuclear export and
translation of host mRNAs [8]. Inhibition of nuclear-cytoplasmic
RNA transport is a strategy shared by the matrix protein M of VSV
[110]. Broad disruption of RNA polymerase II activity is achieved by
representatives of the Bunyaviridae. The NSs of RVFV disturbs
assembly of the general transcriptional factor TFIIH [111] and
promotes degradation of the TFIIH subunit p62 via the E3 ubiquitin
ligase FBXO3 [112,113]. The NSs protein of Bunyamwera virus and
LACV impact on the RNA polymerase II subunit RPB1, disturbing its
phosphorylation (and hence processivity) or driving its proteasomal
degradation [114,115].
6. Conclusions and outlook
NSV-infected cells are flooded with foreign RNAs which are –
compared to the pool of host cell RNAs – rather homogeneous in
sequence and structure. Unusual features like double-stranded-
ness or triphosphorylated 50ends are extremely efficient markers
of infection. However, also structures with less prominent features
are conceivable to act as triggers of antiviral responses if they
appear in high enough amounts.
Since the discoveries of RIG-I and MDA5 [78,116], the research
field of intracellular RNA recognition and viral countermechan-
isms has virtually exploded. There are ongoing discussions on the
physiological ligands of RLRs and on major RLRs engaged during a
particular infection, questions which are touching the very core of
the immune reponse, the distinction between self and non-self. In
our review, we wanted to highlight that NSVs are a quite
heterogeneous taxonomic group, with different genome and
nucleocapsid structures, subcellular localizations, replication
strategies, tendencies to produce DI particles, and a multitude
of IFN antagonists which can obscure RLR–ligand interactions.
Moreover, different infection phases may produce different RLR
triggers. To make things even more complicated, it is meanwhile
established that RLRs can get help from accessory factors such as
e.g. other RNA-binding proteins, helicases or RNases, further
expanding the range of in vivo RLR triggers [17,32,39,117–119],
which may not work as such in vitro. So, again, the question which
RLR recognizes which virus and viral structure under physiologi-
cal conditions may return different answers which depend on the
infection phase, the DI particle content of virus stocks, the specific
activity of virus regulators and IFN antagonists, and on host cell
cofactors.
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The group of negative-stranded RNA viruses (NSVs) with a
segmented genome comprises pathogens like influenza virus
(eight segments), Rift Valley fever virus and Hantavirus (three
segments), or Lassa virus (two segments). Partitioning the
genome allows rapid evolution of new strains by reassortment.
Each segment carries a short double-stranded (ds) ‘panhandle’
structure which serves as promoter. Similar dsRNA structures,
however, represent the optimal ligand for RIG-I, a cytoplasmic
pathogen sensor of the antiviral interferon response. Thus,
segmenting a virus genome can entail an increased RIG-I
sensitivity. Here, we outline the astonishingly diverse and
efficient strategies by which segmented NSVs are compensating
for the elevated number of RIG-I ligands in their genome.
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Introduction
Like eukaryotes, some negative-strand RNA viruses
(NSVs) feature a genome which is divided into semi-
autonomous pieces. The evolutionary advantage is an
extra degree of freedom for recombination, facilitating
the rapid admixture of genome segments to create
hybrid offspring. The success of this strategy is obvious
from the constant flow of new influenza strains afflicting
mankind with epidemics or even pandemics [1].
Besides influenza viruses (belonging to the family
Orthomyxoviridae) which have up to eight segments to
offer for genetic mixing, there are two other families
with a more modest set-up, namely the Bunyaviridae
(three segments) and the Arenaviridae (two segments).
Together these viruses are responsible for an impressive
array of diseases ranging from severe pulmonary,
hepatic or renal ailments (influenza, Rift Valley fever,
Hantavirus) up to deadly hemorrhagic fevers (Lassa
fever, Junin, Crimean Congo hemorrhagic fever, Han-
tavirus, Rift Valley fever).
Host organisms (e.g. us) are however not defenceless.
Adaptive immunity would be too slow to protect from a
first infectious encounter, but mammals can execute an
immediate innate immune response enabled by germ-
line-encoded factors specialized to rapid virus detec-
tion. A well-established example is given by the
cytoplasmic pathogen recognition receptor RIG-I, an
RNA helicase of the DExD/H type [2]. One of the best
ligands for RIG-I is short doubled-stranded RNA
(dsRNA) containing a blunt 50 end with a triphosphate
group, 50 ppp dsRNA [3] (Figure 1a). Ligand-activated
RIG-I is rapidly triggering a signalling chain which
upregulates an antiviral innate immune response. 50
ppp dsRNA structures similar to the ideal RIG-I ligand
are formed by the genome ends of segmented NSVs
(Figure 1b), but are not found on cellular RNA [3].
Thus, RIG-I seems well adapted to the genome of
segmented NSVs, ensuring a specific and rapid immune
reaction to this class of viruses.
In this opinion article, we will briefly outline how RIG-I-
dependent ligand recognition and antiviral signalling
work, how segmented NSVs are activating it, and share
our thoughts on how these viruses are trying to escape
detection and signalling by RIG-I.
RIG-I-mediated antiviral response
RIG-I is composed of an amino-terminal tandem of
CARDs (caspase recruitment domains), a central RNA
helicase domain, and a carboxy-terminal CTD (C-term-
inal domain) [4]. Ligand-mediated activation of RIG-I
results in the binding of the adaptor protein MAVS
(mitochondrial antiviral signalling) via polyubiquitin-
mediated CARD–CARD interactions. After recruitment
of further cofactors, the complex activates the transcrip-
tion factors IRF-3/7 and NF-kB, which, in turn, initiate
transcriptional activation of type I interferons (IFN-
alpha/beta) and other proinflammatory cytokines [5].
Once secreted, IFNs bind to their cognate receptor on
the cell surface to activate numerous ISGs (IFN-stimu-
lated genes). Many ISGs encode antiviral restriction
factors inhibiting different steps of virus replication such
as entry, transcription, replication, translation, assembly
or release from infected cells, thus slowing down or
entirely blocking further viral spread [1,4–6].
Available online at www.sciencedirect.com
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Activation of RIG-I by viral structures
In uninfected cells, RIG-I is present in an auto-inhibited
conformation stabilized by internal interactions between
the inner CARD (CARD2) and a part of the helicase
domain, the Hel2i region [7,8,9]. The CTD is flexibly
exposed and thus available for scanning the cytosol for
viral RNAs. Binding of 50 ppp dsRNA to the CTD
induces a massive conformational switch by disrupting
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Synthetic and natural RNA structures relevant for RIG-I signalling. (a) Minimal RIG-I agonist as determined by RNA transfection experiments [7,10]. (b)
Idealized structure of segmented negative-sense RNA genomes, with a large single-stranded coding region pseudocircularized by a double-stranded
‘panhandle’ promoter. (c)–(f) Predicted structures of viral panhandle regions. (c) Influenza A virus (H9N2) segment 8 (database entry AY790309), drawn
as panhandle (left panel) or ‘corkscrew’ (right panel) [16,22]. (d) Rift Valley fever virus segments M (database entry DQ380206) and L (database entry
DQ375403). (e) Hantaan virus segments S (database entry AF288644) and M (database entry KC344261). Note the monophosphate at the 50 end. (f)
Junin virus segments S (database entry NC_005081) and L (database entry NC_005080), both as corrected by Albarin˜o et al. [24]. The unpaired
nucleotide at the 50 end found in a fraction of the S segment RNAs [24] is shown in lower case. In all subfigures, Watson-Crick basepairs are indicated
by lines, and non-Watson-Crick basepairs [50] are indicated by dots. Sequences are in the viral sense orientation and nucleotides are numbered up to
the first interruption of base pairing.
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the Hel2i–CARD2 interaction, thereby clamping RIG-I
around the RNA ligand and liberating the CARDs to
interact with polyubiquitin and MAVS [4,6].
Besides 50 ppp dsRNA of a minimal length of 10 bp [7,10],
RIG-I responds to long dsRNA molecules of more than
200 bp (irrespective of the 50 ends), to 30-phosphorylated
cleavage products of RNase L, and to poly-U/UC-rich
ssRNA stretches [3,11–13]. Long dsRNA is not produced
in a detectable amount during the course of NSV in-
fection [14]. However, as outlined above, segmented
NSVs form a RIG-I-critical 50 ppp dsRNA region by
base-pairing the terminal 50 and 30 non-translated regions
of their genome (Figure 1c–f). This so-called ‘panhandle’
structure pseudo-circularizes the otherwise single-
stranded RNA genome and serves as promoter for tran-
scription and replication [15–17]. Moreover, at least for
influenza viruses a 30 untranslated ssRNA region of the
genome activates RIG-I in a 50 ppp independent fashion
[18].
In most of the RIG-I studies mentioned above, the
structural characteristics of the ligands had been deter-
mined in vitro or by transfection of naked RNA into cells.
Hence, the question was raised which of those structures
are actually representing the natural ligands of RIG-I.
Rehwinkel et al. [19] and Baum et al. [20] showed that
full-length virus genomes and defective shortened RNAs
arising during the course of the infection are indeed
serving as RIG-I activators. Moreover, our group recently
demonstrated that viral 50 ppp dsRNA structures (i.e. the
panhandle) can bind and activate RIG-I even when
encapsidated by nucleoprotein [21]. Thus, apparently,
RIG-I is capable of recognizing RNAs at all stages of
infection. It is activated by the panhandle on viral
nucleocapsids in the immediate early phase, that is
directly after they entered the cytoplasm [21], but also
by newly synthesized viral RNAs later in infection
[19,20].
Inhibition of RIG-I by segmented NSVs
For all the evolutionary advantages of having a segmen-
ted genome, these viruses face a particular problem: with
every additional piece of RNA they increase their load of
RIG-I ligands. The extreme is represented by influenza
viruses, which expose no less than eight 50 ppp dsRNAs
per infectious particle. Thus, strong and efficient anti-
RIG-I measures are essential for these viruses to survive.
The viral escape mechanisms act on many different levels
(Figure 2). First of all, it might be no coincidence that
influenza viruses and other orthomyxoviruses have
evolved the unusual lifestyle of replicating in the nucleus.
By this, they avoid constant exposure to cytoplasmic
RIG-I, only passing the cytoplasm at the beginning
and at the end of the replication cycle. Avoiding detec-
tion, in fact, represents an efficient way of RIG-I escape,
since it is expected to demand less effort than blocking
the amplified and diversified antiviral signalling events
occurring further downstream. Influenza viruses exhibit
also other features which could be interpreted as RIG-I
escape. Firstly, the panhandle is not a perfect RIG-I
ligand, but possesses mismatches and non-canonical base-
pairs which weaken the dsRNA structure (see Figure 1c,
left panel). Also, the nucleotide sequence of the ortho-
myxoviral panhandle enables the dsRNA panhandle to
convert into a so-called ‘hook’ or ‘corkscrew’ by folding
back the individual strands onto themselves [16,22] (see
Figure 1c, right panel). The dsRNA-disrupting nucleo-
tides and structural switches are known to regulate viral
promoter activity, but it can be speculated they are
disturbing RIG-I binding as well.
The panhandles of the less-segmented Bunyaviridae and
Arenaviridae families often contain larger continuous
double-stranded regions (see Figure 1d–f). However,
some bunyavirus genera (Hantavirus and Nairovirus)
are cleaving off the gamma and beta phosphates of the
RIG-I-critical 50 ppp group [23] (see Figure 1e), and some
arenavirus genome ends can exhibit a single 50 overhan-
ging nucleotide [24] with the potential to disturb RIG-I
function [17] (see Figure 1f).
It must be noted, however, that most of the viral
panhandle modifications are apparently insufficient
for a complete innate immune escape. While genomic
RNAs isolated from particles of those bunyaviruses
which cleave off the 50 ppp do not activate RIG-I or
antiviral signalling [23], the genomic RNAs of other
bunyaviruses, influenza viruses, but also arenaviruses
clearly activate RIG-I-dependent IFN induction if
transfected into cells [23,25]. In the case of arena-
viruses, this might be due to the fact that only a fraction
of the RNAs actually seems to contain the unpaired 50
nucleotide [24]. Moreover, RIG-I is most likely more
flexible in its ligand requirements in vivo, a view which
is supported by the observations that (i) not all nucleo-
tides of the dsRNA helix are bound by amino acids of
RIG-I [7,9], (ii) bulges and 50 overhangs of the 50 ppp
dsRNA can be tolerated by RIG-I to some extent
[10,13], and (iii) RNAs other than 50 ppp dsRNA can
activate RIG-I [11,12,18].
Independent of the 50 end, dsRNA from a certain length
on is a prototypical hallmark of virus infection and a strong
inducer of innate immune responses. In the cytoplasm,
not only RIG-I but also the sister helicase MDA5 and the
RNA-binding antiviral kinase PKR are activated by
dsRNA [4,6]. NSVs avoid formation of dsRNA hybrids
between the viral genome and its complementary RNA
species (antigenome and mRNA) [14], most probably due
to the separate packaging of genome and antigenome into
nucleocapsids. Moreover, influenza viruses use the cel-
lular helicases UAP56 and URH49 to unwind any such
dsRNA replication intermediates [26].
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RIG-I antagonism by segmented negative-strand RNA viruses. Infection with segmented NSVs generates structures with the potential to act as
agonists of RIG-I. The viruses have therefore evolved escape strategies (shown in green) which act on all levels of RIG-I signalling (shown in light red).
For details see text. Abbreviations: Gn: glycoprotein (N-terminal), IFN: type I interferon, IKKe: Inhibitor of nuclear factor kappa-B kinase subunit epsilon,
IRF-3/7: interferon regulatory factors 3/7, ISG: interferon stimulated gene, MAVS: mitochondrial antiviral signalling protein, ML: matrix protein long, NP:
nucleoprotein, NS1: non-structural protein 1, NSs: non-structural protein encoded on the S segment, NSV: negative-strand RNA virus, OTU: ovarian
tumour domain, PA: polymerase acidic, PB: polymerase basic, RIG-I: retinoic acid–inducible gene I, SFTSV: severe fever with thrombocytopenia
syndrome virus (a bunyavirus), TBK1: TANK-binding kinase 1, 50 ppp dsRNA: 50 triphosphorylated double-stranded RNA, TRIM: tripartite motif, Z: Zink
finger protein. Dotted arrows symbolize signalling factors which have been left out for the sake of simplicity.
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The above-described strategies of disrupting RIG-I-
critical panhandle features and of preventing formation
of large dsRNA stretches could be considered as basic,
‘passive’ abilities of segmented NSVs against the antiviral
IFN system. On top of this, there are several active
mechanisms in place. First of all, it is interesting to note
that all segmented NSV families (but not the non-seg-
mented ones) are performing ‘cap-snatching’, that is, they
cleave capped oligonucleotides from host cell mRNAs
and use them as primers for viral transcription. The
responsible endonuclease domain is embedded in the
viral polymerase and likely contributes to the downmo-
dulation of antiviral cell responses [1]. In fact, it was
recently discovered that influenza viruses can express the
endonuclease domain alone, by ribosomal frameshift, and
that this protein (PA-X) strongly suppresses host cell gene
expression [27]. The influenza virus polymerase sub-
units (PB1, PB2 and PA) can also block IFN upregulation
independent of cap-snatching, by binding to MAVS
[28,29]. Prime example of a separate influenza virus factor
dedicated to IFN antagonism is the nonstructural protein
NS1, a truly multifunctional protein known to bind
dsRNA, RIG-I and its regulatory ubiquitin ligases TRIM
25 and Riplet, and PKR, but also to inhibit host cell
mRNA processing, transport, and translation in a strain-
specific manner [1,30]. Some influenza A virus strains
express an additional protein, PB1-F2, which also down-
modulates innate immune reactions [31–33]. A related
orthomyxovirus, Thogoto virus, has evolved a different
strategy. It encodes a splice variant of the viral matrix
protein, ML, which blocks IFN induction by associating
with IRF-7 and the general transcription factor IIB
[34,35]. The three-segmented Bunyaviruses similarly
express IFN antagonists, most prominently the non-
structural protein NSs. NSs proteins of different bunya-
virus genera either bind and degrade RIG-I [36], degrade
PKR [37,38], sequester TBK1 [39], or — in most cases —
suppress host cell mRNA synthesis by dysregulating,
sequestering, or degrading key factors of RNA polymer-
ase II transcription [15,40,41]. Moreover for some Han-
taviruses it was shown that the cytoplasmic tail of the
glycoprotein Gn downregulates IFN induction by inhi-
biting the IRF-3 kinase TBK1 [42], and that the nucleo-
protein inhibits the nuclear import of NF-kB [43].
Likewise, for the bunyavirus genus Nairovirus the ovarian
tumour (OTU) domain of polymerase interferes with NF-
kB activation by a de-ubiquitinylation/de-ISGylation
activity [44]. Also in the case of arenaviruses several
IFN antagonists were described, first of all the nucleo-
protein which degrades viral dsRNA [45,46], and inhibits
NF-kB and the IRF-3 kinase IKKe [47,48]. Moreover, the
Z protein of several arenaviruses directly binds and inhi-
bits RIG-I [49].
Thus, the evolutionary advantage of dividing a viral RNA
genome into several, genetically semi-autonomous pieces
comes at some costs. It has to be counterbalanced by
strong and efficient anti-RIG-I strategies acting on all
possible levels. Nonetheless, at late stages of infection
the viral counter mechanisms can be overrun by accumu-
lating erroneous replication products, eventually tipping
the balance towards activation of antiviral and inflamma-
tory responses. In the extreme case, a cytokine storm
develops causing the severe symptoms typical for so many
of these viruses.
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